

Diagnosis, management, and treatment of hepatitis C: A

Hepatology

49, 1335-1374

DOI: [10.1002/hep.22759](https://doi.org/10.1002/hep.22759)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children. Pakistan Journal of Medical Sciences, 1969, 30, 519-24.	0.3	3
3	Optimal Length of Antiviral Therapy in Patients with Hepatitis C virus Genotypes 2 and 3: A Meta-Analysis. Antiviral Therapy, 2009, 14, 1139-1148.	0.6	16
4	Managing hepatitis C in liver transplant patients with recurrent infection. Transplant Research and Risk Management, 2009, Volume 1, 1-14.	0.7	0
5	Treatment of chronic hepatitis C: present and future. Acta Hepatologica Japonica, 2009, 50, 345-355.	0.0	0
7	Sustained Virological Response During Exenatide Treatment in a Patient With Hepatitis C and Nonalcoholic Steatohepatitis. American Journal of Gastroenterology, 2009, 104, 3112-3114.	0.2	4
8	Managing hepatitis C virus infection. BMJ: British Medical Journal, 2009, 338, b2366-b2366.	2.4	10
9	Chronic hepatitis B and C: update on therapy. Future Virology, 2009, 4, 437-452.	0.9	3
10	Interferon for Hepatitis C Virus in Hemodialysis—An Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1449-1458.	2.2	24
11	Acute Hepatic Injury Associated with Varenicline in a Patient with Underlying Liver Disease. Annals of Pharmacotherapy, 2009, 43, 1539-1543.	0.9	11
12	HBV and HCV Therapy. Viruses, 2009, 1, 484-509.	1.5	7
13	Quantification of Hepatitis C Virus (HCV) RNA in a Multicenter Study: Implications for Management of HCV Genotype 1-Infected Patients. Journal of Clinical Microbiology, 2009, 47, 2931-2936.	1.8	15
14	Age and Prediction of Sustained Virological Response to Hepatitis C Virus (HCV) Infection Treatment Based on 28-Day Decrease in HCV RNA Levels. Journal of Infectious Diseases, 2009, 200, 1484-1485.	1.9	13
15	Diagnosis, management, and treatment of hepatitis C. Hepatology, 2009, 50, 322-322.	3.6	23
16	Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines. Hepatology, 2009, 50, 323-323.	3.6	1
17	Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: Treating active drug users. Hepatology, 2009, 50, 323-324.	3.6	5
18	Reply:. Hepatology, 2009, 50, 324-325.	3.6	3
19	Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology, 2009, 50, 1750-1755.	3.6	195
20	Hepatitis C nonresponders: Re-treat or retreat?. Hepatology, 2009, 50, 1307-1309.	3.6	2

#	ARTICLE	IF	CITATIONS
21	Results of the IDEAL trial: "Mirror, mirror on the wall Which's the fairest peg-interferon of them all?" Hepatology, 2009, 50, 2034-2037.	3.6	5
22	Meta-analysis: Reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. International Journal of Cancer, 2009, 127, NA-NA.	2.3	24
23	Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. Journal of Clinical Apheresis, 2009, 24, 190-196.	0.7	24
24	On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatology International, 2009, 3, 16-23.	1.9	7
26	Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. Journal of Viral Hepatitis, 2009, 16, 833-843.	1.0	19
27	Practice Guidelines: Development, Application to Clinical Care, and Role in Provider Education. Clinical Pharmacology and Therapeutics, 2009, 86, 239-241.	2.3	5
28	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461, 399-401.	13.7	3,394
29	Predictors of Treatment Response in Chronic Hepatitis B. Drugs, 2009, 69, 2167-2177.	4.9	40
30	Management of patients co-infected with HBV and HCV. Expert Review of Anti-Infective Therapy, 2009, 7, 549-558.	2.0	4
31	Pegylated IFN-2a and ribavirin in the treatment of hepatitis C. Expert Review of Anti-Infective Therapy, 2009, 7, 925-935.	2.0	19
32	Optimizing the treatment of chronic viral hepatitis C. Expert Review of Gastroenterology and Hepatology, 2009, 3, 607-613.	1.4	22
33	644 OPTIMAL LENGTH OF ANTIVIRAL THERAPY IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 AND 3: A META-ANALYSIS. Journal of Hepatology, 2009, 50, S237.	1.8	2
34	Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review. Journal of Psychiatric Practice, 2009, 15, 262-281.	0.3	35
35	Research Highlights: Pharmacogenomics of chronic hepatitis C. Pharmacogenomics, 2009, 10, 1039-1042.	0.6	0
36	Individualized Extension of Pegylated Interferon Plus Ribavirin Therapy for Recurrent Hepatitis C Genotype 1b After Living-Donor Liver Transplantation. Transplantation, 2010, 90, 661-665.	0.5	22
37	Chronic Hepatitis C Virus Infection in Children. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 123-131.	0.9	40
38	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids, 2010, 24, F23-F29.	1.0	184
39	Hearing profile in hepatitis C virus patients under dual treatment with interferon and ribavirin. Audiological Medicine, 2010, 8, 142-153.	0.4	1

#	ARTICLE	IF	CITATIONS
40	Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience. <i>Transplantation</i> , 2010, 90, 407-411.	0.5	14
41	Rheumatic manifestations of hepatitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 91-96.	2.0	18
42	Overcoming barriers to new treatment options for hepatitis C. <i>Nurse Practitioner</i> , 2010, 35, 20-29.	0.2	2
43	Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24h. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1211-1220.	0.8	5
44	The A, B, Cs of viral hepatitis in the biologic era. <i>Current Opinion in Rheumatology</i> , 2010, 22, 443-450.	2.0	33
45	Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies. <i>Antiviral Therapy</i> , 2010, 15, 617-631.	0.6	56
46	Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. <i>Antiviral Therapy</i> , 2010, 16, 141-147.	0.6	41
47	Increased Urinary Lipocalin-2 Reflects Matrix Metalloproteinase-9 Activity in Chronic Hepatitis C with Hepatic Fibrosis. <i>Tohoku Journal of Experimental Medicine</i> , 2010, 222, 319-327.	0.5	21
49	Use of Statins in Patients with Chronic Hepatitis C. <i>Southern Medical Journal</i> , 2010, 103, 1018-1024.	0.3	13
50	Quality of Care in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2010, 153, 231.	2.0	55
51	2. Current Treatment and Future Prospects of Viral Hepatitis.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 499-505.	0.0	0
52	The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. <i>Antiviral Therapy</i> , 2010, 15, 91-99.	0.6	25
53	Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response. <i>Antiviral Therapy</i> , 2010, 15, 633-639.	0.6	13
54	Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue. <i>Research in Nursing and Health</i> , 2010, 33, 465-473.	0.8	18
55	Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 355-364.	1.4	8
56	Review: New direct-acting antivirals in the development for hepatitis C virus infection. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 191-202.	1.4	54
57	Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. <i>Medical Microbiology and Immunology</i> , 2010, 199, 1-10.	2.6	27
58	Telaprevir: a new hope in the treatment of chronic hepatitis C?. <i>Advances in Therapy</i> , 2010, 27, 512-522.	1.3	27

#	ARTICLE	IF	CITATIONS
59	How sustained is sustained viral response in patients with hepatitis C virus infection?. Indian Journal of Gastroenterology, 2010, 29, 112-115.	0.7	23
60	New antiviral therapies for chronic hepatitis C. Hepatology International, 2010, 4, 548-561.	1.9	99
61	Hepatitis C Plus Alcohol or Marijuana: Which Is Worse?. Current Hepatitis Reports, 2010, 9, 20-24.	0.3	1
62	Management of Hepatitis C in Patients with End-stage Renal Disease. Current Hepatitis Reports, 2010, 9, 38-46.	0.3	0
63	Viral Kinetics and Duration of Hepatitis C Therapy. Current Hepatitis Reports, 2010, 9, 140-146.	0.3	0
64	Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Current Hepatitis Reports, 2010, 9, 147-154.	0.3	7
65	Hepatitis C After Liver Transplantation: Treatment and Impact on Patient and Graft Survival. Current Hepatitis Reports, 2010, 9, 161-168.	0.3	0
66	Hepatitis C and End-stage Liver Disease. Current Hepatitis Reports, 2010, 9, 243-252.	0.3	0
67	A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. Digestive Diseases and Sciences, 2010, 55, 2629-2635.	1.1	7
68	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. Digestive Diseases and Sciences, 2010, 55, 3541-3547.	1.1	19
69	Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health, 2010, 10, 773.	1.2	5
70	T-cell responses at baseline and during therapy with peginterferon- α and ribavirin are not associated with outcome in chronic hepatitis C infected patients. Antiviral Research, 2010, 87, 353-360.	1.9	5
71	Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: Meta-analysis of prospective studies. Clinical Therapeutics, 2010, 32, 2139-2159.	1.1	28
72	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics, 2010, 32, 2117-2138.	1.1	87
73	Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology, 2010, 51, 1122-1126.	3.6	147
74	Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alpha-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology, 2010, 51, 1176-1184.	3.6	138
75	Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology, 2010, 51, 1897-1903.	3.6	60
76	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. Hepatology, 2010, 51, 1858-1858.	3.6	0

#	ARTICLE	IF	CITATIONS
77	Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 822-832.	3.6	212
78	Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. <i>Hepatology</i> , 2010, 52, 1124-1133.	3.6	340
79	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	3.6	63
80	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1888-1896.	3.6	332
81	Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peginterferon and ribavirin in a patient coinfected with HIV. <i>Journal of Medical Virology</i> , 2010, 82, 1150-1151.	2.5	2
82	Poor performance of hepatitis C antibody tests in hospital patients in Uganda. <i>Journal of Medical Virology</i> , 2010, 82, 1371-1378.	2.5	27
83	An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. <i>Journal of Medical Virology</i> , 2010, 82, 1537-1544.	2.5	4
84	An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1113-1123.	0.9	1
85	Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peginterferon alpha-2b and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1346-1353.	1.9	15
86	Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1251-1267.	1.9	21
87	Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 851-858.	1.9	107
88	Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitis C - an updated Cochrane review. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 840-850.	1.9	9
89	Meta-analysis: retreatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 969-983.	1.9	21
90	Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 778-783.	1.0	5
91	Thymalfasin in the treatment of hepatitis B and C. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 141-146.	1.8	13
92	Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 147-152.	1.8	5
93	Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 957-963.	1.4	7
94	Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995-2004. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1289-1294.	1.4	1

#	ARTICLE	IF	CITATIONS
95	Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1072-1078.	1.4	8
96	Outcomes of HCV treatment: Who does well and who does not?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 846-848.	1.4	1
97	Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 655-656.	1.4	2
98	High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1276-1280.	1.4	36
99	Individualisation of antiviral therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1206-1216.	1.4	17
102	Fatigue and depressive symptoms associated with chronic viral hepatitis patients' health-related quality of life (HRQOL). <i>Annals of Hepatology</i> , 2010, 9, 419-427.	0.6	54
103	Treatment of recurrent hepatitis C post-liver transplantation. <i>Annals of Hepatology</i> , 2010, 9, S84-S91.	0.6	0
104	Usefulness of liver biopsy in chronic hepatitis C. <i>Annals of Hepatology</i> , 2010, 9, S39-S42.	0.6	7
105	Indications for treatment in chronic HCV infection. <i>Annals of Hepatology</i> , 2010, 9, S49-S53.	0.6	3
106	Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. <i>Annals of Hepatology</i> , 2010, 9, S72-S79.	0.6	12
107	Treatment of HCV infection in patients with cirrhosis. <i>Annals of Hepatology</i> , 2010, 9, S80-S83.	0.6	4
108	Acute hepatitis C treatment. <i>Annals of Hepatology</i> , 2010, 9, S107-S111.	0.6	0
109	Insulin resistance, hepatic steatosis and hepatitis C: A complex relationship with relevant clinical implications. <i>Annals of Hepatology</i> , 2010, 9, S112-S118.	0.6	25
110	Latin American Association for the Study of the Liver Practice Guidelines. <i>Annals of Hepatology</i> , 2010, 9, S8-S26.	0.6	3
111	Chronic hepatitis C treatment in naïve patients. <i>Annals of Hepatology</i> , 2010, 9, S65-S71.	0.6	2
113	Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 1.	0.4	3
114	Tailoring Treatment Duration to 12 to 16 Weeks in Hepatitis C Genotype 2 or 3 With Rapid Virologic Response. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 583-587.	1.1	4
115	Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host Factors. <i>PLoS ONE</i> , 2010, 5, e14132.	1.1	25

#	ARTICLE	IF	CITATIONS
116	Response predictors to treatment with pegylated interferon in chronic hepatitis B. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 519-525.	0.3	7
118	Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy. <i>Adolescent Health, Medicine and Therapeutics</i> , 2010, 1, 115.	0.7	14
119	Health Care Costs Associated with Hepatitis C: A Longitudinal Cohort Study. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 717-726.	1.8	50
120	Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV and HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2010, 202, 889-893.	1.9	9
121	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2204-2211.	1.3	29
122	Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2063-2069.	1.3	38
123	Performance Characteristics of the MultiCode-RTx Hepatitis C Virus Load Test Targeting the 3' UTR Untranslated Region. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1771-1774.	1.8	1
124	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	1.5	184
125	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. <i>Gut</i> , 2010, 59, 1401-1409.	6.1	92
126	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	2.9	56
127	Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands. <i>Journal of Clinical Pathology</i> , 2010, 63, 1002-1007.	1.0	33
128	Hepatitis C Virus RNA Replication Requires a Conserved Structural Motif within the Transmembrane Domain of the NS5B RNA-Dependent RNA Polymerase. <i>Journal of Virology</i> , 2010, 84, 11580-11584.	1.5	16
129	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4587-4593.	0.8	150
130	Liver biopsy for histological assessment: The case in favor. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 133.	0.5	9
131	Antiviral therapy in chronic Hepatitis C virus-related decompensated liver cirrhosis - A tightrope walk. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 245.	0.5	1
132	Efficacy and Tolerability of Pegylated Interferon- α 2a plus Ribavirin versus Pegylated Interferon- α 2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients. <i>Intervirology</i> , 2010, 53, 146-153.	1.2	18
133	Interventions for HIV and Hepatitis C Virus Infections in Recreational Drug Users. <i>Clinical Infectious Diseases</i> , 2010, 50, 1505-1511.	2.9	12
134	Performance evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus genotyping. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 469-474.	1.4	17

#	ARTICLE	IF	CITATIONS
135	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2010, 4, 63-79.	1.4	8
136	Hemodialysis-Associated Infections. , 2010, , 335-353.		2
137	Acupuncture for Adverse Effects of Interferon Therapy for Hepatitis C Infection. Medical Acupuncture, 2010, 22, 117-120.	0.3	2
138	Chronic viral hepatitis and chronic kidney disease. Postgraduate Medical Journal, 2010, 86, 486-492.	0.9	35
139	Early Interferon-Based Treatment After Detection of Persistent Hepatitis C Virus Infection: A Critical Decision. Journal of Interferon and Cytokine Research, 2010, 30, 817-824.	0.5	3
140	Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84, 6218-6228.	1.5	135
141	Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation. Hepatitis Research and Treatment, 2010, 2010, 1-9.	2.0	2
142	Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection. Hepatitis Research and Treatment, 2010, 2010, 1-2.	2.0	2
143	Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon. Hepatitis Research and Treatment, 2010, 2010, 1-5.	2.0	1
144	Antiviral therapy for hepatitis C: why are so few patients being treated?. Journal of Antimicrobial Chemotherapy, 2010, 65, 1327-1329.	1.3	29
145	Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update. Hepatitis Research and Treatment, 2010, 2010, 1-6.	2.0	6
146	Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C. Hepatitis Research and Treatment, 2010, 2010, 1-9.	2.0	4
147	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses, 2010, 2, 2696-2739.	1.5	35
148	Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors. Hepatitis Research and Treatment, 2010, 2010, 1-7.	2.0	11
149	Retreatment of Children With Chronic Hepatitis C Who Did Not Respond to Interferon- α Treatment. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 187-190.	0.9	5
150	Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S37-S42.	0.9	39
151	Metabolic Factors and Non-Alcoholic Fatty Liver Disease as Co-Factors in Other Liver Diseases. Digestive Diseases, 2010, 28, 186-191.	0.8	43
152	Hepatitis C Increases the Risk of Progression of Chronic Kidney Disease in Patients with Glomerulonephritis. American Journal of Nephrology, 2010, 32, 311-316.	1.4	27

#	ARTICLE	IF	CITATIONS
153	Treatment Duration for Genotypes 2 and 3. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 527-528.	1.1	0
154	Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin. <i>HIV Clinical Trials</i> , 2010, 11, 1-10.	2.0	4
155	Management of Untreated and Nonresponder Patients with Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2010, 30, 348-360.	1.8	7
156	The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit. <i>Rna</i> , 2010, 16, 1559-1569.	1.6	67
157	Liver Disease in the HIV-Infected Individual. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1002-1012.	2.4	161
158	Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus-Related Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 192-199.	2.4	201
159	Advances in Hepatobiliary Pathology: Update for 2010. <i>Clinics in Liver Disease</i> , 2010, 14, 747-762.	1.0	5
160	Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 924-933.	2.4	103
161	Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 649-658.	1.0	24
162	Treatment of hepatitis C in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 51-61.	1.4	17
163	Why are Cochrane hepato-biliary reviews undervalued by physicians as an aid for clinical decision-making?. <i>Digestive and Liver Disease</i> , 2010, 42, 1-5.	0.4	14
164	Identification of substance use and dependence among patients with viral hepatitis. <i>Digestive and Liver Disease</i> , 2010, 42, 650-656.	0.4	8
165	Bile salts and cholestasis. <i>Digestive and Liver Disease</i> , 2010, 42, 409-418.	0.4	131
166	Preclinical and Clinical Development of Pegylated Interferon-Lambda 1 in Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 591-595.	0.5	52
167	Hepatitis C virus infection in Brazilian long-distance truck drivers. <i>Virology Journal</i> , 2010, 7, 205.	1.4	8
168	Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. <i>Virology Journal</i> , 2010, 7, 36.	1.4	25
169	Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response. <i>Gastroenterology</i> , 2010, 138, 503-512.e1.	0.6	127
170	A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin. <i>Gastroenterology</i> , 2010, 139, 1593-1601.	0.6	293

#	ARTICLE	IF	CITATIONS
171	Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. <i>Gastroenterology</i> , 2010, 139, 1602-1611.e1.	0.6	102
172	Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads. <i>Gastroenterology</i> , 2010, 139, 1972-1983.	0.6	28
173	IL28B and the Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1865-1876.	0.6	212
174	Low Rates of Hepatitis A and B Vaccination in Patients with Chronic Hepatitis C at an Urban Methadone Maintenance Program. <i>Journal of Addictive Diseases</i> , 2010, 29, 461-465.	0.8	8
175	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 52, 191-198.	1.8	188
176	Is response to antiviral treatment influenced by hepatitis B virus genotype?. <i>Journal of Hepatology</i> , 2010, 52, 441-449.	1.8	62
177	Treatment of chronic hepatitis C in children: Is it necessary and, if so, in whom?. <i>Journal of Hepatology</i> , 2010, 52, 472-474.	1.8	8
178	Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa. <i>Journal of Hepatology</i> , 2010, 53, 418-420.	1.8	1
179	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. <i>Journal of Hepatology</i> , 2010, 53, 1000-1005.	1.8	26
180	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). <i>Journal of Hepatology</i> , 2010, 53, 1013-1021.	1.8	386
181	Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b. <i>Journal of Clinical Virology</i> , 2010, 47, 258-262.	1.6	1
182	Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2010, 48, 66-68.	1.6	1
183	Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV/HCV coinfecting patient. <i>Journal of Clinical Virology</i> , 2010, 49, 131-133.	1.6	54
185	Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study. <i>Drug and Alcohol Dependence</i> , 2010, 110, 167-171.	1.6	40
187	HCV carriers with normal alanine aminotransferase levels: Healthy persons or severely ill patients?. <i>European Journal of Internal Medicine</i> , 2010, 21, 57-61.	1.0	25
188	Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. <i>Clinica Chimica Acta</i> , 2010, 411, 86-91.	0.5	34
189	Detection of HCV RNA in saliva does not correlate with salivary flow or xerostomia in patients with chronic hepatitis C. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 109, 851-856.	1.6	11
190	A suggested algorithm for using serum biomarkers for the diagnosis of liver fibrosis in chronic hepatitis C infection. <i>Arab Journal of Gastroenterology</i> , 2010, 11, 206-211.	0.4	2

#	ARTICLE	IF	CITATIONS
191	A Post-cure Complication. American Journal of Medicine, 2010, 123, 223-224.	0.6	2
192	Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatology Research, 2010, 40, 347-368.	1.8	40
193	Significance of interferon- α 2 for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatology Research, 2010, 40, 862-869.	1.8	6
194	High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatology Research, 2010, 40, 956-962.	1.8	14
195	An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. Gastroenterology, 2010, 139, 821-827.e1.	0.6	285
196	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology, 2010, 139, 120-129.e18.	0.6	633
197	Pegylated Interferons for the Treatment of Chronic Hepatitis C. Drugs, 2010, 70, 147-165.	4.9	91
198	ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterologie Clinique Et Biologique, 2010, 34, 388-396.	0.9	33
200	Use of Thrombopoietic Agents for the Thrombocytopenia of Liver Disease. Seminars in Hematology, 2010, 47, 266-273.	1.8	16
201	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut, 2010, 59, 861-866.	6.1	182
202	Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335). Journal of Medicinal Chemistry, 2010, 53, 6466-6476.	2.9	86
203	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	0.6	79
204	Response predictors to treatment with pegylated interferon in chronic hepatitis B. Brazilian Journal of Infectious Diseases, 2010, 14, 519-525.	0.3	0
205	Management of HIV and hepatitis virus coinfection. Expert Opinion on Pharmacotherapy, 2010, 11, 2497-2516.	0.9	19
206	Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Current Medical Research and Opinion, 2010, 26, 1733-1743.	0.9	16
207	Treating hepatitis C in children: an open horizon. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 247-248.	8.2	3
208	Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C. Annals of Pharmacotherapy, 2011, 45, 1085-1093.	0.9	35
209	Liver involvement in subjects with rheumatic disease. Arthritis Research and Therapy, 2011, 13, 226.	1.6	58

#	ARTICLE	IF	CITATIONS
210	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 301-313.	1.4	15
211	Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335. <i>Journal of Biological Chemistry</i> , 2011, 286, 11434-11443.	1.6	43
212	Treatment of acute HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 265-274.	8.2	53
213	Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 285-295.	8.2	26
214	Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging. <i>American Journal of Roentgenology</i> , 2011, 196, 553-561.	1.0	198
215	Care of Chronic Liver Disease. <i>Primary Care - Clinics in Office Practice</i> , 2011, 38, 483-498.	0.7	3
216	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 535-543.	2.0	17
217	Naïves, Nonresponders, Relapsers: Who Is There Left to Treat?. <i>Clinics in Liver Disease</i> , 2011, 15, 483-495.	1.0	6
218	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. <i>Gastroenterology</i> , 2011, 141, 1220-1230.e3.	0.6	268
219	Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon- α 2a and Ribavirin. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 781-785.	2.4	32
220	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. <i>Gastroenterology</i> , 2011, 141, 1656-1664.	0.6	40
221	Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 536-538.	2.4	4
222	Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations. <i>Clinics in Liver Disease</i> , 2011, 15, 573-583.	1.0	2
223	Emerging Therapies in Hepatitis C: Dawn of the Era of the Direct-Acting Antivirals. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 481-494.	1.0	5
224	Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1009-1026.	1.4	203
225	S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. <i>Gastroenterology</i> , 2011, 140, 830-839.e3.	0.6	51
226	The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 450-458.e1.	0.6	122
227	Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 469-477.	0.6	63

#	ARTICLE	IF	CITATIONS
228	Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1021-1031.e10.	0.6	233
229	Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?. <i>Gastroenterology</i> , 2011, 141, 1963-1967.	0.6	13
230	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 455-464.	0.7	4
231	Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C. <i>Digestive and Liver Disease</i> , 2011, 43, 337-344.	0.4	7
232	Ribavirin for chronic hepatitis C: And the mystery goes on. <i>Digestive and Liver Disease</i> , 2011, 43, 425-430.	0.4	22
233	Management of chronic hepatitis C in childhood: The impact of therapy in the clinical practice during the first 2 decades. <i>Digestive and Liver Disease</i> , 2011, 43, 325-329.	0.4	12
234	Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). <i>Digestive and Liver Disease</i> , 2011, 43, 589-595.	0.4	44
235	Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2011, 43, 807-813.	0.4	8
236	Lymphocytosis as a predictor of poor response to treatment of hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 34-40.	0.7	2
237	Interferon alpha for chronic hepatitis D. <i>The Cochrane Library</i> , 2011, , CD006002.	1.5	29
238	MicroRNAs and liver disease. <i>Translational Research</i> , 2011, 157, 241-252.	2.2	94
239	Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. <i>Value in Health</i> , 2011, 14, 1068-1077.	0.1	51
240	Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection. <i>American Journal of Gastroenterology</i> , 2011, 106, 1663-1669.	0.2	171
241	Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2429-2438.	13.9	403
242	Hepatitis C in HIV-infected individuals: cure and control, right now. <i>Journal of the International AIDS Society</i> , 2011, 14, 22-22.	1.2	34
243	Second-wave Protease Inhibitors: Choosing an Heir. <i>Clinics in Liver Disease</i> , 2011, 15, 597-609.	1.0	27
244	Telaprevir User's Guide. <i>Clinics in Liver Disease</i> , 2011, 15, 555-571.	1.0	14
245	Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2011, 45, 639-648.	0.9	20

#	ARTICLE	IF	CITATIONS
246	1990â€“2010: Two Decades of Interferon-Based Therapy. <i>Clinics in Liver Disease</i> , 2011, 15, 473-482.	1.0	8
247	Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections. <i>Gastroenterology</i> , 2011, 141, 881-889.e1.	0.6	164
248	Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 242-248.	2.4	28
249	Case 10-2011. <i>New England Journal of Medicine</i> , 2011, 364, 1259-1270.	13.9	16
250	Molecular Methods and Platforms for Infectious Diseases Testing. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 583-604.	1.2	82
251	Hepatitis C virus infection in nephrology patients. <i>Alexandria Journal of Medicine</i> , 2011, 47, 87-95.	0.4	0
253	Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. <i>Drug and Alcohol Dependence</i> , 2011, 116, 233-237.	1.6	12
254	Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: A single United Arab Emirates center experience. <i>European Journal of Internal Medicine</i> , 2011, 22, 582-586.	1.0	7
255	MicroRNA-like antivirals. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 746-755.	0.9	8
256	Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 53-64.	1.5	39
257	Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. <i>Journal of Clinical Virology</i> , 2011, 50, 217-220.	1.6	9
258	Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2011, 52, 133-137.	1.6	90
259	Hepatocellular Carcinoma Survival in Uninsured and Underinsured Patients. <i>Journal of Surgical Research</i> , 2011, 166, 189-193.	0.8	10
262	The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies â€“ A multicenter prospective trial. <i>Journal of Hepatology</i> , 2011, 54, 219-226.	1.8	24
263	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. <i>Journal of Hepatology</i> , 2011, 54, 415-421.	1.8	202
264	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. <i>Journal of Hepatology</i> , 2011, 54, 604-611.	1.8	45
265	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011, 54, 1114-1122.	1.8	105
266	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. <i>Journal of Hepatology</i> , 2011, 55, 38-44.	1.8	51

#	ARTICLE	IF	CITATIONS
267	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 69-75.	1.8	160
268	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. <i>Journal of Hepatology</i> , 2011, 55, 76-85.	1.8	53
269	Focus. <i>Journal of Hepatology</i> , 2011, 54, 597-598.	1.8	0
270	Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN λ -2a/RBV in hepatitis C patients. <i>Journal of Hepatology</i> , 2011, 55, 972-979.	1.8	48
271	“Easy to treat” genotypes were not created equal: Can rapid virological response (RVR) level the playing field?. <i>Journal of Hepatology</i> , 2011, 55, 466-473.	1.8	9
272	Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. <i>Journal of Hepatology</i> , 2011, 55, 963-971.	1.8	121
273	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 245-264.	1.8	1,083
274	Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design. <i>Antiviral Therapy</i> , 2012, 17, 365-375.	0.6	11
275	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , 2011, 54, 1538-1546.	3.6	49
276	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. <i>Hepatology Research</i> , 2011, 41, 217-224.	1.8	4
277	Efficacy of pegylated interferon λ -2a monotherapy in Japanese children with chronic hepatitis C. <i>Hepatology Research</i> , 2011, 41, 399-404.	1.8	7
278	Prediction of sustained response to low-dose pegylated interferon alpha 2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. <i>Hepatology Research</i> , 2011, 41, 1137-1144.	1.8	11
279	Favorable factors for retreatment with pegylated interferon λ -2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. <i>Hepatology Research</i> , 2011, 41, 1169-1177.	1.8	4
280	Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 712-721.	2.3	18
281	Interleukin 28B Polymorphisms and Hepatitis C “Translating the Association into Clinical Decision Making. <i>Journal of Clinical and Experimental Hepatology</i> , 2011, 1, 27-33.	0.4	4
282	Host-specific HCV evolution and response to the combined interferon and ribavirin therapy. , 2011, , .		0
283	HIV Infection and the Liver: The Importance of HCV-HIV Coinfection and Drug-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2011, 15, 131-152.	1.0	13
284	Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 212-223.	8.2	119

#	ARTICLE	IF	CITATIONS
285	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
287	Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S4015.	0.4	2
288	Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?. <i>Annals of Hepatology</i> , 2011, 10, 260-269.	0.6	1
289	Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011, 10, 452-457.	0.6	22
290	Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice. <i>Annals of Hepatology</i> , 2011, 10, 469-476.	0.6	19
292	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. <i>Annals of Hepatology</i> , 2011, 10, 445-451.	0.6	11
293	Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 997-1003.	0.8	17
295	Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. <i>Infection and Chemotherapy</i> , 2011, 43, 89.	1.0	13
296	Management of liver cirrhosis between primary care and specialists. <i>World Journal of Gastroenterology</i> , 2011, 17, 2273.	1.4	45
297	Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. <i>Patient Preference and Adherence</i> , 2011, 5, 587.	0.8	5
298	Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 225.	3.0	26
300	Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at) <i>Tj ETQq1 1 0.784314 rgBT₁₀ Overlook</i> 2011, 25, 503-510.	1.8	10
301	Inadequate awareness of hepatitis C among nonspecialist physicians in China. <i>Advances in Medical Education and Practice</i> , 2011, 2, 209.	0.7	12
302	IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection. <i>PLoS ONE</i> , 2011, 6, e18322.	1.1	75
303	Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon- α /ribavirin treatment for chronic hepatitis C. <i>Antiviral Therapy</i> , 2011, 16, 771-774.	0.6	0
304	Hepatitis C testing and treatment among active drug users in Amsterdam. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 23-31.	0.8	81
305	Unmet Needs Among People Reported With Hepatitis C, New York City. <i>Journal of Public Health Management and Practice</i> , 2011, 17, E9-E17.	0.7	6
306	IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. <i>Aids</i> , 2011, 25, 1025-1033.	1.0	41

#	ARTICLE	IF	CITATIONS
307	Diagnosis and Management of Hepatitis C Virusâ€“infected Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 983-985.	1.1	21
308	Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression. <i>Gastroenterology Nursing</i> , 2011, 34, 102-106.	0.2	5
309	Outcomes After Lung Transplantation and Practices of Lung Transplant Programs in the United States Regarding Hepatitis C Seropositive Recipients. <i>Transplantation</i> , 2011, 91, 1293-1296.	0.5	39
310	Management of HCV and HIV infections among people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 501-507.	1.5	68
311	Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. <i>Aids</i> , 2011, 25, F21-F27.	1.0	141
312	Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 711-715.	0.8	3
313	Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. <i>Aids</i> , 2011, 25, 1333-1336.	1.0	35
314	Ribavirin Plasma Concentration Measurements in Patients With Hepatitis C: Early Ribavirin Concentrations Predict Steady-State Concentrations. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 40-44.	1.0	25
315	Prevalence and risk factors of HCV infection in Poland. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1213-1217.	0.8	49
316	Magnetic Resonance Elastography and Biomarkers to Assess Fibrosis From Recurrent Hepatitis C in Liver Transplant Recipients. <i>Transplantation</i> , 2011, 92, 581-586.	0.5	57
317	Building a Departmental Quality Program: A Patient-Based and Provider-Led Approach. <i>Academic Medicine</i> , 2011, 86, 314-320.	0.8	11
318	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	0.9	2
320	Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). <i>Pharmacogenetics and Genomics</i> , 2011, 21, 851-860.	0.7	18
321	Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey. <i>Annals of Internal Medicine</i> , 2011, 154, 319.	2.0	142
322	The Vitamin D Receptor Gene Bat (Cca) Haplotype Impairs the Response to Pegylated-Interferon/Ribavirin-Based Therapy in Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2012, 17, 541-547.	0.6	29
323	Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2011, 16, 1187-1201.	0.6	30
324	Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2011, 155, 353.	2.0	53
325	Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. <i>Antiviral Therapy</i> , 2011, 16, 173-180.	0.6	1

#	ARTICLE	IF	CITATIONS
326	Partial Splenic Embolization Facilitates the Adherence to Peginterferon in Chronic Hepatitis C with Thrombocytopenia. <i>Internal Medicine</i> , 2011, 50, 2731-2736.	0.3	7
327	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	0.6	41
328	Efficacy of peginterferon- α 2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 469-476.	1.4	21
329	Treatment of hepatitis C virus infection in patients with end-stage renal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 228-239.	1.4	80
330	Hepatitis C virus: How genetic variability affects pathobiology of disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 83-95.	1.4	58
331	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian Patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, no-no.	1.4	34
332	Use of the AST to platelet ratio index in HCV/HIV infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 566-577.	1.9	30
333	IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1162-1172.	1.9	83
334	Meta-analysis: insulin resistance and sustained virological response in hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 297-305.	1.9	96
335	Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 454-461.	1.9	27
336	Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 443-453.	1.9	49
337	Liver stiffness diminishes with antiviral response in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 656-663.	1.9	113
338	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	1.9	111
339	UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. <i>Haemophilia</i> , 2011, 17, e877-83.	1.0	13
340	Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2011, 18, 393-399.	1.0	9
341	Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. <i>Journal of Viral Hepatitis</i> , 2011, 18, 474-481.	1.0	58
342	Quantification of hepatitis C virus in patients treated with peginterferon- α 2a plus ribavirin treatment by COBAS TaqMan HCV test. <i>Journal of Viral Hepatitis</i> , 2011, 18, e292-7.	1.0	19
343	Reproducibility of liver stiffness measurements in hepatitis C virus (HCV) infected patients in Egypt. <i>Journal of Viral Hepatitis</i> , 2011, 18, e358-65.	1.0	15

#	ARTICLE	IF	CITATIONS
344	Nonstructural protein 3: the Swiss army knife of hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2011, 18, 305-315.	1.0	129
345	Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment. <i>Liver International</i> , 2011, 31, 903-904.	1.9	0
346	Antioxidants as therapeutic agents for liver disease. <i>Liver International</i> , 2011, 31, 1432-1448.	1.9	179
347	Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2011, 24, 272-274.	0.7	13
348	Role of the nurse practitioner in the management of patients with chronic hepatitis C. <i>Journal of the American Academy of Nurse Practitioners</i> , 2011, 23, 410-420.	1.4	9
349	A siege of hepatitis: Fighting a defiant virus. <i>Nature Medicine</i> , 2011, 17, 253-254.	15.2	4
350	Hepatitis C " pipeline update. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 93-94.	21.5	28
351	Twenty-four mini-pool HCV RNA screening in a routine clinical virology laboratory setting: A six-year prospective study. <i>Journal of Virological Methods</i> , 2011, 171, 303-305.	1.0	2
352	Real-time polymerase chain reaction assay based on high-resolution melting analysis for the determination of the rs12979860 polymorphism involved in hepatitis C treatment response. <i>Journal of Virological Methods</i> , 2011, 175, 125-128.	1.0	8
353	Mechanism of HCV's resistance to IFN- α in cell culture involves expression of functional IFN- α receptor 1. <i>Virology Journal</i> , 2011, 8, 351.	1.4	15
354	Current Therapies for Chronic Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 92-111.	1.2	9
355	Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974.	1.2	8
356	Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2011, 31, 357-368.	1.2	11
357	Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: A meta-analysis of randomised trials. <i>Antiviral Research</i> , 2011, 89, 156-164.	1.9	17
358	HCV RNA decline in the first 24h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. <i>Antiviral Research</i> , 2011, 90, 92-97.	1.9	7
359	The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2011, 92, 247-254.	1.9	10
360	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	2.5	186
361	Discovery of a highly potent series of TLR7 agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5939-5943.	1.0	19

#	ARTICLE	IF	CITATIONS
362	Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 955-961.	0.6	35
363	Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. <i>Nature Biotechnology</i> , 2011, 29, 993-1003.	9.4	246
364	Non-Invasive Index for Predicting Significant Liver Fibrosis: Comparison of Diagnostic Performances in Patients with Chronic Hepatitis B and C. <i>Digestive Diseases and Sciences</i> , 2011, 56, 555-563.	1.1	12
365	Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 545-554.	1.1	70
366	Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1509-1515.	1.1	8
367	The Protease Inhibitor Era: An Opportunity to Improve the Quality of Care. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1252-1254.	1.1	0
368	Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2221-2226.	1.1	22
369	Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2449-2455.	1.1	28
370	High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. <i>Journal of Gastroenterology</i> , 2011, 46, 501-509.	2.3	10
371	Dendritic cells in hepatitis C infection: can they (help) win the battle?. <i>Journal of Gastroenterology</i> , 2011, 46, 432-447.	2.3	23
372	The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. <i>Journal of Gastroenterology</i> , 2011, 46, 944-952.	2.3	18
373	Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. <i>Journal of Gastroenterology</i> , 2011, 46, 1031-1037.	2.3	13
374	Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. <i>Journal of Gastroenterology</i> , 2011, 46, 1335-1343.	2.3	9
375	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 291-303.	1.0	119
376	Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. <i>Infection</i> , 2011, 39, 433-437.	2.3	1
377	Vertical transmission of hepatitis C virus in low to middle socio-economic pregnant population of Karachi. <i>Hepatology International</i> , 2011, 5, 677-680.	1.9	13
378	Non-invasive assessment of liver fibrosis in chronic hepatitis C. <i>Hepatology International</i> , 2011, 5, 625-634.	1.9	72
379	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. <i>Hepatology International</i> , 2011, 5, 789-799.	1.9	10

#	ARTICLE	IF	CITATIONS
380	Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. <i>Hepatology International</i> , 2011, 5, 985-990.	1.9	2
381	^{99m} Tc-GSA SPECT analysis was clinically useful to evaluate the effect of interferon in a patient with interferon non-responsive chronic hepatitis C. <i>Annals of Nuclear Medicine</i> , 2011, 25, 520-523.	1.2	1
383	News from the CDC: Translating science into HCV infection screening recommendations. <i>Translational Behavioral Medicine</i> , 2011, 1, 509-510.	1.2	0
384	IL28B Polymorphisms and Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2011, 10, 70-78.	0.3	0
385	HCV Eradication: Implications for Disease Resolution. <i>Current Hepatitis Reports</i> , 2011, 10, 27-32.	0.3	0
386	Management of Hepatitis C Antiviral Therapy Adverse Effects. <i>Current Hepatitis Reports</i> , 2011, 10, 33-40.	0.3	31
387	Ribavirin: How Does it Work and is it Still Needed?. <i>Current Hepatitis Reports</i> , 2011, 10, 168-178.	0.3	8
388	Patient acceptance of universal screening for hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2011, 11, 160.	1.3	14
389	Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. <i>BMC Infectious Diseases</i> , 2011, 11, 315.	1.3	18
390	Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. <i>BMC Endocrine Disorders</i> , 2011, 11, 10.	0.9	4
391	Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. <i>Retrovirology</i> , 2011, 8, 75.	0.9	20
392	Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2011, 83, 101-107.	2.5	1
393	Hepatitis C virus sequences from different patients confirm the existence and transmissibility of subtype 2q, a rare subtype circulating in the metropolitan area of Barcelona, Spain. <i>Journal of Medical Virology</i> , 2011, 83, 820-826.	2.5	10
394	Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2011, 83, 1203-1211.	2.5	6
395	Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. <i>Journal of Medical Virology</i> , 2011, 83, 1559-1564.	2.5	1
396	Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. <i>Hepatology</i> , 2011, 53, 42-52.	3.6	49
397	Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. <i>Hepatology</i> , 2011, 53, 1436-1445.	3.6	30
398	The importance of the definition of early virological response for predicting treatment efficacy for chronic hepatitis C. <i>Hepatology</i> , 2011, 53, 1403-1403.	3.6	2

#	ARTICLE	IF	CITATIONS
399	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108.	3.6	55
400	Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 60-69.	3.6	166
401	Racial differences in hepatitis C treatment eligibility. <i>Hepatology</i> , 2011, 54, 70-78.	3.6	47
402	A glimpse at the future of hepatitis C therapy: The INFORM trial. <i>Hepatology</i> , 2011, 54, 360-363.	3.6	2
403	Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?. <i>Hepatology</i> , 2011, 54, 1454-1462.	3.6	48
404	Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. <i>Hepatology</i> , 2011, 54, 1547-1558.	3.6	54
405	Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. <i>Hepatology</i> , 2011, 54, 1956-1965.	3.6	171
406	Drug therapy: Telaprevir. <i>Hepatology</i> , 2011, 54, 1463-1469.	3.6	6
407	Boceprevir. <i>Hepatology</i> , 2011, 54, 2254-2258.	3.6	7
408	Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials. <i>International Journal of Cancer</i> , 2011, 129, 1254-1264.	2.3	46
409	Diagnosis of hepatitis C virus infection by enzyme-linked immunosorbent assay and reverse transcriptase-nested polymerase chain reaction: A comparative evaluation. <i>IUBMB Life</i> , 2011, 63, 430-434.	1.5	15
410	Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): Central amino acid linker and right-hand-side SAR studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3664-3670.	1.0	10
411	Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. <i>Infection, Genetics and Evolution</i> , 2011, 11, 382-390.	1.0	8
412	Interferon combination therapy for HIV/hepatitis C virus coinfection. <i>Immunotherapy</i> , 2011, 3, 1087-1102.	1.0	1
413	Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006-2009): A retrospective cohort study. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 145-148.	1.5	20
414	Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. <i>Rheumatology</i> , 2011, 50, 1700-1711.	0.9	127
415	Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 529-544.	1.0	15
416	Multilectin Assay for Detecting Fibrosis-Specific Glyco-Alteration by Means of Lectin Microarray. <i>Clinical Chemistry</i> , 2011, 57, 48-56.	1.5	68

#	ARTICLE	IF	CITATIONS
417	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011, 105, 982-989.	1.2	10
418	Chromatin Dynamics of Gene Activation and Repression in Response to Interferon $\hat{\pm}$ (IFN $\hat{\pm}$) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2. <i>Journal of Biological Chemistry</i> , 2011, 286, 20217-20227.	1.6	51
419	CXCL9 and CXCL10 Chemokines as Predictors of Liver Fibrosis in a Cohort of Primarily African-American Injection Drug Users With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2011, 204, 832-836.	1.9	48
420	A Review of Commonly Prescribed Antiviral and Antiretroviral Agents. <i>Journal of Pharmacy Technology</i> , 2011, 27, 99-110.	0.5	0
421	Successful clearance of hepatitis C virus with pegylated interferon $\hat{\text{A}}$ -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1343-1344.	0.5	11
422	Oral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver Cirrhosis. <i>Digestive Diseases</i> , 2011, 29, 326-332.	0.8	57
423	Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. <i>Clinical Infectious Diseases</i> , 2011, 52, 889-900.	2.9	225
424	Hepatitis C "Removing Barriers to Diagnosing the "Silent Epidemic". <i>Clinical Chemistry</i> , 2011, 57, 939-940.	1.5	1
425	Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 294-301.	3.8	41
426	Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3309-3315.	1.8	30
427	Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy. <i>Journal of Virology</i> , 2011, 85, 3649-3663.	1.5	20
428	Noninvasive Monitoring of Hepatic Damage from Hepatitis C Virus Infection. <i>Computational and Mathematical Methods in Medicine</i> , 2011, 2011, 1-13.	0.7	0
429	FATE OF PATIENTS WITH LATE-DETECTED HEPATITIS C INFECTION - CASE REPORTS. <i>Acta Medica Medianae</i> , 2011, , 49-52.	0.0	0
430	Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy. <i>Journal of the International Association of Providers of AIDS Care</i> , 2011, 10, 183-186.	1.2	11
431	Treatment of Hepatitis C-Mediated Glomerular Disease. <i>Nephron Clinical Practice</i> , 2011, 119, c121-c130.	2.3	15
432	Safety and Efficacy of Combination Therapy with Pegylated Interferon Alpha-2a and Ribavirin in Treating Patients with Chronic Hepatitis C and Beta-Thalassaemia Major: A Greek Single-Center Experience. <i>Acta Haematologica</i> , 2011, 126, 231-233.	0.7	8
433	Rapid Multiplexed Immunoassay for Simultaneous Serodiagnosis of HIV-1 and Coinfections. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3584-3590.	1.8	47
434	Gamma-glutamyl transpeptidase and $\hat{\pm}$ -fetoprotein. <i>Egyptian Liver Journal</i> , 2011, 1, 18-24.	0.3	5

#	ARTICLE	IF	CITATIONS
435	Case 10-2011: Fever, Confusion, and Liver Failure. <i>New England Journal of Medicine</i> , 2011, 365, 185-187.	13.9	0
436	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1351-1353.	1.3	10
437	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 13-32.	1.4	23
438	Evidence-based clinical guidelines for immigrants and refugees. <i>Cmaj</i> , 2011, 183, E824-E925.	0.9	373
439	Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. <i>BMJ Open</i> , 2011, 1, e000140-e000140.	0.8	10
440	Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3040-3043.	1.8	29
441	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	3.3	56
442	Host-Based Ribavirin Resistance Influences Hepatitis C Virus Replication and Treatment Response. <i>Journal of Virology</i> , 2011, 85, 7273-7283.	1.5	14
443	A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 1255-1263.	0.2	87
444	Impact of HCV genetic differences on pathobiology of disease. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 747-759.	2.0	34
445	Quality of Care for Gastrointestinal Conditions: A Primer for Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2011, 106, 1182-1187.	0.2	22
446	Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114.	2.0	12
447	BISTABILITY AND LONG-TERM CURE IN A WITHIN-HOST MODEL OF HEPATITIS C. <i>Journal of Biological Systems</i> , 2011, 19, 533-550.	0.5	19
448	High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2011, 204, 1730-1740.	1.9	51
449	Concurrent autoimmune hepatitis and graveâ€™s disease in Hepatitis C during pegylated Interferon Î±-2a and ribavirin therapy. <i>Saudi Journal of Gastroenterology</i> , 2011, 17, 348.	0.5	3
450	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. <i>Gut</i> , 2011, 60, 108-115.	6.1	30
451	Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy. <i>PLoS Computational Biology</i> , 2011, 7, e1001072.	1.5	30
452	Treatment of HCV Patients Before and After Renal Transplantation. <i>Hepatitis Monthly</i> , 2011, 11, 880-886.	0.1	6

#	ARTICLE	IF	CITATIONS
453	The Evaluation of Hepatitis C Virus Core Antigen in Immunized Balb/C Mice. <i>Hepatitis Monthly</i> , 2012, 12, 391-397.	0.1	2
454	Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. <i>Hepatitis Monthly</i> , 2012, 12, 77-84.	0.1	14
455	It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274.	2.9	6
456	Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8.	3.8	180
457	Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
458	Interferon Alpha Concentrations in Blood and Peritoneal Fluid during Treatment for Hepatitis C. <i>Peritoneal Dialysis International</i> , 2012, 32, 664-666.	1.1	3
459	Boceprevir and personalized medicine in hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, Volume 5, 125-137.	0.4	4
460	Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin's Lymphoma. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 58-61.	0.1	1
461	Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. <i>Bulletin of the World Health Organization</i> , 2012, 90, 540-550.	1.5	56
462	Thyroid Dysfunction in Chinese Patients with Chronic Hepatitis C Treated with Interferon Alpha: Incidence, Long-Term Outcome and Predictive Factors. <i>Hepatitis Monthly</i> , 2012, 12, e6390.	0.1	15
463	Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital. <i>Hepatitis Monthly</i> , 2012, 12, e6178.	0.1	10
464	The p7 Protein of Hepatitis C Virus Forms Structurally Plastic, Minimalist Ion Channels. <i>PLoS Computational Biology</i> , 2012, 8, e1002702.	1.5	60
465	Treatment Response and Tolerability of Pegylated Interferon- α Plus Ribavirin Combination Therapy in elderly Patients (\geq 65 years) With Chronic Hepatitis C in Korea. <i>Hepatitis Monthly</i> , 2012, 12, 430-436.	0.1	12
466	Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
467	Accuracy of Routine Clinical Ultrasound for Staging of Liver Fibrosis. <i>Journal of Clinical Imaging Science</i> , 2012, 2, 58.	0.4	54
468	Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	55
469	Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	0.7	2
470	SHORTENED PEGINTERFERON AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 398-406.	0.2	3

#	ARTICLE	IF	CITATIONS
471	Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274.	3.8	134
472	Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel <i>In Vitro</i> Pharmacodynamic System. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1170-1181.	1.4	12
473	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.	2.0	176
474	Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Patients. <i>Journal of Addiction Medicine</i> , 2012, 6, 179-185.	1.4	9
475	The vasculitic neuropathies. <i>Current Opinion in Neurology</i> , 2012, 25, 573-585.	1.8	52
476	HIV and viral hepatitis C coinfection in people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 339-344.	1.5	20
477	Long-term follow-up of responder and super-responder chronic hepatitis C Egyptian patients treated with interferon α -2a plus ribavirin. <i>Egyptian Liver Journal</i> , 2012, 2, 103-107.	0.3	0
478	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 722-728.	1.0	31
479	Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. <i>Gut</i> , 2012, 61, 128-134.	6.1	76
480	Role for TBC1D20 and Rab1 in Hepatitis C Virus Replication via Interaction with Lipid Droplet-Bound Nonstructural Protein 5A. <i>Journal of Virology</i> , 2012, 86, 6491-6502.	1.5	51
481	Analysis of the RNA chaperoning activity of the hepatitis C virus core protein on the conserved 3'X region of the viral genome. <i>Nucleic Acids Research</i> , 2012, 40, 2540-2553.	6.5	21
482	Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 640-646.	0.4	45
483	Chronic Viral and Autoimmune Hepatitis. , 2012, , 973-979.		2
484	Retreatment with Peginterferon α -2a + Ribavirin in Patients Who Failed Previous Peginterferon α -2b + Ribavirin Combination Therapy. <i>Digestive Diseases</i> , 2012, 30, 554-560.	0.8	2
485	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. <i>Gut</i> , 2012, 61, 1076-1084.	6.1	51
486	Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 2135-2139.	0.5	4
487	Epidemiology, Responses, and Way Forward. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 311-320.	1.2	20
488	The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV. <i>HIV Clinical Trials</i> , 2012, 13, 33-45.	2.0	9

#	ARTICLE	IF	CITATIONS
489	Assessment of the Quality of Evidence Underlying International Guidelines in Liver Disease. American Journal of Gastroenterology, 2012, 107, 1276-1282.	0.2	17
490	Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. Clinical Infectious Diseases, 2012, 55, 1047-1055.	2.9	154
492	Appropriateness of Hepatitis A Vaccination in Patients With Hepatitis C. American Journal of Gastroenterology, 2012, 107, 485.	0.2	1
493	The Performance of Process Measures in Hepatitis C. American Journal of Gastroenterology, 2012, 107, 1512-1521.	0.2	17
494	Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein. Journal of Virology, 2012, 86, 12686-12694.	1.5	29
495	Performance of Real-Time Strain Elastography, Transient Elastography, and Aspartate-to-Platelet Ratio Index in the Assessment of Fibrosis in Chronic Hepatitis C. American Journal of Roentgenology, 2012, 199, 19-25.	1.0	53
496	Role of Signal-to-Cutoff Ratios in Hepatitis C Virus Antibody Detection. Vaccine Journal, 2012, 19, 1329-1331.	3.2	20
497	The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells. Antimicrobial Agents and Chemotherapy, 2012, 56, 903-908.	1.4	7
498	Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clinical Chemistry and Laboratory Medicine, 2012, 50, 693-9.	1.4	28
499	Hepatitis C Clinic Operated by Infectious Disease Specialists at a Comprehensive Cancer Center: Help Is on the Way. Clinical Infectious Diseases, 2012, 54, 740-742.	2.9	9
500	Successful Treatment of HCV/HBV/HDV-Coinfection with Pegylated Interferon and Ribavirin. Clinics and Practice, 2012, 2, 157-169.	0.6	2
501	SASLT practice guidelines: Management of hepatitis C virus infection. Saudi Journal of Gastroenterology, 2012, 18, 1.	0.5	8
502	Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis. Scientifica, 2012, 2012, 1-22.	0.6	5
503	Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C. Clinical and Developmental Immunology, 2012, 2012, 1-15.	3.3	5
504	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. Hepatitis Research and Treatment, 2012, 2012, 1-21.	2.0	4
505	Health-Related Quality of Life in Chinese Patients with Chronic Liver Disease. Gastroenterology Research and Practice, 2012, 2012, 1-7.	0.7	19
506	Hepatitis C and substance use. Current Opinion in Psychiatry, 2012, 25, 206-212.	3.1	6
507	Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
508	The Impact of Host Factors on Management of Hepatitis C Virus. <i>Hepatitis Monthly</i> , 2012, 12, 235-241.	0.1	3
509	Performance of the Abbott RealTime and Roche Cobas TaqMan Hepatitis C Virus (HCV) Assays for Quantification of HCV Genotypes. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1769-1772.	1.8	19
510	Individualized Therapy for Chronic Hepatitis C. , 2012, , 373-394.		0
511	Hepatitis C and Hepatocellular Carcinoma: Implications for Pathogenesis and Treatment. , 2012, , 143-203.		0
512	Prevalence of Fibromyalgia Among Patients With Chronic Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 407-412.	1.1	33
513	Differences in Virological Response to Peginterferon- α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123.	0.9	12
514	Improving Access to Hepatitis C Care for Urban, Underserved Patients Using a Primary Care-Based Hepatitis C Clinic. <i>Journal of the National Medical Association</i> , 2012, 104, 244-250.	0.6	17
515	Efeitos colaterais do tratamento da hepatite C no polo aplicador do ABC. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 543-549.	0.3	1
516	The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S6792.	0.4	0
517	Alisporivir for the treatment of chronic HCV. <i>Future Virology</i> , 2012, 7, 9-18.	0.9	1
518	Insulin Resistance Impairs Viral Dynamics Independently of Ethnicity or Genotypes. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 228-234.	1.1	10
519	Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care Setting. <i>American Journal of Public Health</i> , 2012, 102, e115-e121.	1.5	39
520	NASPGHAN Practice Guidelines. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 838-855.	0.9	176
521	Hepatitis C virus infection in alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1178-1184.	0.8	48
522	Acute on Chronic Liver Disease in Children From the Developing World. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 77-82.	0.9	63
523	An Elevated Arterial Enhancement Fraction Is Associated With Clinical and Imaging Indices of Liver Fibrosis and Cirrhosis. <i>Journal of Computer Assisted Tomography</i> , 2012, 36, 681-689.	0.5	14
525	Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860. <i>Transplantation</i> , 2012, 94, 275-280.	0.5	21
526	IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 817-823.	0.8	4

#	ARTICLE	IF	CITATIONS
527	Twelve-Week Posttreatment Follow-Up to Predict Sustained Virologic Response for Recurrent Hepatitis C Infection in Liver Recipients. <i>Transplantation</i> , 2012, 93, 450-453.	0.5	6
528	Association of Serum Adipocytokines With Insulin Resistance and Liver Injury in Patients With Chronic Hepatitis C Genotype 4. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 871-879.	1.1	8
529	Comparison of Current US Risk Strategy to Screen for Hepatitis C Virus With a Hypothetical Targeted Birth Cohort Strategy. <i>American Journal of Public Health</i> , 2012, 102, e101-e106.	1.5	17
530	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	0.6	23
531	Prevention and Treatment of Cancer-Related Infections. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1412-1445.	2.3	169
532	Prevalence and Characteristics of Herpes Simplex Virus Type-2 Coinfection in Veterans With Hepatitis C. <i>American Journal of the Medical Sciences</i> , 2012, 344, 436-440.	0.4	5
533	Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. <i>International Journal of Circumpolar Health</i> , 2012, 71, 18445.	0.5	10
534	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012, 26, 1009-1015.	1.0	12
535	Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial. <i>HIV Clinical Trials</i> , 2012, 13, 142-152.	2.0	66
536	Telaprevir for retreatment of HCV infection: review of the REALIZE trial. <i>Future Virology</i> , 2012, 7, 435-440.	0.9	0
537	The H63D Mutation of the Hemochromatosis Gene is Associated with Sustained Virological Response in Chronic Hepatitis C Patients Treated with Interferon-Based Therapy: A Meta-Analysis. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 226, 293-299.	0.5	7
539	The cryoglobulinaemias. <i>Lancet, The</i> , 2012, 379, 348-360.	6.3	460
541	Diagnostic Performances of Hepatitis C Virus-NS4 Antigen in Patients with Different Liver Pathologies. <i>Archives of Medical Research</i> , 2012, 43, 555-562.	1.5	6
542	Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes. <i>Molecular Therapy</i> , 2012, 20, 1724-1736.	3.7	66
543	Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. <i>Journal of Viral Hepatitis</i> , 2012, 19, 623-634.	1.0	9
544	SCCA serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study. <i>Journal of Viral Hepatitis</i> , 2012, 19, 704-710.	1.0	11
545	HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon- α and ribavirin. <i>Tissue Antigens</i> , 2012, 80, 424-430.	1.0	2
546	Evaluation of Two Hepatitis C Virus Genotyping Assays Based on the 5' Untranslated Region (UTR): the Limitations of 5' UTR-Based Assays and the Need for a Supplementary Sequencing-Based Approach. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3741-3743.	1.8	13

#	ARTICLE	IF	CITATIONS
547	Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon- α . <i>Renal Failure</i> , 2012, 34, 429-434.	0.8	9
548	Virology of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 381-389.	1.0	10
549	Prediction of response to pegylated-interferon- α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. <i>Virology Journal</i> , 2012, 9, 123.	1.4	17
550	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	1.9	31
551	Fueling fibrosis in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14293-14294.	3.3	16
552	Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 2245-2256.	2.5	12
553	Pegylated interferon α 2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. <i>Hepatology Research</i> , 2012, 42, 33-41.	1.8	5
554	Back from the Future: Treating Hepatitis C Virus with Conventional Interferon. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 3-6.	0.4	0
555	Peginterferon alpha α 2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1705-1710.	1.4	0
556	Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Infection. <i>AAPS Journal</i> , 2012, 14, 571-580.	2.2	18
557	Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa α 2a/ribavirin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 766-774.	1.0	14
558	Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. <i>Hepatology</i> , 2012, 56, 1651-1660.	3.6	98
559	Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 1641-1650.	3.6	60
560	Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. <i>Hepatology</i> , 2012, 56, 2398-2403.	3.6	31
561	A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2012, 84, 1913-1919.	2.5	6
562	New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India. <i>Archives of Virology</i> , 2012, 157, 2083-2093.	0.9	30
563	Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naïve hepatitis C genotype 1 patients. <i>International Journal of Infectious Diseases</i> , 2012, 16, e748-e752.	1.5	3
564	Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: A case control study. <i>Journal of Psychosomatic Research</i> , 2012, 73, 218-224.	1.2	28

#	ARTICLE	IF	CITATIONS
565	Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 424-432.	1.5	57
566	Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14.	1.1	76
567	Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. <i>Journal of Hepatology</i> , 2012, 57, 1379-1390.	1.8	194
568	The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 879-891.	1.9	0
569	Efeitos colaterais do tratamento da hepatite C no polo aplicador do ABC. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 543-549.	0.3	9
570	Liver Biopsy Has a Low Diagnostic Performance for Intermediate Stages of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1420-1421.	2.4	0
571	Hepatoprotective and Free Radical Scavenging Activities of Extracts and a Major Compound Isolated from the Leaves of <i>Cineraria abyssinica</i> Sch. Bip. ex A. Rich.. <i>Pharmacognosy Journal</i> , 2012, 4, 40-46.	0.3	13
573	Real-time elastography as a noninvasive technique for quantification of fibrosis in patients with chronic viral liver disease: Preliminary findings. <i>Journal of Ultrasound</i> , 2012, 15, 220-225.	0.7	7
574	Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1270-1277.e3.	2.4	16
575	TGF- β 2 Blockade Does Not Improve Control of an Established Persistent Viral Infection. <i>Viral Immunology</i> , 2012, 25, 120523091504003.	0.6	26
576	An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.	1.6	42
577	Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 901-909.	1.0	4
578	An electrochemical approach for direct detection and discrimination of fully match and single base mismatch double-stranded oligonucleotides corresponding to universal region of hepatitis C virus. <i>Analytical Methods</i> , 2012, 4, 967.	1.3	15
579	Kinetics of hepatitis C virus load and hemodialysis: Is there any influence of the reuse of dialysis membrane on HCV viremia?. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 190-196.	1.5	3
580	Care of the Cirrhotic Patient. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 979-994.	1.9	5
581	Surgical Clearance for the Patient with Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, 421-433.	1.0	7
582	Staging of Liver Disease. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 849-861.	1.9	4
583	Chapter 9: Infection-related glomerulonephritis. <i>Kidney International Supplements</i> , 2012, 2, 200-208.	4.6	26

#	ARTICLE	IF	CITATIONS
584	Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. <i>New England Journal of Medicine</i> , 2012, 366, 216-224.	13.9	580
585	Liver Protein Profiling in Chronic Hepatitis C: Identification of Potential Predictive Markers for Interferon Therapy Outcome. <i>Journal of Proteome Research</i> , 2012, 11, 717-727.	1.8	17
586	Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2012, 54, 1259-1271.	2.9	95
587	Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. <i>Liver International</i> , 2012, 32, 826-836.	1.9	33
588	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. <i>Liver International</i> , 2012, 32, 937-944.	1.9	29
589	Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.	1.9	27
590	Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. <i>Liver International</i> , 2012, 32, 1270-1277.	1.9	10
591	Peripheral blood cytopenia before treatment in HCV patients: is it a limitation for HCV treatment in the era of DAA?. <i>Liver International</i> , 2012, 32, 1033-1036.	1.9	2
592	Hepatitis C and Renal Disease: Epidemiology, Diagnosis, Pathogenesis and Therapy. <i>Contributions To Nephrology</i> , 2012, 176, 10-23.	1.1	43
593	Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5387-5396.	1.4	173
594	Basic answers to complicated questions for the course of chronic hepatitis C treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 371-382.	1.4	3
595	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2012, 56, 34-40.	1.8	77
596	A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. <i>Journal of Hepatology</i> , 2012, 56, 334-340.	1.8	34
597	Gaps in the achievement of effectiveness of HCV treatment in national VA practice. <i>Journal of Hepatology</i> , 2012, 56, 320-325.	1.8	86
598	Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Journal of Hepatology</i> , 2012, 56, 1276-1282.	1.8	21
599	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012, 56, 1247-1253.	1.8	98
600	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. <i>Journal of Hepatology</i> , 2012, 56, 1230-1238.	1.8	19
601	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. <i>Journal of Hepatology</i> , 2012, 57, 260-266.	1.8	22

#	ARTICLE	IF	CITATIONS
602	National patterns and predictors of liver biopsy use for management of hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 252-259.	1.8	7
603	Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. <i>Journal of Hepatology</i> , 2012, 57, 534-540.	1.8	37
604	Preventive versus "on-demand" nutritional support during antiviral treatment for hepatitis C: A randomized controlled trial. <i>Journal of Hepatology</i> , 2012, 57, 1069-1075.	1.8	10
605	Assessing Candidacy for Acute Hepatitis C Treatment Among Active Young Injection Drug Users: A Case-Series Report. <i>Journal of the Association of Nurses in AIDS Care</i> , 2012, 23, 16-29.	0.4	3
606	Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study. <i>Journal of Clinical Virology</i> , 2012, 54, 218-222.	1.6	11
607	Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4431-4436.	1.0	15
608	The association between alcohol use and hepatitis C status among injecting drug users in Glasgow. <i>Drug and Alcohol Dependence</i> , 2012, 123, 180-189.	1.6	6
611	NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection. <i>Hepatology</i> , 2012, 56, 797-799.	3.6	7
612	LecT-hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 2012, 56, 1448-1456.	3.6	35
613	Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. <i>Hepatology</i> , 2012, 56, 1699-1705.	3.6	14
614	High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050.	3.6	92
615	Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study. <i>Hepatology</i> , 2012, 56, 2125-2133.	3.6	563
616	Hepatitis C virus: The role of molecular mimicry in response to interferon treatment. <i>Journal of Medical Virology</i> , 2012, 84, 1571-1585.	2.5	2
617	Hepatitis C virus infection of human cytotrophoblasts cultured in vitro. <i>Journal of Medical Virology</i> , 2012, 84, 1586-1592.	2.5	26
618	The high comorbidity burden of the hepatitis C virus infected population in the United States. <i>BMC Infectious Diseases</i> , 2012, 12, 86.	1.3	70
619	Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. <i>Virology Journal</i> , 2012, 9, 143.	1.4	45
620	Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C Virus in the United States, 1999-2008. <i>BMC Research Notes</i> , 2012, 5, 142.	0.6	10
621	Diagnosis and Treatment of Acute Hepatitis C Virus Infection. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 995-1010.	1.9	16

#	ARTICLE	IF	CITATIONS
622	Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. <i>Journal of Viral Hepatitis</i> , 2012, 19, 784-791.	1.0	9
623	IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. <i>PLoS ONE</i> , 2012, 7, e37054.	1.1	85
624	Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review. <i>Hepatology Research</i> , 2012, 42, 1248-1251.	1.8	9
625	Telaprevir. <i>Drugs</i> , 2012, 72, 619-641.	4.9	40
626	Boceprevir. <i>Drugs</i> , 2012, 72, 2431-2456.	4.9	17
627	Laboratory Diagnostics for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2012, 55, S43-S48.	2.9	135
628	New Pharmacotherapy for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 294-305.	2.3	24
629	Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. <i>The Cochrane Library</i> , 2012, , CD008516.	1.5	8
630	Complete Definition of Immunological Correlates of Protection and Clearance of Hepatitis C Virus Infection: A Relevant Pending Task for Vaccine Development. <i>International Reviews of Immunology</i> , 2012, 31, 223-242.	1.5	11
631	Telaprevir: An oral protease inhibitor for hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 19-33.	0.5	18
632	Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. <i>American Journal of Gastroenterology</i> , 2012, 107, 669-689.	0.2	84
633	The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 112-115.	0.4	11
634	Answers to Multiple Choice Questions. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 200-205.	0.4	0
635	Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. <i>Gastroenterology</i> , 2012, 142, 1293-1302.e4.	0.6	533
636	New Virologic Tools for Management of Chronic Hepatitis B and C. <i>Gastroenterology</i> , 2012, 142, 1303-1313.e1.	0.6	109
637	Hepatobiliary Quiz-3 (2012). <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 295-296.	0.4	0
638	Hepatobiliary Quiz-3 (2012). <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 297-302.	0.4	0
639	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.	1.0	14

#	ARTICLE	IF	CITATIONS
640	Public health issues of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 371-380.	1.0	30
641	Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 429-444.	1.0	13
642	Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. <i>Digestive and Liver Disease</i> , 2012, 44, 419-425.	0.4	10
643	Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. <i>Digestive and Liver Disease</i> , 2012, 44, 497-503.	0.4	72
644	Liver stiffness measurement in cirrhotic patient – Implications of disease activity and treatment efficacy. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 641-648.	0.8	0
646	Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup. <i>Hepatitis Monthly</i> , 2012, 12, e6718.	0.1	30
647	Viral Hepatitis in India. <i>Clinics in Laboratory Medicine</i> , 2012, 32, 159-174.	0.7	41
648	Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 156-166.	12.5	148
649	Telaprevir and Boceprevir: The Future Is Now. <i>Current Hepatitis Reports</i> , 2012, 11, 160-171.	0.3	2
650	Hepatitis C Therapy: Lessons of the Last Two Decades. <i>Current Hepatitis Reports</i> , 2012, 11, 119-127.	0.3	1
651	Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 657-663.e7.	2.4	97
652	Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010. <i>Brazilian Journal of Infectious Diseases</i> , 2012, 16, 448-451.	0.3	4
653	Case definitions for acute hepatitis C virus infection: A systematic review. <i>Journal of Hepatology</i> , 2012, 57, 1349-1360.	1.8	46
654	Pre-treatment waking cortisol response and vulnerability to interferon α induced depression. <i>European Neuropsychopharmacology</i> , 2012, 22, 892-896.	0.3	8
655	Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 619-621.	2.0	9
656	Why Should Infectious Disease Physicians Care for the Hepatitis C-Infected Patient?. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 839-847.	1.9	1
657	Treating HCV Prior to Liver Transplantation. , 2012, , 301-312.		0
658	Treatment of Hepatitis C in Dialysis Patients. <i>Contributions To Nephrology</i> , 2012, 176, 54-65.	1.1	8

#	ARTICLE	IF	CITATIONS
659	Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 761-765.	1.5	6
660	Viral Hepatitis in the Elderly. <i>American Journal of Gastroenterology</i> , 2012, 107, 691-697.	0.2	40
661	Efficacy of pegylated interferon α -2a and α -2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. <i>BMC Infectious Diseases</i> , 2012, 12, 357.	1.3	45
662	Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. <i>BMC Infectious Diseases</i> , 2012, 12, 324.	1.3	7
663	Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN- α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients. <i>PLoS ONE</i> , 2012, 7, e28115.	1.1	6
664	Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam. <i>PLoS ONE</i> , 2012, 7, e34548.	1.1	39
665	VAPC, an Human Endogenous Inhibitor for Hepatitis C Virus (HCV) Infection, Is Intrinsically Unstructured but Forms a "Fuzzy Complex" with HCV NS5B. <i>PLoS ONE</i> , 2012, 7, e40341.	1.1	12
666	Liver Stiffness Using Transient Elastography is Applicable to Canines for Hepatic Disease Models. <i>PLoS ONE</i> , 2012, 7, e41557.	1.1	7
667	Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e45698.	1.1	24
668	None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis. <i>PLoS ONE</i> , 2012, 7, e48217.	1.1	3
669	Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. <i>PLoS ONE</i> , 2012, 7, e48959.	1.1	2
670	Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, child's status and institution of specific treatment for hepatitis C with success. <i>Annals of Hepatology</i> , 2012, 11, 921-929.	0.6	26
671	Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients (). <i>Annals of Hepatology</i> , 2012, 11, 15-31.	0.6	37
673	Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study. <i>Annals of Hepatology</i> , 2012, 11, 338-342.	0.6	9
674	Does the persistently normal aminotransferase levels in hepatitis C still have relevance?. <i>Annals of Hepatology</i> , 2012, 11, 412-414.	0.6	2
675	IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. <i>Annals of Hepatology</i> , 2012, 11, 876-881.	0.6	17
676	Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin \pm amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. <i>Annals of Hepatology</i> , 2012, 11, 52-61.	0.6	2
677	Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance. <i>Antiviral Therapy</i> , 2012, 17, 1471-1475.	0.6	7

#	ARTICLE	IF	CITATIONS
678	Hepatitis in the Elderly: Still a Scourge. <i>The Consultant Pharmacist</i> , 2012, 27, 472-481.	0.4	2
679	Hepatitis C among Clients of Health Care for the Homeless Primary Care Clinics. <i>Journal of Health Care for the Poor and Underserved</i> , 2012, 23, 811-833.	0.4	48
680	Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. <i>Patient Preference and Adherence</i> , 2012, 6, 285.	0.8	17
681	Initial implementation and evaluation of a Hepatitis C treatment clinical decision support system (CDSS). <i>Applied Clinical Informatics</i> , 2012, 03, 337-348.	0.8	10
682	Evaluation of Drug Toxicity for DNA Vaccine Candidates Against Infectious Diseases: Hepatitis C as Experimental Model. , 0, , .		0
684	Assessment of the treatment of chronic hepatitis C in the state of Mato Grosso, central Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 217-223.	0.8	5
685	A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 888-892.	0.8	16
686	New agents for the treatment of hepatitis C virus – focus on telaprevir. <i>Virus Adaptation and Treatment</i> , 0, , 75.	1.5	1
687	Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. <i>BMC Gastroenterology</i> , 2012, 12, 7.	0.8	18
688	Treatment and follow up of children with chronic hepatitis C in Albania. <i>Virology Journal</i> , 2012, 9, 17.	1.4	3
689	Boceprevir: A Novel <sc>NS</sc>3/4 Protease Inhibitor for the Treatment of Hepatitis <sc>C</sc>. <i>Pharmacotherapy</i> , 2012, 32, 173-190.	1.2	18
690	<sc>SRM</sc> targeted proteomics in search for biomarkers of <sc>HCV</sc>â€induced progression of fibrosis to cirrhosis in <sc>HALT</sc>â€<sc>C</sc> patients. <i>Proteomics</i> , 2012, 12, 1244-1252.	1.3	30
691	Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3670-3681.	1.4	103
692	Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 360-368.	1.9	8
693	Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. <i>Journal of Gastroenterology</i> , 2012, 47, 596-605.	2.3	33
694	Interâ€genotypic recombinant hepatitis C virus strains in Japan noted by discrepancies between immunoassay and sequencing. <i>Journal of Medical Virology</i> , 2012, 84, 1018-1024.	2.5	15
695	Hepatitis C and Renal Transplantation. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 342-350.	1.9	4
696	Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. <i>Hepatology</i> , 2012, 55, 1048-1057.	3.6	62

#	ARTICLE	IF	CITATIONS
697	Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. <i>Hepatology</i> , 2012, 55, 1684-1691.	3.6	63
698	Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. <i>Hepatology</i> , 2012, 56, 239-247.	3.6	219
699	Pegylated interferon- α induced hypoferrremia is associated with the immediate response to treatment in hepatitis C. <i>Hepatology</i> , 2012, 56, 492-500.	3.6	48
700	Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation. <i>Hepatology</i> , 2012, 56, 501-506.	3.6	10
701	Management of rheumatic disease with comorbid HBV or HCV infection. <i>Nature Reviews Rheumatology</i> , 2012, 8, 348-357.	3.5	67
702	The horizon: New targets and new agents. <i>Clinical Liver Disease</i> , 2012, 1, 24-27.	1.0	1
703	Demographics of hepatitis C virus today. <i>Clinical Liver Disease</i> , 2012, 1, 2-5.	1.0	1
704	Is there still a role for liver biopsy in managing hepatitis C virus infections?. <i>Clinical Liver Disease</i> , 2012, 1, 32-35.	1.0	0
705	The long-term horizon: Patients who will remain untreated in the era of triple therapy. <i>Clinical Liver Disease</i> , 2012, 1, 20-23.	1.0	1
706	Hepatitis C viral infection in patients with chronic kidney disease. <i>Clinical Liver Disease</i> , 2012, 1, 91-94.	1.0	0
707	Chronic hepatitis. , 2012, , 992-998.e1.		0
708	Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. <i>Annual Review of Medicine</i> , 2012, 63, 373-387.	5.0	36
709	Loop-Mediated Isothermal Amplification Assay for Rapid Detection of Hepatitis C virus. <i>Indian Journal of Virology: an Official Organ of Indian Virological Society</i> , 2012, 23, 18-23.	0.7	21
710	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	1.1	27
711	Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1469-1474.	1.1	33
712	Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C. <i>Archives of Virology</i> , 2012, 157, 1113-1121.	0.9	4
713	Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic <sc>HCV</sc> patients. <i>Liver International</i> , 2012, 32, 102-109.	1.9	1
714	Barriers to hepatitis <sc>C</sc> treatment. <i>Liver International</i> , 2012, 32, 151-156.	1.9	141

#	ARTICLE	IF	CITATIONS
715	Telaprevir user's guide. <i>Liver International</i> , 2012, 32, 17-25.	1.9	7
716	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140.	1.9	14
717	Treatment of patients with genotype 3 chronic hepatitis C: current and future therapies. <i>Liver International</i> , 2012, 32, 141-145.	1.9	23
718	Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated interferon and ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 69-75.	1.4	10
719	Integrated internist + addiction medicine + hepatology model for hepatitis C management for individuals on methadone maintenance. <i>Journal of Viral Hepatitis</i> , 2012, 19, 47-54.	1.0	48
720	Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review. <i>Journal of Viral Hepatitis</i> , 2012, 19, e220-4.	1.0	35
721	Serum PAL-1 is a novel predictor for response to pegylated interferon-1a plus ribavirin therapy in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, e126-33.	1.0	6
722	Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 3-6.	1.0	8
723	How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 18-32.	1.0	46
724	Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 14-17.	1.0	5
725	Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 52-59.	1.0	17
726	Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 77-87.	1.0	14
727	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, e134-42.	1.0	113
728	Hepatic expression of MxA and OAS1 in an <i>ex vivo</i> liver slice assay independently predicts treatment outcomes in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, e154-62.	1.0	8
729	Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 77-92.	1.1	9
730	Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.	1.9	41
731	Implications of rapid virological response in hepatitis C therapy in the US veteran population. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 105-115.	1.9	10
732	Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 37-47.	1.9	10

#	ARTICLE	IF	CITATIONS
733	Noninvasive algorithms for liver fibrosis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 311-313.	1.9	0
734	HCV-related liver cancer in people with haemophilia. <i>Haemophilia</i> , 2012, 18, 17-24.	1.0	13
735	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	1.9	44
736	Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay. <i>Antiviral Research</i> , 2012, 94, 54-56.	1.9	10
737	Lo esencial en hepatitis C. Cuándo derivar al hepatólogo. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2012, 19, 23-27.	0.0	0
738	New approaches to the management of hepatitis C in haemophilia in 2012. <i>Haemophilia</i> , 2012, 18, 28-33.	1.0	21
739	Dendritic cell-based immunity and vaccination against hepatitis C virus infection. <i>Immunology</i> , 2012, 136, 385-396.	2.0	38
740	Influence of HLA alleles in response to treatment with pegylated interferon- α and ribavirin in patients with chronic hepatitis C. <i>International Journal of Immunogenetics</i> , 2012, 39, 296-302.	0.8	2
741	Antimitochondrial antibody α M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. <i>Hepatology Research</i> , 2012, 42, 428-432.	1.8	3
742	Weight-based high- and low-dose ribavirin in combination with peginterferon α 2b therapy for genotype 2 chronic hepatitis C: A randomized trial. <i>Hepatology Research</i> , 2012, 42, 351-358.	1.8	1
743	Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. <i>Hepatology Research</i> , 2012, 42, 549-557.	1.8	10
744	Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2012, 42, 714-720.	1.8	3
745	Response-guided peginterferon- α 2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. <i>Hepatology Research</i> , 2012, 42, 854-863.	1.8	13
746	Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon- α 2b and ribavirin combination therapy. <i>Hepatology Research</i> , 2012, 42, 966-973.	1.8	0
747	Recent Developments in the Treatment of Chronic Hepatitis C. <i>Journal for Nurse Practitioners</i> , 2012, 8, 225-230.	0.4	0
748	Development of new IL28B genotyping method using Invader Plus assay. <i>Microbiology and Immunology</i> , 2012, 56, 318-323.	0.7	6
749	Hepatocellular carcinoma: Towards personalized medicine. <i>Cancer Science</i> , 2012, 103, 846-850.	1.7	44
750	Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon α 2b and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 91-103.	1.9	55

#	ARTICLE	IF	CITATIONS
751	Meta-analysis: IL28B genotype and sustained viral clearance in HCV genotype 1 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 104-114.	1.9	39
752	Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 370-378.	1.9	3
753	IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV coinfected patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 599-606.	1.7	27
754	Should we treat HCV carriers with normal ALT levels? The "5Ws" dilemma. <i>Journal of Viral Hepatitis</i> , 2012, 19, 229-235.	1.0	21
755	Detection of specific antibodies to HCV-NS5A/NS5B protein in patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 182-188.	1.0	8
756	Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. <i>Journal of Viral Hepatitis</i> , 2012, 19, 236-243.	1.0	13
757	Steatosis is the predictor of relapse in HCV genotype 3 but not 2 infected patients treated with 12 weeks of pegylated interferon plus ribavirin and RVR. <i>Journal of Viral Hepatitis</i> , 2012, 19, 346-353.	1.0	26
758	Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. <i>Journal of Viral Hepatitis</i> , 2012, 19, 423-430.	1.0	21
759	Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action. <i>Journal of Viral Hepatitis</i> , 2012, 19, 480-487.	1.0	8
760	Outcome of hepatitis C virus infection in Chinese paid plasma donors: A 12-year cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 526-532.	1.4	21
761	Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1106-1111.	1.4	12
762	Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). <i>Virology Journal</i> , 2012, 9, 18.	1.4	15
763	Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. <i>Hepatology</i> , 2012, 55, 39-48.	3.6	103
764	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012, 55, 336-342.	3.6	81
765	Normal liver stiffness measure (LSM) values are higher in both lean and obese individuals: A population-based study from a developing country. <i>Hepatology</i> , 2012, 55, 584-593.	3.6	77
766	Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. <i>Hepatology</i> , 2012, 55, 742-748.	3.6	318
767	Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. <i>Hepatology</i> , 2012, 55, 634-641.	3.6	54
768	Diagnostic algorithms for liver fibrosis in hepatitis C: Are they ready to avoid liver biopsy?. <i>Hepatology</i> , 2012, 55, 652-653.	3.6	0

#	ARTICLE	IF	CITATIONS
769	Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the <i>IL28B</i> gene in patients infected with HCV genotype 1b. Journal of Medical Virology, 2012, 84, 61-70.	2.5	8
770	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated interferon-alpha 2b and ribavirin. Journal of Medical Virology, 2012, 84, 438-444.	2.5	20
771	Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. Journal of Medical Virology, 2012, 84, 601-607.	2.5	22
772	A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis and Rheumatism, 2012, 64, 835-842.	6.7	204
773	A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and Rheumatism, 2012, 64, 843-853.	6.7	337
774	Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Irish Journal of Medical Science, 2012, 181, 53-58.	0.8	5
775	IL28B: Implications for Clinical Practice. Current Hepatitis Reports, 2012, 11, 15-22.	0.3	0
776	HCV In At Risk Populations: Who Can be Treated and How?. Current Hepatitis Reports, 2012, 11, 1-9.	0.3	0
777	The Role of Iron in Hepatitis C Infection. Current Hepatitis Reports, 2012, 11, 41-47.	0.3	2
778	Clinical Significance of Discordant Positive Hepatitis C Virus Transcription-Mediated Amplification Following End of Treatment Response. Digestive Diseases and Sciences, 2012, 57, 239-242.	1.1	1
779	Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-1± and ribavirin therapy for chronic hepatitis C patients. Journal of Gastroenterology, 2012, 47, 169-178.	2.3	9
780	Multixponential <i>T</i>₂ analyses in a murine model of hepatic fibrosis at 11.7 T MRI. NMR in Biomedicine, 2013, 26, 83-90.	1.6	5
781	Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: A review and analysis of 36 cases. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 771-778.	1.3	65
782	Differential Reactivity to IMPDH2 by Anti-rods/rings Autoantibodies and Unresponsiveness to Pegylated Interferon-alpha/Ribavirin Therapy in US and Italian HCV Patients. Journal of Clinical Immunology, 2013, 33, 420-426.	2.0	46
783	Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Research and Therapy, 2013, 10, 9.	0.7	19
784	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection, 2013, 41, 21-26.	2.3	6
785	AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. Hepatology, 2013, 58, 2142-2152.	3.6	54
786	Correlation and Multiple Regression Analyses of Pituitary Growth Hormone and Hepatic Activities in Hepatitis C Infection and Interferon Response. Indian Journal of Clinical Biochemistry, 2013, 28, 348-357.	0.9	0

#	ARTICLE	IF	CITATIONS
787	Multicenter comparison of PEG-IFN $\hat{1}\pm 2a$ or $\hat{1}\pm 2b$ plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterology, 2013, 13, 74.	0.8	16
788	Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infectious Diseases, 2013, 13, 234.	1.3	29
789	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infectious Diseases, 2013, 13, 190.	1.3	48
790	Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Medicine, 2013, 11, 6.	2.3	80
791	Seroprevalence and clinico-epidemiological correlates of hepatitis C viral antibodies at an antenatal booking clinic of a tertiary hospital in Nigeria. Archives of Gynecology and Obstetrics, 2013, 288, 495-500.	0.8	10
792	Hepatitis C infection and chronic renal diseases. Hepatology International, 2013, 7, 16-27.	1.9	0
793	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatology International, 2013, 7, 162-170.	1.9	4
794	Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. Journal of Gastroenterology, 2013, 48, 535-543.	2.3	2
795	Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for "middle"? Journal of Gastroenterology, 2013, 48, 555-556.	2.3	1
796	Treatment of Hepatitis C: How Will We Use Viral Kinetics, Response-Guided Therapy?. Current Gastroenterology Reports, 2013, 15, 309.	1.1	10
797	Immunizations in Chronic Liver Disease: What Should be Done and What is the Evidence. Current Gastroenterology Reports, 2013, 15, 300.	1.1	48
798	Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63, 145-150.	1.4	6
799	Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine, 2013, 2, 9.	1.7	27
800	The Natural Course of Chronic Hepatitis B Virus Infection and Its Management. Advances in Pharmacology, 2013, 67, 247-291.	1.2	21
801	Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 766-776.	1.4	37
802	The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. Journal of Clinical Virology, 2013, 58, 254-257.	1.6	8
803	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013, 144, 751-760.e2.	0.6	76
804	Hepatitis Outreach Network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities. Journal of Hepatology, 2013, 58, 890-897.	1.8	58

#	ARTICLE	IF	CITATIONS
805	Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients?. <i>International Journal of Infectious Diseases</i> , 2013, 17, e50-e53.	1.5	4
806	Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. <i>Journal of Hepatology</i> , 2013, 59, 169-177.	1.8	163
807	Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 601-605.	0.3	13
808	Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities. <i>Seminars in Dialysis</i> , 2013, 26, 439-446.	0.7	26
809	Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. <i>Journal of Clinical Virology</i> , 2013, 58, 593-597.	1.6	5
810	Effects of triple drug therapy with nitazoxanide, high dose ribavirin and peginterferon alpha 2a in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2013, 43, 589-595.	1.8	1
811	Health related quality of life in genotype 1 treatment naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133.	1.9	41
812	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	1.8	35
813	Genotype impact on HCV RNA levels determined with the VERSANT HCV RNA 1.0 Assay (kPCR). <i>Journal of Clinical Virology</i> , 2013, 58, 522-527.	1.6	16
814	The importance of HCV RNA measurement for tailoring treatment duration. <i>Digestive and Liver Disease</i> , 2013, 45, S323-S331.	0.4	14
815	Modulation of Fatty Acid Synthase Enzyme Activity and Expression during Hepatitis C Virus Replication. <i>Chemistry and Biology</i> , 2013, 20, 570-582.	6.2	71
816	Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts. <i>American Journal of Kidney Diseases</i> , 2013, 62, 789-795.	2.1	30
817	Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 961-967.	2.9	71
818	Biomarkers of Liver Fibrosis. <i>Advances in Clinical Chemistry</i> , 2013, 62, 33-122.	1.8	6
819	Spontaneous Clearance of Hepatitis C Virus during Pregnancy. <i>Obstetric Medicine</i> , 2013, 6, 28-29.	0.5	2
820	Hepatitis C Infection Is Very Rarely Treated among Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2013, 38, 405-412.	1.4	132
821	Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6467-6473.	1.0	14
822	Lead in treatment with interferon/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha 2b/ribavirin combination for chronic hepatitis C patients with the minor genotype. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 443-449.	1.4	2

#	ARTICLE	IF	CITATIONS
823	Boceprevir With Peginterferon Alfa-2a“Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 81-87.e4.	2.4	61
824	Predictors of treatment response in patients with hepatitis C 1b genotype. <i>Open Medicine (Poland)</i> , 2013, 8, 822-829.	0.6	0
825	Cost-effectiveness of viral hepatitis B & C treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 973-985.	1.0	12
826	Natural History of HCV-induced Liver Disease. <i>Current Hepatitis Reports</i> , 2013, 12, 251-260.	0.3	2
827	Virologic response and characterisation of HCV genotype 2“6 in patients receiving TMC435 monotherapy (study TMC435-C202). <i>Journal of Hepatology</i> , 2013, 58, 445-451.	1.8	82
828	Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1448-1450.	1.3	2
829	Host-targeting agents in the treatment of hepatitis C: A beginning and an end?. <i>Antiviral Research</i> , 2013, 100, 555-561.	1.9	42
830	Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. <i>Virology</i> , 2013, 444, 384-393.	1.1	2
831	Treatment of Genotype 2 and Genotype 3 Hepatitis C Virus (HCV) Infection in Human Immunodeficiency Virus Positive Patients. <i>Current HIV/AIDS Reports</i> , 2013, 10, 420-427.	1.1	3
832	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. <i>Journal of Hepatology</i> , 2013, 58, 655-662.	1.8	225
833	Dynamic changes in viral population structure and compartmentalization during chronic hepatitis C virus infection in children. <i>Virology</i> , 2013, 447, 187-196.	1.1	23
834	Genetic variations in host <sc>IL</sc>28<sc>B</sc> links to the detection of peripheral blood mononuclear cells“associated hepatitis <sc>C</sc> virus <sc>RNA</sc> in chronically infected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 263-272.	1.0	17
835	Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 25-30.	0.8	5
836	Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays. <i>Antiviral Research</i> , 2013, 99, 119-124.	1.9	23
837	Natural killer cells: multifaceted players with key roles in hepatitis C immunity. <i>Immunological Reviews</i> , 2013, 255, 68-81.	2.8	65
838	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis <sc>C</sc> virus cirrhosis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 867-874.	1.0	91
839	Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32.	1.9	48
840	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929.	3.6	255

#	ARTICLE	IF	CITATIONS
841	Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. <i>Harm Reduction Journal</i> , 2013, 10, 7.	1.3	206
842	HCV infected prisoners: should they be still considered a difficult to treat population?. <i>BMC Infectious Diseases</i> , 2013, 13, 374.	1.3	15
843	Health-related quality of life and survival in Chinese patients with chronic liver disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 131.	1.0	25
844	Racial/Ethnic Differences in Spontaneous HCV Clearance in HIV Infected and Uninfected Women. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1341-1348.	1.1	13
845	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (80% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. <i>Hepatology International</i> , 2013, 7, 1000-1009.	1.9	2
846	Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review. <i>International Journal for Equity in Health</i> , 2013, 12, 92.	1.5	9
847	Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. <i>American Journal of Medicine</i> , 2013, 126, 718-722.	0.6	36
848	In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. <i>Antiviral Research</i> , 2013, 100, 439-445.	1.9	21
849	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 158, 807.	2.0	294
850	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 221-228.	1.8	34
851	Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?. <i>Journal of Clinical Virology</i> , 2013, 56, 146-149.	1.6	64
852	Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 713-728.	8.2	17
854	Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. <i>Current Hepatitis Reports</i> , 2013, 12, 236-245.	0.3	1
855	Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response. <i>Digestive Diseases and Sciences</i> , 2013, 58, 556-561.	1.1	12
856	The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1149-1156.	1.1	24
857	Serum apolipoprotein B100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2013, 85, 1180-1190.	2.5	8
858	Perspectivas a largo plazo: pacientes que seguirán sin tratamiento en la era de la terapia triple. <i>Clinical Liver Disease</i> , 2013, 2, S16A-S19A.	1.0	0
859	Rates and predictors of response to antiviral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1373-1384.	1.9	14

#	ARTICLE	IF	CITATIONS
860	Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study. <i>Journal of Medical Virology</i> , 2013, 85, 1724-1733.	2.5	65
861	Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2533-2544.	0.9	24
862	Guidelines for the Management of Hepatitis C Virus Infection. <i>Hepatology Research</i> , 2013, 43, 1-34.	1.8	56
863	Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. <i>Hepatology</i> , 2013, 57, 925-933.	3.6	44
864	Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. <i>Gut</i> , 2013, 62, 766-773.	6.1	26
865	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. <i>Gene</i> , 2013, 513, 292-296.	1.0	23
866	Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30.	2.3	28
867	Stereoselective Addition of 2-Phenyloxazol-4-yl Trifluoromethanesulfonate to <i>N</i> -Sulfinyl Imines: Application to the Synthesis of the HCV Protease Inhibitor Boceprevir. <i>Journal of Organic Chemistry</i> , 2013, 78, 706-710.	1.7	5
868	The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11.	1.0	52
869	Correlation between salivary anti-HCV antibodies and HCV RNA in saliva and salivary glands of patients with chronic hepatitis C. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 222-228.	1.4	10
870	Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study. <i>Hepatology Research</i> , 2013, 43, 557-562.	1.8	3
871	Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103.	1.4	6
872	Future therapies for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 268-276.	8.2	36
873	Pulmonary hazards of chronic hepatitis C virus infection treatment with Pegylated interferon and ribavirin vs. untreated patients. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2013, 62, 325-329.	0.1	2
874	Hepatitis C Screening: Summary of Recommendations From the Clinical Decision Tool. <i>Gastroenterology</i> , 2013, 145, 1146-1149.	0.6	4
875	Acute Exacerbation Among Chronic Hepatitis C Patients: Tip of the Iceberg That Deserves More Attention. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1181-1182.	2.4	1
876	Fibroscan of chronic HCV patients coinfecting with schistosomiasis. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 109-112.	0.4	20
877	Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b. <i>Infection, Genetics and Evolution</i> , 2013, 13, 1-10.	1.0	4

#	ARTICLE	IF	CITATIONS
878	Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. <i>Journal of Hepatology</i> , 2013, 58, 1104-1112.	1.8	26
879	A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. <i>Parasitology International</i> , 2013, 62, 283-288.	0.6	14
880	Preparing the patient for success: Treat or wait?. <i>Digestive and Liver Disease</i> , 2013, 45, S332-S336.	0.4	1
881	A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 921-922, 81-86.	1.2	16
882	Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2013, 56, 291-295.	1.6	18
883	Thyroid Disease in Chronic Hepatitis C Infection Treated With Combination Interferon-a and Ribavirin: Management Strategies and Future Perspective. <i>Endocrine Practice</i> , 2013, 19, 292-300.	1.1	14
884	Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1269-1279.	2.0	35
886	A new system to measure and compare hepatitis C virus replication capacity using full-length, replication competent viruses. <i>Journal of Virological Methods</i> , 2013, 194, 82-88.	1.0	0
887	Chronic HCV infection is a risk factor of ischemic stroke. <i>Atherosclerosis</i> , 2013, 231, 22-26.	0.4	80
888	Interferon-Free Regimens for Chronic Hepatitis C – A Step Forward. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 76-78.	0.4	0
889	Aqueous Flare and Choroidal Thickness in Patients with Chronic Hepatitis C Virus Infection. <i>Ophthalmology</i> , 2013, 120, 2258-2263.	2.5	9
890	The effect of stimulant use on antiviral treatment in an integrated hepatitis clinic. <i>General Hospital Psychiatry</i> , 2013, 35, 387-392.	1.2	2
891	Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 479-484.	0.7	7
892	A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. <i>Journal of Clinical Virology</i> , 2013, 57, 29-35.	1.6	15
893	Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. <i>Journal of Hepatology</i> , 2013, 59, 957-963.	1.8	3
894	Re-treatment with Highly Purified nIFN α in Mexican Nonresponder Patients with Chronic Genotype 1 Hepatitis C. <i>Archives of Medical Research</i> , 2013, 44, 444-448.	1.5	1
895	Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. <i>Journal of Clinical Virology</i> , 2013, 58, 249-253.	1.6	40
896	Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons. <i>Gastroenterology</i> , 2013, 144, 59-61.e6.	0.6	35

#	ARTICLE	IF	CITATIONS
897	Daclatasvir: a promising triple therapy for children with chronic hepatitis C. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 17-18.	4.6	1
898	An Epidemiologic Update on Hepatitis C Infection in Persons Living With or at Risk of HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S1-S6.	1.9	88
899	Absolute and relative contraindications to pegylated interferon or ribavirin in the <sc>US</sc> general patient population with chronic hepatitis C: results from a <sc>US</sc> database of over 45,000 <sc>HCV</sc>-infected, evaluated patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 473-481.	1.9	42
900	Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 95-102.	1.0	30
901	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 113-121.	1.0	16
902	Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2585-2589.	1.0	19
903	A multicenter survey of retreatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2013, 43, 35-43.	1.8	9
904	Fluvastatin helps interferon-based therapy in chronic hepatitis <sc>C</sc>: Fact or fiction?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 7-9.	1.4	6
905	Best strategies for global <sc>HCV</sc> eradication. <i>Liver International</i> , 2013, 33, 68-79.	1.9	97
906	Optimal treatment with telaprevir for chronic HCV infection. <i>Liver International</i> , 2013, 33, 3-13.	1.9	11
907	HCV therapy in <sc>HIV</sc>-infected patients. <i>Liver International</i> , 2013, 33, 63-67.	1.9	30
908	Treatment of Chronic Hepatitis C: Current and Future. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 321-342.	0.7	79
909	Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. <i>Hepatology Research</i> , 2013, 43, 919-924.	1.8	1
910	The use of metabolomics as a tool to investigate hepatitis C. <i>Metabolomics</i> , 2013, 9, 497-505.	1.4	5
911	Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 5673-5681.	1.6	16
912	Severe Neutropenia in Patients with Chronic Hepatitis C: A Benign Condition. <i>Acta Haematologica</i> , 2013, 129, 96-100.	0.7	9
913	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495.	0.6	38
914	Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. <i>New England Journal of Medicine</i> , 2013, 368, 34-44.	13.9	689

#	ARTICLE	IF	CITATIONS
915	Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536.	1.9	71
916	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	1.9	44
917	Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936.	1.9	105
918	Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue Diseases<i>Possibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure</i>. <i>Assay and Drug Development Technologies</i> , 2013, 11, 70-92.	0.6	226
919	Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV. <i>Current Rheumatology Reports</i> , 2013, 15, 319.	2.1	10
920	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013, 57, 1752-1762.	3.6	113
921	Point-of-care testing and the control of infectious diseases. <i>Biomarkers in Medicine</i> , 2013, 7, 333-347.	0.6	31
922	Acute hepatitis C in a pregnant HIV infected woman: Case report and literature review. <i>HIV and AIDS Review</i> , 2013, 12, 23-25.	0.1	0
923	<i>IL28</i> polymorphism is associated with early hepatitis C virus (<i>HCV</i>) treatment failure in human immunodeficiency virus<i>-</i>coinfected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 358-366.	1.0	17
924	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	13.9	1,605
925	Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole. <i>Biochemistry</i> , 2013, 52, 3752-3764.	1.2	37
926	Meta-analysis: pegylated interferon α 2a achieves higher early virological responses than α 2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	1.9	6
927	Hepatocellular Carcinoma in Chronic Hepatitis C in the Absence of Advanced Fibrosis or Cirrhosis. <i>American Journal of Roentgenology</i> , 2013, 200, W610-W616.	1.0	22
928	HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2013, 108, 471-475.	0.2	26
929	Telaprevir for Chronic Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2013, 17, 47-62.	1.0	3
931	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	1.1	42
932	Role of Liver Biopsy in the Era of Direct-Acting Antivirals. <i>Current Gastroenterology Reports</i> , 2013, 15, 307.	1.1	19
934	Hepatic interferon- γ -induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28<i>B</i> single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C. <i>Hepatology Research</i> , 2013, 43, 1139-1147.	1.8	5

#	ARTICLE	IF	CITATIONS
935	Current progress in development of hepatitis C virus vaccines. <i>Nature Medicine</i> , 2013, 19, 869-878.	15.2	144
936	Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response. <i>Journal of Clinical Virology</i> , 2013, 57, 381.	1.6	0
937	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
938	Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917.	13.9	418
939	Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. <i>Clinical Science</i> , 2013, 125, 439-448.	1.8	21
940	Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies. <i>Gastroenterology</i> , 2013, 144, 1450-1455.e2.	0.6	153
941	Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121.	1.9	67
942	Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. <i>Clinical Infectious Diseases</i> , 2013, 57, S62-S69.	2.9	97
943	Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 806-816.	2.9	127
944	Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1466-1470.	2.9	10
945	Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. <i>Social Science and Medicine</i> , 2013, 83, 19-26.	1.8	65
946	IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfecting with hepatitis C virus. <i>Journal of Infection</i> , 2013, 66, 170-178.	1.7	13
947	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. <i>Value in Health</i> , 2013, 16, 973-986.	0.1	63
948	Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 309-310.	2.4	11
949	Protease Inhibitors for Hepatitis C: Economic Implications. <i>Pharmacoeconomics</i> , 2013, 31, 739-751.	1.7	4
950	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.	2.9	80
951	Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. <i>Journal of Viral Hepatitis</i> , 2013, 20, e115-23.	1.0	15
952	Hepatitis and Cirrhosis. , 2013, , 343-351.		0

#	ARTICLE	IF	CITATIONS
953	HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1231-1238.	1.0	15
954	Prediction of Hepatic Fibrosis in Patients Coinfected With HIV and Hepatitis C Virus Based on Genetic Markers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 434-442.	0.9	6
955	The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. <i>Aids</i> , 2013, 27, 1941-1947.	1.0	6
956	Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. <i>BMJ Open</i> , 2013, 3, e003231.	0.8	8
957	Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. <i>Journal of Clinical Microbiology</i> , 2013, 51, 571-577.	1.8	60
958	Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 853-862.	1.9	1
959	Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?. <i>Hepatology</i> , 2013, 57, 438-440.	3.6	15
960	Prevention of infection caused by immunosuppressive drugs in gastroenterology. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 167-185.	1.1	72
961	Effect of HIV on Liver Fibrosis Among HCV-Infected African Americans. <i>Clinical Infectious Diseases</i> , 2013, 56, 1280-1283.	2.9	7
962	Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype. <i>Journal of Virology</i> , 2013, 87, 7593-7607.	1.5	88
963	Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran. <i>Hepatitis Monthly</i> , 2013, 13, e11038.	0.1	5
964	Sexual Transmission of Hepatitis C Virus Between HIV Infected Subjects and Their Main Heterosexual Partners. <i>Hepatitis Monthly</i> , 2013, 13, e13593.	0.1	14
965	Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. <i>Hepatitis Monthly</i> , 2013, 13, e14481.	0.1	1
966	Hepatitis C Virus in Pregnancy. <i>American Journal of Perinatology</i> , 2013, 30, 149-160.	0.6	92
967	Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	35
968	Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature Review. <i>Hepatitis Monthly</i> , 2013, 13, e8340.	0.1	39
969	Evaluation of the Significance of Pretreatment Liver Biopsy and Baseline Mental Health Disorder Diagnosis on Hepatitis C Treatment Completion Rates at a Veterans Affairs Medical Center. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-6.	2.0	1
970	Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction. <i>Clinical Infectious Diseases</i> , 2013, 57, S111-S117.	2.9	37

#	ARTICLE	IF	CITATIONS
971	Living-Donor Liver Transplantation and Hepatitis C. <i>HPB Surgery</i> , 2013, 2013, 1-13.	2.2	8
972	Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-11.	0.7	5
973	Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection. <i>Hepatitis Monthly</i> , 2013, 13, e8988.	0.1	4
974	Prevalence of Occult Hepatitis B Virus in Plasma and Peripheral Blood Mononuclear Cell Compartments of Patients With Chronic Hepatitis C Infection in Tehran-Iran. <i>Hepatitis Monthly</i> , 2013, 13, e10134.	0.1	19
975	Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin. <i>Hepatitis Monthly</i> , 2013, 13, e14146.	0.1	1
976	Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy. <i>Hepatitis Monthly</i> , 2013, 13, e11892.	0.1	2
977	Prevalence of Hepatitis C Virus Infection in Alcoholic Patients: Cohort Study and Systematic Review. <i>Alcohol and Alcoholism</i> , 2013, 48, 564-569.	0.9	27
978	Explaining Differences in Hepatitis C Between U.S. Veterans and Nonveterans in Treatment for Substance Abuse: Results From a Regression Decomposition. <i>Substance Use and Misuse</i> , 2013, 48, 854-862.	0.7	5
979	Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 240-246.	2.9	118
980	A novel program for treating patients with trimorbidity. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1377-1384.	0.8	18
981	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. <i>Clinical Infectious Diseases</i> , 2013, 57, 1014-1020.	2.9	97
982	Age-based screening recommendations for hepatitis C virus infection. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2013, 26, 50-52.	0.1	0
983	Comparison of Magnetic Resonance Elastography and Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging for the Evaluation of Hepatic Fibrosis. <i>Investigative Radiology</i> , 2013, 48, 607-613.	3.5	45
984	Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response. <i>World Journal of Gastroenterology</i> , 2013, 19, 2691.	1.4	39
985	Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children. <i>PLoS ONE</i> , 2013, 8, e53519.	1.1	24
986	Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 150-157.	3.6	73
987	Expression of Biliverdin Reductase A in Peripheral Blood Leukocytes Is Associated with Treatment Response in HCV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e57555.	1.1	12
988	Laboratory Methods for Diagnosis and Management of Hepatitis C Virus Infection. <i>Laboratory Medicine</i> , 2013, 44, 292-299.	0.8	9

#	ARTICLE	IF	CITATIONS
989	Moving the Agenda Forward: The Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S29-S31.	2.9	9
990	What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636.	2.9	23
991	Protection Against Hepatitis C and Other Enveloped Viruses? Another Reason Why "Breast Is Best". <i>Journal of Infectious Diseases</i> , 2013, 208, 1932-1933.	1.9	1
992	Antiviral Lectins from Red and Blue-Green Algae Show Potent In Vitro and In Vivo Activity against Hepatitis C Virus. <i>PLoS ONE</i> , 2013, 8, e64449.	1.1	116
993	Directly Observed Pegylated Interferon Plus Self-Administered Ribavirin for the Treatment of Hepatitis C Virus Infection in People Actively Using Drugs: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, S90-S96.	2.9	30
994	Effect of interleukin-6 and insulin resistance on early virological response of Egyptian chronic hepatitis C patients to combined pegylated interferon plus ribavirin therapy. <i>Egyptian Liver Journal</i> , 2013, 3, 21-27.	0.3	2
995	The impact of infectious diseases consultation on oncology practice. <i>Current Opinion in Oncology</i> , 2013, 25, 353-359.	1.1	18
996	Efficacy of Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C Virus (Genotypes 1 and 4) Infection. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 694-699.	0.9	9
997	Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137.	2.9	99
998	Combination therapy of natural human interferon β and ribavirin for chronic hepatitis C patients with injection drug use. <i>Hepatology Research</i> , 2013, 43, 1013-1019.	1.8	3
999	Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6097-6105.	1.4	22
1000	Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation. <i>Jundishapur Journal of Microbiology</i> , 2013, 6, .	0.2	7
1001	Impact of Lifetime Alcohol Use on Liver Fibrosis in a Population of HIV-Infected Patients With and Without Hepatitis C Coinfection. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1527-1535.	1.4	20
1002	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin β . <i>Hepatology Research</i> , 2013, 43, 580-588.	1.8	2
1003	Hepatitis C virus and HIV type 1 co-infection. <i>Gastroenterology Insights</i> , 2013, 5, e7.	0.7	20
1004	Model for hepatitis C virus transmissions. <i>Mathematical Biosciences and Engineering</i> , 2013, 10, 1045-1065.	1.0	28
1005	Ophthalmologic complications of antiviral therapy in hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013, 19, 8227.	1.4	9
1006	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013, 14, 1-71.	1.0	43

#	ARTICLE	IF	CITATIONS
1007	Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 573-582.	1.9	5
1008	Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. <i>Hepatology</i> , 2013, 57, 1697-1704.	3.6	47
1009	Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. <i>Transplant International</i> , 2013, 26, 358-372.	0.8	15
1010	Transcript Analysis of P2X Receptors in PBMCs of Chronic HCV Patients: An Insight into Antiviral Treatment Response and HCV-Induced Pathogenesis. <i>Viral Immunology</i> , 2013, 26, 343-350.	0.6	17
1012	Multicenter evaluation of the Elecsys® anti-HCV II assay for the diagnosis of hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2013, 85, 1362-1368.	2.5	18
1013	Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 404-413.	1.0	20
1014	Hepatitis C virus. <i>Journal of the American Dental Association</i> , 2013, 144, 1340-1347.	0.7	16
1015	Clinicopathological significance of hepatitis C virus core antigen levels in chronic infection. <i>Journal of Medical Virology</i> , 2013, 85, 1913-1918.	2.5	12
1016	Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. <i>Journal of Viral Hepatitis</i> , 2013, 20, e131-7.	1.0	8
1017	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.	1.0	11
1018	Successful Treatment of Chronic HCV Infection Should Not Preclude Kidney Donation to an HCV Negative Recipient. <i>American Journal of Transplantation</i> , 2013, 13, 2773-2774.	2.6	23
1019	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 745-760.	1.0	78
1021	Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin. <i>Journal of Viral Hepatitis</i> , 2013, 20, e82-9.	1.0	1
1022	Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 415-423.	1.9	102
1023	Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. <i>Liver International</i> , 2013, 33, 420-427.	1.9	19
1024	Upregulation of OX40 ligand on monocytes contributes to early virological control in patients with chronic hepatitis C. <i>European Journal of Immunology</i> , 2013, 43, 1953-1962.	1.6	11
1025	Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: A 5 years survey. <i>Journal of Medical Virology</i> , 2013, 85, 2072-2078.	2.5	8
1026	The correlation between T helper type 17 cells and clinical characters in Chinese paediatric patients with chronic hepatitis B. <i>Clinical and Experimental Immunology</i> , 2013, 171, 307-312.	1.1	6

#	ARTICLE	IF	CITATIONS
1027	The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. <i>British Journal of Dermatology</i> , 2013, 169, 1295-1303.	1.4	123
1028	Características demográficas actuales del virus de la hepatitis C. <i>Clinical Liver Disease</i> , 2013, 2, S12A-S15A.	1.0	0
1029	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. <i>Journal of Viral Hepatitis</i> , 2013, 20, e107-14.	1.0	16
1031	Hepatitis C infection in non-treatment-seeking heroin users: The burden of cocaine injection. <i>American Journal on Addictions</i> , 2013, 22, 613-618.	1.3	15
1032	Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus coinfection and baseline anaemia. <i>Journal of Viral Hepatitis</i> , 2013, 20, 463-469.	1.0	7
1033	Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943.	1.1	42
1036	Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 804-810.	1.4	39
1037	The Association of Cytopenias and Weight Loss with Hepatitis C Virus Virologic Response in HIV/HCV-Coinfected Patients Treated with PEG-IFN and RBV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 354-362.	0.6	2
1038	Outcome of HCV Genotype 1 Treatment in HIV-Coinfected Patients with Chronic Kidney Disease. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 55-57.	0.6	0
1039	Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7418-7422.	3.3	49
1040	Sustained and rapid virological responses in hepatitis C clinical trials. <i>Clinical Investigation</i> , 2013, 3, 1083-1093.	0.0	2
1041	Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114.	2.0	99
1042	Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2013, 159, 349.	2.0	428
1043	Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 158, 101.	2.0	79
1044	Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2013, 158, 329.	2.0	734
1045	Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.	1.6	24
1046	Women with Chronic Hepatitis C Virus Infection. <i>Southern Medical Journal</i> , 2013, 106, 422-426.	0.3	3
1047	Low-dose pegylated interferon-alpha-2a plus ribavirin therapy for elderly and/or cirrhotic patients with hepatitis C virus genotype-1b and high viral load. <i>Antiviral Therapy</i> , 2013, 19, 107-115.	0.6	4

#	ARTICLE	IF	CITATIONS
1048	Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 333-337.	0.8	25
1049	PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.	3.6	39
1050	Intensified Peginterferon α -2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 271-279.	1.1	3
1051	Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013, 27, 2541-2549.	1.0	29
1052	A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 601-605.	0.8	4
1053	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696.	1.0	10
1054	High Proportion of Hepatitis C Virus in Community Asian American Patients With Non-Liver-related Complaints. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 367-371.	1.1	14
1055	Assessment and Utilization of Rapid Virologic Response in US Veterans With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 264-270.	1.1	4
1056	Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 798-805.	0.8	14
1057	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173.	1.0	12
1058	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	0.6	12
1059	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235.	2.0	187
1060	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	0.6	9
1061	HIV, Age, and the Severity of Hepatitis C Virus-Related Liver Disease. <i>Annals of Internal Medicine</i> , 2013, 158, 658.	2.0	156
1062	A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. <i>Scientific Reports</i> , 2013, 3, 1065.	1.6	292
1063	Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goiás, Central Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 24-29.	0.4	28
1064	Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. <i>International Journal of Medical Sciences</i> , 2013, 10, 1015-1021.	1.1	9
1065	The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 17.	0.9	11

#	ARTICLE	IF	CITATIONS
1066	Novel drugs in the management of difficult-to-treat hepatitis C genotypes. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 53.	0.9	8
1067	An insight into the diagnosis and pathogenesis of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 7896.	1.4	56
1068	Enhanced Chronic Hepatitis C Surveillance in New York City, April 2009–January 2011. <i>Public Health Reports</i> , 2013, 128, 510-518.	1.3	5
1069	Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis. <i>PLoS ONE</i> , 2013, 8, e55364.	1.1	25
1070	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e58380.	1.1	1
1071	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. <i>PLoS ONE</i> , 2013, 8, e58975.	1.1	61
1072	Nonresponse to Interferon- α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e61568.	1.1	8
1073	Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients. <i>PLoS ONE</i> , 2013, 8, e61992.	1.1	28
1074	Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis. <i>PLoS ONE</i> , 2013, 8, e71039.	1.1	60
1075	Impact of Rural Residence and Health System Structure on Quality of Liver Care. <i>PLoS ONE</i> , 2013, 8, e84826.	1.1	23
1076	Hepatitis C virus (HCV) infection in Africa: a review. <i>Pan African Medical Journal</i> , 2013, 2, 44.	0.3	119
1077	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	2.0	179
1078	Hepatitis C Virus Infection: Looking for Interferon Free Regimens. <i>Scientific World Journal</i> , The, 2013, 2013, 1-11.	0.8	11
1080	Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy. <i>Annals of Hepatology</i> , 2013, 12, 373-379.	0.6	3
1081	Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. <i>Annals of Hepatology</i> , 2013, 12, 380-391.	0.6	54
1082	Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI. <i>Annals of Hepatology</i> , 2013, 12, 926-934.	0.6	20
1083	Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit. <i>Annals of Hepatology</i> , 2013, 12, 364-370.	0.6	10
1084	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. <i>Annals of Hepatology</i> , 2013, 12, S3-S35.	0.6	9

#	ARTICLE	IF	CITATIONS
1085	Patients younger than forty years old with hepatitis C virus genotypeâ€‘1 chronic infection had treatment responses similar to genotypeâ€‘2 infection and not related to interleukinâ€‘28B polymorphism. <i>Annals of Hepatology</i> , 2013, 12, 62-69.	0.6	5
1086	Protease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virus. <i>The Cochrane Library</i> , 0, , .	1.5	0
1088	Management of HCV Infection in the Elderly. , 2013, , .		0
1089	Distribution of HCV genotypes in the metropolitan area of Naples. <i>Microbiologia Medica</i> , 2013, 28, .	0.3	1
1090	Hepatitis C in Argentina: epidemiology and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 35.	0.9	6
1091	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 493.	0.9	29
1092	Treatment Outcome in Chronic Hepatitis C Infection: A Four Years Survey Among Iranian Patients. <i>Global Journal of Health Science</i> , 2014, 7, 75-81.	0.1	2
1093	Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e90295.	1.1	19
1094	IL-28B Polymorphisms Correlated with Treatment Response in HCV-4 Mono-Infected Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e91316.	1.1	7
1095	The Performance of Enhanced Liver Fibrosis (ELF) Test for the Staging of Liver Fibrosis: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e92772.	1.1	62
1096	HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients. <i>PLoS ONE</i> , 2014, 9, e99468.	1.1	2
1097	The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e101554.	1.1	362
1098	Intact Dendritic Cell Pathogen-Recognition Receptor Functions Associate with Chronic Hepatitis C Treatment-Induced Viral Clearance. <i>PLoS ONE</i> , 2014, 9, e102605.	1.1	5
1099	Characterization of Hepatitis C Virus Genotypes by Direct Sequencing of HCV 5â€‘UTR Region of Isolates from Saudi Arabia. <i>PLoS ONE</i> , 2014, 9, e103160.	1.1	13
1100	Chronic HCV Infection Affects the NK Cell Phenotype in the Blood More than in the Liver. <i>PLoS ONE</i> , 2014, 9, e105950.	1.1	29
1101	CD100 Up-Regulation Induced by Interferon-Î± on B Cells Is Related to Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2014, 9, e113338.	1.1	11
1102	Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, e1-e4.	0.8	1
1103	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633.	1.4	135

#	ARTICLE	IF	CITATIONS
1104	Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 25.	0.9	22
1105	Management of patients with hepatitis B and C before and after liver and kidney transplantation. <i>World Journal of Hepatology</i> , 2014, 6, 315.	0.8	11
1106	Patient adherence issues in the treatment of hepatitis C. <i>Patient Preference and Adherence</i> , 2014, 8, 763.	0.8	16
1107	Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 109.	1.8	2
1108	Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients. <i>Annals of Hepatology</i> , 2014, 13, 219-230.	0.6	0
1109	Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy. <i>Annals of Hepatology</i> , 2014, 13, 503-509.	0.6	2
1110	Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. <i>Annals of Hepatology</i> , 2014, 13, 525-532.	0.6	24
1111	Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection. <i>Annals of Hepatology</i> , 2014, 13, 350-355.	0.6	5
1113	Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV Antigen test. <i>Annals of Hepatology</i> , 2014, 13, 337-342.	0.6	16
1114	Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a+Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1136-1145.	1.4	19
1115	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 763-773.	2.0	41
1116	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. <i>Hepatology International</i> , 2014, 8, 517-526.	1.9	6
1117	The future of dual therapy for hepatitis C virus. <i>Future Virology</i> , 2014, 9, 905-912.	0.9	1
1118	Association of interferon- γ -induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1349-1358.	0.6	1
1119	Hepatitis C for Primary Care Physicians. <i>Journal of the American Board of Family Medicine</i> , 2014, 27, 284-291.	0.8	9
1120	Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies. <i>BMC Infectious Diseases</i> , 2014, 14, S8.	1.3	11
1121	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. <i>Future Virology</i> , 2014, 9, 9-20.	0.9	0
1122	Hepatitis C treatment eligibility among HIV+ hepatitis C virus coinfecting patients in Oregon: a population-based sample. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1178-1185.	0.6	9

#	ARTICLE	IF	CITATIONS
1123	LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. <i>Clinical Proteomics</i> , 2014, 11, 44.	1.1	1
1124	Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. <i>BMC Infectious Diseases</i> , 2014, 14, 705.	1.3	6
1125	Changes in hepatitis C virus genotype distribution in Japan. <i>Epidemiology and Infection</i> , 2014, 142, 2624-2628.	1.0	56
1126	Efficacy of daclatasvir in hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1025-1031.	2.0	11
1127	Shear Wave Elastography for Liver Stiffness Measurement in Clinical Sonographic Examinations. <i>Journal of Ultrasound in Medicine</i> , 2014, 33, 437-447.	0.8	85
1128	Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1033-1043.	2.0	19
1129	GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1179-1186.	2.0	10
1130	<scp>CUFA</scp> algorithm: assessment of liver fibrosis using routine laboratory data. <i>Journal of Viral Hepatitis</i> , 2014, 21, 956-964.	1.0	4
1131	Sustained Virological Response Rates to Antiviral Therapy in Genotype 1 and 3 Chronic Hepatitis C Patients: A Study from North India. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 287-292.	0.4	6
1132	A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity. <i>PLoS Pathogens</i> , 2014, 10, e1004064.	2.1	66
1133	Prevalence of thyroid disorders and the correlation of thyroid profile with liver enzymes, serum activin-A and follistatin during the treatment of patients with chronic hepatitis C genotype 1 and 4. <i>Journal of Clinical and Experimental Investigations</i> , 2014, 5, .	0.1	0
1134	Indeterminate RIBA results were associated with the absence of hepatitis C virus RNA (HCV-RNA) in blood donors. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2014, 47, 12-17.	0.4	11
1135	Nucleic acid electrochemical and electromechanical biosensors: a review of techniques and developments. <i>Reviews in Analytical Chemistry</i> , 2014, 33, .	1.5	19
1136	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , 2014, 63, 1150-1158.	6.1	41
1137	Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. <i>International Journal of Infectious Diseases</i> , 2014, 27, 49-53.	1.5	14
1138	Challenging clinical cases in HCV infection. <i>BMC Infectious Diseases</i> , 2014, 14, S7.	1.3	1
1139	Diagnostic Usefulness of Real-Time Elastography for Liver Fibrosis in Chronic Viral Hepatitis B and C. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-7.	0.7	12
1140	Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-9.	0.7	8

#	ARTICLE	IF	CITATIONS
1141	Histological and Clinical Characteristics of Patients with Chronic Hepatitis C and Persistently Normal Alanine Aminotransferase Levels. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-6.	2.0	8
1142	Severity of Hepatitis C Virus (Genotype-3) Infection Positively Correlates with Circulating MicroRNA-122 in Patients Sera. <i>Disease Markers</i> , 2014, 2014, 1-6.	0.6	28
1143	An empirical study of alcohol consumption by patients considering HCV treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2014, 40, 484-489.	1.1	15
1144	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2014, 15, 10578-10604.	1.8	60
1145	Risk of Echocardiographic Pulmonary Hypertension in Individuals with Human Immunodeficiency Virus–Hepatitis C Virus Coinfection. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1553-1559.	1.5	19
1146	Supervised conventional interferon λ 2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. <i>Indian Journal of Pharmacology</i> , 2014, 46, 490.	0.4	0
1147	A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate. <i>Clinical Infectious Diseases</i> , 2014, 58, 130-133.	2.9	4
1148	SNP rs8099917 in Gene <i>IL28B</i> Might Be Associated with Risk of Chronic Infection by HCV but Not with Response to Treatment. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	9
1149	Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	34
1150	HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. <i>BMJ Open</i> , 2014, 4, e005694.	0.8	11
1151	Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. <i>BMJ Open</i> , 2014, 4, e006255.	0.8	2
1152	“Seek, test, treat and retain” for hepatitis C in the United States criminal justice system. <i>International Journal of Prisoner Health</i> , 2014, 10, 164-171.	0.5	17
1153	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	2.0	129
1154	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 351-358.	1.4	5
1155	Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. <i>Journal of Medical Economics</i> , 2014, 17, 862-871.	1.0	15
1156	Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 973-983.	1.4	0
1157	Clinical and <i>In Vitro</i> Resistance to GS-9669, a Thumb Site II Nonnucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6599-6606.	1.4	11
1158	Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 277-286.	1.0	28

#	ARTICLE	IF	CITATIONS
1159	The Spectrum of Undiagnosed Hepatitis C Virus Infection in a US HIV Clinic. <i>AIDS Patient Care and STDs</i> , 2014, 28, 4-9.	1.1	10
1160	Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 204-208.	0.5	3
1161	Prediction of efficacy to pegylated interferon-1a plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. <i>Hepatology Research</i> , 2014, 44, 179-186.	1.8	6
1162	Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. <i>Liver International</i> , 2014, 34, 24-28.	1.9	28
1163	Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258.	1.9	12
1164	12 Years of Universal Access to Hepatitis C Treatment. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 560-567.	0.6	5
1165	Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver prognosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 178-188.	1.9	36
1166	Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. <i>Hepatology Research</i> , 2014, 44, 829-836.	1.8	7
1167	What are the Management Issues for Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 446-448.	0.7	4
1168	Sticker shock and the price of new therapies for hepatitis C: Is it worth it?. <i>Hepatology</i> , 2014, 59, 1246-1249.	3.6	42
1169	FDA Perspective on Sofosbuvir Therapy for Patients With Chronic Hepatitis C Virus Genotype 1 Infection Who Did Not Respond to Treatment With Pegylated Interferon and Ribavirin. <i>Gastroenterology</i> , 2014, 147, 1196-1200.	0.6	11
1170	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfecting adults: Prospective analysis of 435 liver biopsy pairs. <i>Hepatology</i> , 2014, 59, 767-775.	3.6	81
1171	In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions. <i>Liver International</i> , 2014, 34, e217-28.	1.9	1
1172	Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. <i>Journal of Viral Hepatitis</i> , 2014, 21, 198-207.	1.0	112
1173	Determination of Normal Hepatic Elasticity by Using Real-time Shear-wave Elastography. <i>Radiology</i> , 2014, 271, 895-900.	3.6	67
1174	Hepatic Fibrosis: Prospective Comparison of MR Elastography and US Shear-Wave Elastography for Evaluation. <i>Radiology</i> , 2014, 273, 772-782.	3.6	147
1175	Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 350-357.	0.5	1
1176	Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 545-553.	1.4	113

#	ARTICLE	IF	CITATIONS
1177	An inexpensive and worldwide available digital image analysis technique for histological fibrosis quantification in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2014, 21, 216-222.	1.0	20
1178	What are the Management Issues for Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 451-455.	0.7	2
1179	Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. <i>Clinical Transplantation</i> , 2014, 28, 713-721.	0.8	42
1180	Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection. <i>Pharmacotherapy</i> , 2014, 34, 1341-1354.	1.2	33
1181	Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment. <i>Hepatology Research</i> , 2014, 44, 597-607.	1.8	2
1182	Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2014, 20, 2854.	1.4	62
1183	Robust and Persistent Replication of the Genotype 6a Hepatitis C Virus Replicon in Cell Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2638-2646.	1.4	29
1184	Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10690-10695.	3.3	43
1185	Impact of Isolated Hepatitis C Virus (HCV) Core-Specific Antibody Detection and Viral RNA Amplification among HCV-Seronegative Dialysis Patients at Risk for Infection. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3053-3056.	1.8	7
1186	Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials). <i>Drug Safety</i> , 2014, 37, 57-62.	1.4	29
1187	Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. <i>BMC Gastroenterology</i> , 2014, 14, 47.	0.8	10
1188	Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study. <i>BMC Infectious Diseases</i> , 2014, 14, 716.	1.3	23
1189	Maternal-Fetal Transmission of Hepatitis C Infection. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 278-282.	0.9	15
1190	Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 80-84.	0.7	8
1191	Words Matter. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e110-e111.	0.9	35
1192	Meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1189-1201.	0.8	4
1193	Prediction of response to pegylated interferon and ribavirin in Egyptian patients with chronic hepatitis C using serum neopterin. <i>Egyptian Liver Journal</i> , 2014, 4, 63-68.	0.3	0
1194	Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 65-73.	0.8	3

#	ARTICLE	IF	CITATIONS
1195	PPARÎ³2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 113-119.	0.9	5
1196	Lack of Access to Treatment as a Barrier to HCV Screening. <i>Journal of Public Health Management and Practice</i> , 2014, 20, 420-423.	0.7	6
1197	Physician Nonadherence With a Hepatitis C Screening Program. <i>Quality Management in Health Care</i> , 2014, 23, 1-9.	0.4	20
1198	Real-world outcomes in patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 388-395.	0.8	3
1199	Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope. <i>American Journal of the Medical Sciences</i> , 2014, 348, 426-430.	0.4	6
1200	A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease. <i>International Journal of STD and AIDS</i> , 2014, 25, 830-832.	0.5	4
1201	Hepatitis B and C. <i>Journal of the Intensive Care Society</i> , 2014, 15, 135-141.	1.1	1
1203	Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. <i>Asian Journal of Transfusion Science</i> , 2014, 8, 19.	0.1	116
1204	Diagnostic Challenges of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2536.	3.8	5
1205	HCV Genomic RNA Activates the NLRP3 Inflammasome in Human Myeloid Cells. <i>PLoS ONE</i> , 2014, 9, e84953.	1.1	73
1206	Chronic hepatitis C and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 11033.	1.4	178
1207	Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection. <i>ISRN Gastroenterology</i> , 2014, 2014, 1-7.	1.5	11
1208	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	1.4	28
1209	Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 157-164.	1.4	20
1210	Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Naïve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3. <i>Intervirology</i> , 2014, 57, 23-30.	1.2	15
1211	Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy. <i>Intervirology</i> , 2014, 57, 289-296.	1.2	2
1212	Cost Savings of Red Cell Salvage During Cesarean Delivery. <i>Obstetrics and Gynecology</i> , 2014, 124, 690-696.	1.2	22
1213	Current status of fibrosis markers. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 253-259.	1.0	38

#	ARTICLE	IF	CITATIONS
1214	Distinctive intrahepatic characteristics of paediatric and adult pathogenesis of chronic hepatitis C infection. <i>Clinical Microbiology and Infection</i> , 2014, 20, O998-O1009.	2.8	12
1215	Pretreatment prediction of the outcome of response-guided peginterferon- α and ribavirin therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1996-2005.	1.4	2
1216	Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. <i>Epidemiology and Infection</i> , 2014, 142, 270-286.	1.0	161
1217	What is the future of ribavirin therapy for hepatitis C?. <i>Antiviral Research</i> , 2014, 104, 34-39.	1.9	41
1218	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.	1.8	88
1219	Vaccinations in Older Adults with Gastrointestinal Diseases. <i>Clinics in Geriatric Medicine</i> , 2014, 30, 17-28.	1.0	10
1220	Sexually transmitted infections in men who have sex with men. <i>Clinics in Dermatology</i> , 2014, 32, 181-188.	0.8	23
1221	The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. <i>Drug and Alcohol Dependence</i> , 2014, 134, 222-227.	1.6	2
1222	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterology and Hepatology</i> , 2014, 37, 1-8.	0.2	2
1223	Fibrosis in Hepatitis C Patients Predicts Complications After Elective Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 7-10.	1.5	45
1224	Coût-efficacité et VHC: mise au point. <i>Journal Des Anti-infectieux</i> , 2014, 16, 50-63.	0.1	0
1225	Adiponectin: A multitasking player in the field of liver diseases. <i>Diabetes and Metabolism</i> , 2014, 40, 95-107.	1.4	54
1226	Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1051-1054.e1.	2.4	19
1227	TP53 polymorphism as a risk factor for hepatocellular carcinoma in hepatitis C virus-infected Egyptian patients. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2014, 1, 9-15.	0.2	8
1228	Chemopreventive strategies in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 45-54.	8.2	247
1229	Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. <i>Journal of Gastroenterology</i> , 2014, 49, 138-147.	2.3	73
1230	Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary. <i>Quality of Life Research</i> , 2014, 23, 1489-1496.	1.5	1
1231	MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 719-728.	1.9	32

#	ARTICLE	IF	CITATIONS
1232	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, E163-71.	1.8	12
1233	Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2014, 146, 420-429.	0.6	188
1234	Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 14-24.	0.7	22
1235	Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP and PROPEL studies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 533-542.	1.1	2
1236	Genetic diversity of hepatitis C virus quasispecies in chronic renal failure patients in Midwest Brazil. <i>Archives of Virology</i> , 2014, 159, 1917-1925.	0.9	0
1237	Caregiver burden and its determinants among family members of patients with chronic viral hepatitis in Shanghai, China: a community-based survey. <i>BMC Infectious Diseases</i> , 2014, 14, 82.	1.3	6
1238	Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 273-281.	1.1	4
1239	Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. <i>Hepatology International</i> , 2014, 8, 83-93.	1.9	8
1240	The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 322-330.	1.9	21
1241	Can hepatitis C virus infection be eradicated in people who inject drugs?. <i>Antiviral Research</i> , 2014, 104, 62-72.	1.9	96
1242	Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD005441.	1.5	23
1243	Pegylated interferon 2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose. <i>Liver International</i> , 2014, 34, 1522-1531.	1.9	5
1244	Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent C-Nucleoside Monophosphate Prodrug. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1930-1942.	1.4	38
1245	Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. <i>Hepatology</i> , 2014, 59, 49-57.	3.6	81
1246	Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. <i>Journal of Hepatology</i> , 2014, 60, 490-499.	1.8	135
1247	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Hepatology</i> , 2014, 60, 477-486.	3.6	14
1248	Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2014, 60, 22-26.	1.6	28
1249	HCV RNA detection in HCV antibody-positive patients with the COBAS AmpliPrep/COBAS TaqMan HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. <i>Journal of Clinical Virology</i> , 2014, 60, 336-340.	1.6	9

#	ARTICLE	IF	CITATIONS
1250	Hepatitis C Virus. , 2014, , 859-877.		0
1251	Multiplex Microfluidic Paper-based Immunoassay for the Diagnosis of Hepatitis C Virus Infection. Analytical Chemistry, 2014, 86, 5338-5344.	3.2	106
1252	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. Journal of Oncology Practice, 2014, 10, e167-e174.	2.5	19
1253	Pegylated interferons α1 and α2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells. Journal of Viral Hepatitis, 2014, 21, e1-9.	1.0	11
1254	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs, 2014, 23, 1211-1223.	1.9	28
1255	Correlates of drug use cessation among participants in the Canadian HIV&HCV Co-infection Cohort. Drug and Alcohol Dependence, 2014, 137, 121-128.	1.6	13
1256	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology, 2014, 59, 2101-2109.	3.6	38
1257	ABT-450&Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine, 2014, 370, 1983-1992.	13.9	669
1258	Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies. Molecular Biology Reports, 2014, 41, 337-345.	1.0	13
1259	Sustained Virological Response After 4&Weeks of Telaprevir, Peginterferon, and Ribavirin in an Asian Patient with Genotype 1 Chronic Hepatitis C and IL28B Genotype CC. Digestive Diseases and Sciences, 2014, 59, 737-739.	1.1	2
1260	Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. Molecular Diagnosis and Therapy, 2014, 18, 25-38.	1.6	2
1261	Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology, 2014, 59, 1343-1350.	3.6	11
1262	Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Medicine, 2014, 15, 108-115.	1.0	28
1263	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-&Based Regimens. Clinical Pharmacology and Therapeutics, 2014, 95, 141-146.	2.3	83
1264	Sequence Analysis of Hepatitis C Virus From Patients With Relapse After a Sustained Virological Response: Relapse or Reinfection?. Journal of Infectious Diseases, 2014, 209, 38-45.	1.9	30
1265	Fast, reliable and low cost user-developed protocol for detection, quantification and genotyping of hepatitis C virus. Journal of Virological Methods, 2014, 196, 104-112.	1.0	17
1266	Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. International Journal of Antimicrobial Agents, 2014, 43, 17-25.	1.1	11
1267	Phylogeny and molecular evolution of the hepatitis C virus. Infection, Genetics and Evolution, 2014, 21, 67-82.	1.0	59

#	ARTICLE	IF	CITATIONS
1268	How to optimize current treatment of genotype 2 hepatitis C virus infection. <i>Liver International</i> , 2014, 34, 13-17.	1.9	5
1269	Integrated Strategies for Identifying Leads That Target the NS3 Helicase of the Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2074-2090.	2.9	17
1270	Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1880-1892.	2.9	32
1271	No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2106-2112.e1.	2.4	37
1272	Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 561-571.	1.9	43
1273	Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. <i>Liver International</i> , 2014, 34, 1198-1206.	1.9	90
1274	Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD005642.	1.5	9
1275	Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. <i>British Journal of Pharmacology</i> , 2014, 171, 237-252.	2.7	137
1276	Hepatitis C Virus Infection and Kidney Transplantation in 2014: What's New?. <i>American Journal of Transplantation</i> , 2014, 14, 2206-2220.	2.6	67
1277	Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. <i>Clinical Therapeutics</i> , 2014, 36, 2047-2063.e3.	1.1	10
1278	HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals. <i>Current HIV/AIDS Reports</i> , 2014, 11, 241-249.	1.1	12
1279	The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201.	1.2	11
1281	Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 960-969.	2.9	8
1282	Hospitalizations And Costs Associated With Hepatitis C And Advanced Liver Disease Continue To Increase. <i>Health Affairs</i> , 2014, 33, 1728-1735.	2.5	39
1283	CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients. <i>Journal of Clinical Virology</i> , 2014, 61, 423-429.	1.6	13
1284	Quantification of portal bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. <i>Modern Pathology</i> , 2014, 27, 1035-1045.	2.9	19
1285	Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, S91-S97.	1.8	24
1286	Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. <i>Hepatology International</i> , 2014, 8, 540-549.	1.9	6

#	ARTICLE	IF	CITATIONS
1287	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 716-721.	0.8	8
1288	Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	3
1289	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
1290	Personalized Medicine and Human Genetic Diversity. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a008581-a008581.	2.9	140
1291	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.4	57
1292	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 518-531.	1.9	107
1293	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.	0.2	33
1294	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet, The</i> , 2014, 384, 1597-1605.	6.3	316
1295	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	1.9	62
1296	Low IL10 serum levels as key factor for predicting the sustained virological response to IFN±/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype. <i>Human Immunology</i> , 2014, 75, 895-900.	1.2	9
1297	Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. <i>Hepatology</i> , 2014, 59, 1293-1302.	3.6	242
1298	Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3496-3503.	1.4	30
1299	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. <i>Archives of Disease in Childhood</i> , 2014, 99, 505-510.	1.0	25
1300	Daclatasvir+Asunaprevir: First Global Approval. <i>Drugs</i> , 2014, 74, 1559-1571.	4.9	50
1301	Cyclohexane-Fused Octahydroquinolizine Alkaloids from <i>Myrioneuron faberi</i> with Activity against Hepatitis C Virus. <i>Journal of Organic Chemistry</i> , 2014, 79, 7945-7950.	1.7	33
1302	Neurotoxicity of commonly used hepatic drugs. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 120, 675-682.	1.0	10
1303	Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3485-3495.	1.4	56
1304	Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. <i>BMC Public Health</i> , 2014, 14, 645.	1.2	33

#	ARTICLE	IF	CITATIONS
1305	Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar Pakistan. <i>Virology Journal</i> , 2014, 11, 127.	1.4	15
1306	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246.	1.8	126
1307	Comparison of transient elastography (<scp>FibroScan</scp>), <scp>FibroTest</scp>, <scp>APRI</scp> and two algorithms combining these noninvasive tests for liver fibrosis staging in <scp>HIV</scp>/<scp>HCV</scp> coinfected patients: <scp>ANRS CO13 HEPAVIH</scp> and <scp>FIBROSTIC</scp> collaboration. <i>HIV Medicine</i> , 2014, 15, 30-39.	1.0	50
1308	Youâ€™re Not the One: Treating Subjects Co-infected with Hepatitis C Genotypes 2 and 3 and Human Immunodeficiency Virus. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1681-1683.	1.1	0
1309	Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1725-1732.	1.3	27
1310	Response-Guided Therapy for Hepatitis C Genotype 2 and 3 in Those with HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1946-1949.	1.1	2
1311	Impact of Anti-Thymocyte Globulin During Immunosuppression Induction in Patients with Hepatitis C After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2804-2812.	1.1	11
1312	Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 31.	2.5	16
1314	Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 162-165.	2.3	17
1315	Alternative interferons and immunomodulators in the treatment of hepatitis C. <i>Liver International</i> , 2014, 34, 133-138.	1.9	3
1316	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	1.7	3
1317	Identification of Weak Points of Hepatitis C Virus NS3 Protease Inhibitors Using Surface Plasmon Resonance Biosensor-Based Interaction Kinetic Analysis and Genetic Variants. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1802-1811.	2.9	4
1318	Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 145-151.	1.1	10
1319	Susceptibility-weighted MR Imaging in the Grading of Liver Fibrosis: A Feasibility Study. <i>Radiology</i> , 2014, 270, 149-158.	3.6	37
1320	Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. <i>Quality of Life Research</i> , 2014, 23, 561-570.	1.5	22
1321	Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. <i>Quality of Life Research</i> , 2014, 23, 877-886.	1.5	18
1322	Community-based HCV screening: knowledge and attitudes in a high risk urban population. <i>BMC Infectious Diseases</i> , 2014, 14, 74.	1.3	45
1323	Tickling the TLR7 to cure viral hepatitis. <i>Journal of Translational Medicine</i> , 2014, 12, 129.	1.8	26

#	ARTICLE	IF	CITATIONS
1324	High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Research Notes, 2014, 7, 266.	0.6	8
1326	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Research, 2014, 105, 135-142.	1.9	16
1327	Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2014, 59, 765-773.	2.9	376
1328	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	13.9	1,065
1329	Response to guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1574-1581.	1.4	17
1330	Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks. Clinical Infectious Diseases, 2014, 59, 411-415.	2.9	15
1331	Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. British Journal of Dermatology, 2014, 171, 1307-1317.	1.4	24
1332	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut, 2014, 63, 207-215.	6.1	29
1333	Hepatitis B and hepatitis C virus infections among antiretroviral-naïve and -experienced HIV co-infected adults. Journal of Medical Microbiology, 2014, 63, 742-747.	0.7	14
1334	High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney International, 2014, 86, 619-624.	2.6	35
1335	Nitazoxanide for chronic hepatitis C. The Cochrane Library, 2014, 2014, CD009182.	1.5	11
1336	Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. Antiviral Research, 2014, 107, 23-30.	1.9	115
1337	Review: Occult hepatitis C virus infection: Still remains a controversy. Journal of Medical Virology, 2014, 86, 1491-1498.	2.5	21
1338	Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C. Journal of Clinical Virology, 2014, 60, 190-195.	1.6	11
1339	Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 958, 43-47.	1.2	32
1340	Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection. Experimental and Molecular Pathology, 2014, 96, 36-41.	0.9	4
1341	Efficacy and safety of peginterferon plus ribavirin for patients aged 65 years with chronic hepatitis C: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 440-450.	0.7	17
1342	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. Journal of Pharmaceutical and Biomedical Analysis, 2014, 90, 119-126.	1.4	20

#	ARTICLE	IF	CITATIONS
1343	Hepatitis B and C. Clinics in Geriatric Medicine, 2014, 30, 149-167.	1.0	4
1344	Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology, 2014, 146, 442-452.e1.	0.6	123
1345	Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. Journal of Hepatology, 2014, 60, 1118-1126.	1.8	18
1346	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. Clinical Gastroenterology and Hepatology, 2014, 12, 327-333.e1.	2.4	11
1347	Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C. Drugs, 2014, 74, 1127-1146.	4.9	75
1348	Review article: <scp>HCV</scp> genotype 3 – the new treatment challenge. Alimentary Pharmacology and Therapeutics, 2014, 39, 686-698.	1.9	103
1349	The Rapid Evolution of Treatment Strategies for Hepatitis C. American Journal of Gastroenterology, 2014, 109, 628-635.	0.2	71
1350	The cost-effectiveness of boceprevir for hepatitis C. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 319-334.	0.7	1
1351	Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 264-269.	1.3	22
1352	Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFN–2a and ribavirin in Iranian patients with chronic hepatitis C. Journal of Medical Virology, 2014, 86, 1499-1506.	2.5	23
1353	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine, 2014, 370, 1993-2001.	13.9	752
1354	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transplant International, 2014, 27, 877-891.	0.8	23
1355	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics, 2014, 53, 409-427.	1.6	35
1356	Hepatitis <scp>C</scp> virus core antigen testing in liver and kidney transplant recipients. Journal of Viral Hepatitis, 2014, 21, 769-779.	1.0	25
1357	The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 240-247.	0.6	16
1358	A survey of breakthrough therapy designations. Nature Biotechnology, 2014, 32, 323-330.	9.4	32
1359	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2014, 384, 414-426.	6.3	376
1360	Factors associated with efficacy of pegylated interferon–1± plus ribavirin for chronic hepatitis C after renal transplantation. Gene, 2014, 544, 101-106.	1.0	3

#	ARTICLE	IF	CITATIONS
1361	Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, 770-776.	1.8	10
1362	Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 179-181.	0.4	1
1363	Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 58-62.	0.4	9
1364	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI est fini". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 432-439.	0.7	10
1365	microRNAs: Novel players in hepatitis C virus infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 664-675.	0.7	20
1366	Hepatitis C. <i>Disease-a-Month</i> , 2014, 60, 201-212.	0.4	4
1367	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2014, 19, 747-753.	0.6	6
1368	HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. <i>Antiviral Therapy</i> , 2015, 20, 177-183.	0.6	17
1369	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051.	3.3	19
1370	Hepatitis C virus associated glomerulopathies. <i>World Journal of Gastroenterology</i> , 2014, 20, 7544.	1.4	90
1371	Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. <i>World Journal of Gastroenterology</i> , 2014, 20, 2927.	1.4	48
1372	Management of hepatitis C virus infection in hemodialysis patients. <i>World Journal of Hepatology</i> , 2014, 6, 419.	0.8	10
1373	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546.	2.0	77
1374	Implementation and Evaluation of a Multicomponent Quality Improvement Intervention to Improve Efficiency of Hepatitis C Screening and Diagnosis. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2014, 40, 351-AP1.	0.4	20
1375	Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B. <i>Antiviral Therapy</i> , 2014, 19, 479-490.	0.6	38
1376	Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125.	1.5	2
1378	Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1123-1126.	0.8	5
1379	Hepatitis C virus infection. , 0, , 295-310.		0

#	ARTICLE	IF	CITATIONS
1380	Follow-up Testing for Hepatitis C Virus Infection: An Analysis of Massachusetts Surveillance Data, 2007â€“2010. Public Health Reports, 2014, 129, 403-407.	1.3	0
1381	Evaluation of Hepatic Fibrosis Using Intravoxel Incoherent Motion in Diffusion-Weighted Liver MRI. Journal of Computer Assisted Tomography, 2014, 38, 110-116.	0.5	82
1382	Prevalence of HCV Infection Among Clients in Community-Based Health Settings in Hawaii, 2002â€“2010: Assessing Risk Factors. American Journal of Public Health, 2014, 104, 1534-1539.	1.5	8
1383	Multicenter Study of Pegylated Interferon Î±2a Monotherapy for Hepatitis C Virusâ€“Infected Patients on Hemodialysis: <sc>REACH</sc> Study. Therapeutic Apheresis and Dialysis, 2014, 18, 603-611.	0.4	17
1384	Previous Exposure to HCV Among Persons Born During 1945â€“1965: Prevalence and Predictors, United States, 1999â€“2008. American Journal of Public Health, 2014, 104, 474-481.	1.5	40
1385	Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132.		4
1386	Long-term Pegylated Interferon-Î±2a Treatment for Chronic Hepatitis C in an Elderly Renal Transplant Recipient. Medicine (United States), 2015, 94, e390.	0.4	3
1387	Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection. Medicine (United States), 2015, 94, e1234.	0.4	6
1388	Hepatitis C guidance: AASLDâ€“IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 2015, 62, 932-954.	3.6	1,139
1389	Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the <sc>QUEST</sc>â€“1, <sc>QUEST</sc>â€“2 and <sc>PROMISE</sc> studies. Journal of Viral Hepatitis, 2015, 22, 639-650.	1.0	13
1392	Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C. Molecular Medicine Reports, 2015, 12, 323-330.	1.1	18
1393	Use of antiviral therapy in patients with chronic hepatitis C. Open Medicine (Poland), 2014, 10, 209-215.	0.6	4
1394	Efficacy and Safety of Telaprevir, Pegylated Interferon α-2b and Ribavirin Triple Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b. Internal Medicine, 2015, 54, 2551-2560.	0.3	7
1395	Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 41-50.	2.3	22
1396	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). Antiviral Therapy, 2016, 21, 195-205.	0.6	18
1397	The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antiviral Therapy, 2015, 20, 185-194.	0.6	5
1398	PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 465-474.	0.7	0
1399	Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterology, 2015, 2, e000049.	1.1	13

#	ARTICLE	IF	CITATIONS
1400	MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomarker Insights, 2015, 10s4, BML.S29512.	1.0	26
1401	Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis. Intervirology, 2015, 58, 373-381.	1.2	7
1402	Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Scientific Reports, 2015, 5, 17030.	1.6	26
1403	Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression. Scientific Reports, 2015, 5, 13994.	1.6	7
1404	New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Effectiveness and Resource Allocation, 2015, 13, 17.	0.6	13
1405	Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clinical Pharmacology and Therapeutics, 2015, 98, 394-402.	2.3	15
1406	Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. Journal of Medical Virology, 2015, 87, 1361-1367.	2.5	0
1407	Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. Journal of Medical Virology, 2015, 87, 1904-1912.	2.5	7
1408	Role of complement component C4 in treatment response and disease progression in chronic hepatitis C patients. Journal of Viral Hepatitis, 2015, 22, 671-674.	1.0	7
1409	Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transplant International, 2015, 28, 980-989.	0.8	21
1410	IFN-free combination of sofosbuvir and simeprevir for treatment of genotype 1 hepatitis C infection. Future Virology, 2015, 10, 1133-1144.	0.9	0
1411	The birth and potential death of IL28B genotyping for hepatitis C therapy. Personalized Medicine, 2015, 12, 55-57.	0.8	2
1412	A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. BMC Infectious Diseases, 2015, 15, 553.	1.3	10
1413	Development of sofosbuvir for the treatment of hepatitis C virus infection. Annals of the New York Academy of Sciences, 2015, 1358, 56-67.	1.8	31
1414	A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients. Apmis, 2015, 123, 482-489.	0.9	4
1415	Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag. Journal of Medical Virology, 2015, 87, 2090-2097.	2.5	3
1416	A Window of Opportunity: Maximizing the Effectiveness of New HCV Regimens in the United States With the Expansion of the Affordable Care Act. American Journal of Public Health, 2015, 105, 457-463.	1.5	7
1417	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1768-1774.	1.4	14

#	ARTICLE	IF	CITATIONS
1418	Therapy for hepatitis C genotype 3: moving forward. <i>Journal of Viral Hepatitis</i> , 2015, 22, 683-690.	1.0	12
1419	Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 977-982.	1.0	17
1420	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2015, 45, 745-754.	1.8	12
1421	Monocyte-derived dendritic cells in children with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1170-1174.	0.8	0
1422	Evaluating the performance of the focus HerpeSelect [®] HSV-2 IgG in veterans with chronic hepatitis C infection. <i>Journal of Medical Virology</i> , 2015, 87, 1377-1381.	2.5	2
1423	Hepatitis C in children in times of change. <i>Current Opinion in Pediatrics</i> , 2015, 27, 614-618.	1.0	7
1424	Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. <i>Addiction</i> , 2015, 110, 129-143.	1.7	39
1425	Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. <i>Hepatology</i> , 2015, 62, 409-416.	3.6	58
1426	Activity-based profiling of the proteasome pathway during hepatitis C virus infection. <i>Proteomics</i> , 2015, 15, 3815-3825.	1.3	6
1427	Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon-13 and carbon-14. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 250-260.	0.5	1
1428	Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs. <i>Hepatology</i> , 2015, 62, 1298-1303.	3.6	26
1429	IFN- γ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naïve patients without access to protease inhibitors. <i>Journal of Medical Virology</i> , 2015, 87, 1702-1715.	2.5	8
1430	Role of fibroscan, TGF- β 1, and YKL-40 in the detection of hepatic fibrosis in chronic hepatitis c patients with and without schistosomiasis. <i>Egyptian Liver Journal</i> , 2015, 5, 47-53.	0.3	1
1431	Project P.E.A.C.H. (Pathway and Education Toward Adherence and Completion in Hepatitis C Therapy). <i>Gastroenterology Nursing</i> , 2015, 38, 369-378.	0.2	4
1432	Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18439-18453.	1.8	22
1433	Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. <i>Risk Management and Healthcare Policy</i> , 2015, 8, 45.	1.2	18
1434	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1843.	0.8	41
1435	Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. <i>Journal of Korean Medical Science</i> , 2015, 30, 1577.	1.1	0

#	ARTICLE	IF	CITATIONS
1436	Hepatitis: Prevalence, Risk Factors and Associated Co-morbidities in Local Population of Karachi, Pakistan. <i>Journal of Bioequivalence & Bioavailability</i> , 2015, 07, .	0.1	1
1437	Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.	0.8	41
1440	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. <i>Viruses</i> , 2015, 7, 5206-5224.	1.5	102
1441	Hepatitis C Related Chronic Liver Cirrhosis: Feasibility of Texture Analysis of MR Images for Classification of Fibrosis Stage and Necroinflammatory Activity Grade. <i>PLoS ONE</i> , 2015, 10, e0118297.	1.1	33
1442	The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection. <i>PLoS ONE</i> , 2015, 10, e0120866.	1.1	2
1443	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	1.1	2
1444	Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. <i>PLoS ONE</i> , 2015, 10, e0126031.	1.1	10
1445	Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004â€“2009. <i>PLoS ONE</i> , 2015, 10, e0132056.	1.1	8
1446	Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. <i>PLoS ONE</i> , 2015, 10, e0135963.	1.1	18
1447	Non-Invasive Evaluation of Hepatic Fibrosis: The Diagnostic Performance of Magnetic Resonance Elastography in Patients with Viral Hepatitis B or C. <i>PLoS ONE</i> , 2015, 10, e0140068.	1.1	24
1448	Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Na ⁺ ve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0145953.	1.1	60
1449	Prediction of liver cirrhosis, using diagnostic imaging tools. <i>World Journal of Hepatology</i> , 2015, 7, 2069.	0.8	100
1450	Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 279.	0.9	10
1451	IFN-Î»: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	0.7	8
1452	Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	0.9	6
1453	Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-Î±Based Therapy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-16.	1.4	7
1454	Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?. <i>International Journal of Hepatology</i> , 2015, 2015, 1-9.	0.4	2
1455	A case of chronic hepatitis C, genotype 3b relapsed after interferon monotherapy, treated with pegylated interferon plus ribavirin and achieved sustained virological response. <i>Acta Hepatologica Japonica</i> , 2015, 56, 88-95.	0.0	0

#	ARTICLE	IF	CITATIONS
1456	Pegylated Interferon- α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat. <i>Mediators of Inflammation</i> , 2015, 2015, 1-4.	1.4	2
1457	Organizing Pneumonia Associated with Pegylated Interferon- α and Ribavirin Therapy. <i>Case Reports in Pulmonology</i> , 2015, 2015, 1-4.	0.2	1
1458	Autoantibodies in chronic hepatitis C: A clinical perspective. <i>World Journal of Hepatology</i> , 2015, 7, 1074.	0.8	30
1459	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-189.	0.6	18
1460	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-332.	0.6	3
1462	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. <i>Annals of Hepatology</i> , 2015, 14, S7-S48.	0.6	4
1463	Percutaneous injury: risks and prevention. , 0, , 703-708.		0
1464	Viral hepatitis prevalence in patients with active and latent tuberculosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 8920.	1.4	20
1465	Hepatitis C infection in hemodialysis patients: A review. <i>World Journal of Hepatology</i> , 2015, 7, 885.	0.8	49
1467	Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. <i>Open Medicine (Poland)</i> , 2015, 10, 25-33.	0.6	0
1468	Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. <i>Annals of Hepatology</i> , 2015, 14, 36-45.	0.6	2
1469	Treating hepatitis C virus in children: time for a new paradigm. <i>Journal of Virus Eradication</i> , 2015, 1, 203-205.	0.3	10
1470	Hepatitis C " Overview and Update in Treatment. , 2015, , .		0
1471	Advances in HCV Therapy. , 2015, , .		0
1472	New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. , 2015, , .		0
1473	rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 184-191.	1.0	4
1474	Effect of Steady-State Faldaprevir on the Pharmacokinetics of Steady-State Methadone and Buprenorphine-Naloxone in Subjects Receiving Stable Addiction Management Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 498-504.	1.4	4
1475	Biomarkers in HCV Infection. <i>Advances in Clinical Chemistry</i> , 2015, 70, 131-196.	1.8	4

#	ARTICLE	IF	CITATIONS
1476	Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9954.	1.6	53
1477	Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients. <i>Infectious Diseases</i> , 2015, 47, 658-661.	1.4	4
1478	Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype–genotype correlation study. <i>Genes and Immunity</i> , 2015, 16, 321-329.	2.2	25
1479	Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon ± Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection. <i>Gut and Liver</i> , 2015, 9, 516.	1.4	2
1480	Hepatitis C virus genetic variability and evolution. <i>World Journal of Hepatology</i> , 2015, 7, 831.	0.8	85
1481	Gene Therapy for Hepatitis C Virus Infection. , 2015, , 191-226.		0
1482	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 11.	0.9	4
1483	Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection. <i>Medicine (United States)</i> , 2015, 94, e1296.	0.4	1
1484	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. <i>BMJ Open</i> , 2015, 5, e008876.	0.8	34
1485	Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing. <i>United European Gastroenterology Journal</i> , 2015, 3, 364-370.	1.6	3
1486	Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1447-1462.	1.4	1
1487	Epstein–Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. <i>Arab Journal of Gastroenterology</i> , 2015, 16, 84-89.	0.4	1
1488	Long-term follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2015, 71, 18-21.	1.6	13
1489	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015, 16, 100-110.	2.0	22
1490	Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population. <i>Kidney and Blood Pressure Research</i> , 2015, 40, 258-265.	0.9	11
1491	How will we manage acute <sc>HCV</sc> in men having sex with men in the era of all oral therapy?. <i>Journal of Viral Hepatitis</i> , 2015, 22, 2-7.	1.0	7
1492	Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 91-96.	0.1	8
1493	Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. <i>International Journal of Pharmaceutics</i> , 2015, 479, 181-188.	2.6	24

#	ARTICLE	IF	CITATIONS
1494	Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2015, 42, 329-338.	0.8	22
1495	TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67.	1.6	6
1496	Vasculitides and Hepatitis C Infection. , 2015, , 773-791.		0
1497	Current evidence in the field of the management with TNF- α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 641-650.	1.4	31
1498	Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 671-685.	1.9	24
1499	Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2813-2823.	1.6	30
1500	Hepatitis C in Hospital Medicine. <i>Hospital Medicine Clinics</i> , 2015, 4, 163-176.	0.2	0
1501	Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. <i>Archives of Virology</i> , 2015, 160, 1105-1112.	0.9	6
1502	Targeting Cellular Squalene Synthase, an Enzyme Essential for Cholesterol Biosynthesis, Is a Potential Antiviral Strategy against Hepatitis C Virus. <i>Journal of Virology</i> , 2015, 89, 2220-2232.	1.5	24
1503	Diagnosis and Management of Hepatitis C Virus Infection. <i>Journal of the Association for Laboratory Automation</i> , 2015, 20, 519-538.	2.8	32
1504	Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort. <i>Clinical Infectious Diseases</i> , 2015, 60, 514-522.	2.9	11
1505	Acoustic radiation force impulse quantification of spleen elasticity for assessing liver fibrosis. <i>Abdominal Imaging</i> , 2015, 40, 738-744.	2.0	17
1506	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	1.4	10
1507	Impaired induction of <i>interleukin 28B</i> and expression of <i>interferon-γ</i> 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1075-1084.	1.4	14
1508	Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection. <i>Clinical Therapeutics</i> , 2015, 37, 243-267.	1.1	28
1509	Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis. <i>Hepatology Research</i> , 2015, 45, E89-98.	1.8	9
1510	Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfecting patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 385-393.	1.3	4
1511	Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 471-479.	1.5	10

#	ARTICLE	IF	CITATIONS
1512	Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian Patients. <i>Journal of Medical Virology</i> , 2015, 87, 428-440.	2.5	6
1513	Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. <i>Lupus</i> , 2015, 24, 1029-1036.	0.8	14
1514	The genotype <sc>CC</sc> of <i><sc>IL</sc>28B</i>...<sc>SNP</sc> rs12979860 is significantly associated with a sustained virological response in chronic HCVâ€infecte<sc>P</sc>akistani patients. <i>Journal of Digestive Diseases</i> , 2015, 16, 293-298.	0.7	14
1515	Genetic variant of <i><sc>IL</sc>28B</i> rs12979860, as predictive marker of interferonâ€based therapy in Pakistani population. <i>Apmis</i> , 2015, 123, 342-349.	0.9	11
1516	Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 303-311.	0.8	20
1517	Health state utilities associated with attributes of treatments for hepatitis C. <i>European Journal of Health Economics</i> , 2015, 16, 1005-1018.	1.4	35
1518	Drugâ€induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. <i>Hepatology Research</i> , 2015, 45, E156-60.	1.8	5
1519	Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin. <i>Current Hepatology Reports</i> , 2015, 14, 53-59.	0.4	0
1520	Hepatitis C Virus Testing Perspectives Among Primary Care Physicians in Four Large Primary Care Settings. <i>Health Promotion Practice</i> , 2015, 16, 256-263.	0.9	19
1521	Faldaprevir for the Treatment of Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4985-4996.	1.8	16
1522	A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic Data. <i>Evolutionary Bioinformatics</i> , 2015, 11, EBO.S20853.	0.6	0
1523	Rapid detection of HCV genotyping 1a, 1b, 2a, 3a, 3b and 6a in a single reaction using two-melting temperature codes by a real-time PCR-based assay. <i>Journal of Virological Methods</i> , 2015, 222, 85-90.	1.0	13
1524	Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3984-3991.	1.0	11
1525	Effect of Gender on the Response to Hepatitis C Treatment in anInner-City Population. <i>Women's Health Issues</i> , 2015, 25, 289-293.	0.9	6
1526	Pay for Performance in Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2042-2047.	2.4	8
1527	Structureâ€activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. <i>Molecular Diversity</i> , 2015, 19, 829-853.	2.1	8
1528	Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1015-1030.	0.9	14
1529	12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. <i>Digestive and Liver Disease</i> , 2015, 47, 864-868.	0.4	0

#	ARTICLE	IF	CITATIONS
1530	Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C Infection: An exploratory study. Indian Journal of Pharmacology, 2015, 47, 72.	0.4	4
1531	Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings. American Journal of Drug and Alcohol Abuse, 2015, 41, 88-92.	1.1	10
1532	Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?. Journal of Hepatology, 2015, 63, 1254-1262.	1.8	48
1533	Clinical Applications of Quantitative Real-Time PCR in Virology. Methods in Microbiology, 2015, 42, 161-197.	0.4	6
1534	Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients. Archives of Virology, 2015, 160, 2181-2195.	0.9	21
1535	Non-invasive serum fibrosis markers: A study in chronic hepatitis. BiolImpacts, 2015, 5, 17-23.	0.7	35
1536	Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1157-1165.	1.5	1
1537	The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection. Jundishapur Journal of Microbiology, 2015, 8, e17841.	0.2	4
1539	Prevalence of Hepatitis C Virus Testing in Cohorts Born Between 1945 and 1965 in the U.S.. American Journal of Preventive Medicine, 2015, 48, e7-e9.	1.6	16
1540	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. Addiction Science & Clinical Practice, 2015, 10, 6.	1.2	1
1541	Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. European Journal of Internal Medicine, 2015, 26, 292-296.	1.0	4
1542	Natural History of Hepatitis C. , 2015, , 120-130.		0
1543	Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences, 2015, 60, 1045-1051.	1.1	21
1544	Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers. Journal of Urban Health, 2015, 92, 193-213.	1.8	49
1545	Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System. Journal of Urban Health, 2015, 92, 379-386.	1.8	33
1546	A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. Journal of Urban Health, 2015, 92, 635-649.	1.8	18
1547	The Need for Higher Standards in Correctional Healthcare to Improve Public Health. Journal of General Internal Medicine, 2015, 30, 503-507.	1.3	20
1548	Is rs8099917 Polymorphism of IL-28B Gene a Good Predictor of Response to Therapy of HCV than rs12979860? An Egyptian Study. Cell Biochemistry and Biophysics, 2015, 71, 307-314.	0.9	5

#	ARTICLE	IF	CITATIONS
1549	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. <i>Annals of Internal Medicine</i> , 2015, 162, 619-629.	2.0	92
1550	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. <i>Journal of Hepatology</i> , 2015, 63, 337-345.	1.8	148
1551	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	1.8	54
1552	<i>IL28B</i> polymorphism and early anemia predict the rapid null response in genotype 1 chronic hepatitis C with dual therapy. <i>Advances in Digestive Medicine</i> , 2015, 2, 128-134.	0.1	0
1553	The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus. <i>JAMA Internal Medicine</i> , 2015, 175, 169.	2.6	10
1554	Prevalence of abnormal glycometabolism in treatment-naïve patients with hepatitis C virus infection in a Chinese Han population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1049-1056.	1.4	4
1555	Organotin(iv) based anti-HCV drugs: synthesis, characterization and biochemical activity. <i>Dalton Transactions</i> , 2015, 44, 10467-10478.	1.6	26
1556	Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. <i>Liver Transplantation</i> , 2015, 21, 823-830.	1.3	90
1557	Hepatic progenitor cells in children with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 561-569.	0.8	11
1558	Rapid identification of pathogens using molecular techniques. <i>Pathology</i> , 2015, 47, 191-198.	0.3	16
1559	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.	2.0	303
1560	Differential characteristics of primary infection and re-infection can cause backward bifurcation in HCV transmission dynamics. <i>Mathematical Biosciences</i> , 2015, 263, 51-69.	0.9	7
1561	Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. <i>Journal of General Internal Medicine</i> , 2015, 30, 950-957.	1.3	76
1562	Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. <i>Drugs in R and D</i> , 2015, 15, 335-349.	1.1	4
1563	Prospective comparison of transient elastography and liver biopsy for the assessment of fibrosis in chronic hepatitis C infection. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2015, 46, 293-297.	0.3	2
1564	Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 974-977.	2.9	9
1565	Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey. <i>BMC Infectious Diseases</i> , 2015, 15, 353.	1.3	7
1566	IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 649-653.	0.5	5

#	ARTICLE	IF	CITATIONS
1567	Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.	1.0	6
1568	Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation. <i>Indian Journal of Gastroenterology</i> , 2015, 34, 305-309.	0.7	7
1569	Assessment of health-related quality of life and related factors in patients with chronic liver disease. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 590-595.	0.3	23
1570	Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 555-565.	0.7	5
1571	Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. <i>BMC Gastroenterology</i> , 2015, 15, 98.	0.8	42
1572	Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. <i>BMC Public Health</i> , 2015, 15, 566.	1.2	11
1573	Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin. <i>Intervirology</i> , 2015, 58, 27-34.	1.2	7
1574	Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 2-7.	0.4	1
1575	A reliable multiplex genotyping assay for HCV using a suspension bead array. <i>Microbial Biotechnology</i> , 2015, 8, 93-102.	2.0	4
1576	Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 178-183.	1.4	6
1577	Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 337-344.	1.4	0
1578	Depression is not associated with peripheral insulin resistance in patients with chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 272-280.	1.0	2
1579	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882.	2.0	54
1580	Hepatitis C virus infection: a risk factor for Parkinson's disease. <i>Journal of Viral Hepatitis</i> , 2015, 22, 784-791.	1.0	75
1581	The effects of pegylated interferon- α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. <i>BMC Research Notes</i> , 2015, 8, 265.	0.6	4
1582	Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. <i>Health Affairs</i> , 2015, 34, 1666-1674.	2.5	30
1583	Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1307-1317.	2.0	7
1584	Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. <i>Clinics in Liver Disease</i> , 2015, 19, 591-604.	1.0	0

#	ARTICLE	IF	CITATIONS
1585	Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 901-909.	1.0	16
1586	Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 2171-2175.	1.3	2
1587	Discovery of Imidazo[1,2- <i>b</i>][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 977-981.	1.3	19
1588	HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. <i>American Journal of Preventive Medicine</i> , 2015, 49, 423-427.	1.6	1
1589	Screening of Imported Infectious Diseases Among Asymptomatic Sub-Saharan African and Latin American Immigrants: A Public Health Challenge. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 848-856.	0.6	64
1590	Direct-acting antivirals for hepatitis C treatment: effectiveness versus cost-effectiveness. <i>Future Virology</i> , 2015, 10, 929-932.	0.9	3
1591	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843.	1.0	17
1592	Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis. <i>Alexandria Journal of Medicine</i> , 2015, 51, 231-239.	0.4	3
1593	Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 871-881.	1.0	6
1594	The safety of daclatasvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1787-1797.	1.0	3
1595	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	1.6	44
1596	Treatment discontinuation with peg-interferon: what to consider. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 761-768.	1.3	1
1597	Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 390-398.	0.3	3
1598	Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 705-710.	0.7	2
1599	Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 981-989.	0.5	12
1600	Interferon- α plus ribavirin yields 98% sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. <i>Hepatology International</i> , 2015, 9, 578-585.	1.9	5
1601	Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study. <i>Internal Medicine Journal</i> , 2015, 45, 48-54.	0.5	6
1602	Hepatitis C virus and lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 246-256.	2.0	23

#	ARTICLE	IF	CITATIONS
1603	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	3.6	107
1604	The continuum of hepatitis C testing and care. <i>Hepatology</i> , 2015, 61, 783-789.	3.6	64
1605	Prevention of portal hypertension: From variceal development to clinical decompensation. <i>Hepatology</i> , 2015, 61, 375-381.	3.6	24
1606	Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 652-658.	0.8	3
1607	Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 829-834.	0.8	3
1608	Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. <i>Hepatology</i> , 2015, 61, 769-775.	3.6	114
1609	Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. <i>Hepatology</i> , 2015, 61, 834-842.	3.6	43
1610	<i>IL28B</i> genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. <i>Journal of Digestive Diseases</i> , 2015, 16, 90-97.	0.7	16
1611	Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection. <i>International Journal of Infectious Diseases</i> , 2015, 33, 15-21.	1.5	4
1612	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2015, 30, 115-129.	2.5	32
1614	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	0.6	49
1615	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45.	3.6	173
1616	Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 18-24.	1.0	19
1617	Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV genotype 4 in Egypt. <i>Journal of Viral Hepatitis</i> , 2015, 22, 245-253.	1.0	35
1618	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 49-54.	0.5	37
1619	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
1620	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
1621	Derivation of Phase 3 dosing for peginterferon lambda in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 63-72.	1.0	6

#	ARTICLE	IF	CITATIONS
1622	Derivation of Phase 3 dosing for peginterferon lambda in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 73-80.	1.0	8
1623	The long-term effects of anti-TNF- α agents on patients with chronic viral hepatitis C and B infections. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 40-45.	0.9	13
1624	Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. <i>Critical Reviews in Microbiology</i> , 2016, 42, 535-547.	2.7	33
1625	Specimen Requirements Selection, Collection, Transport, and Processing. , 0, , 57-77.		3
1626	Hepatitis C Virus. , 0, , 351-361.		0
1627	Assessment of 4 Cases of Kidney Transplantation from Hepatitis C Virus Antibody-Positive and RNA-Negative Donors to Antibody-Negative Recipients. <i>Transplantation Direct</i> , 2016, 2, e102.	0.8	1
1628	A Pilot Study of Rapid Hepatitis C Testing in Probation and Parole Populations in Rhode Island. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 214-223.	0.4	10
1629	High Hepatitis C Infection Rate among Baby Boomers in an Urban Primary Care Clinic: Results from the HepTLC Initiative. <i>Public Health Reports</i> , 2016, 131, 49-56.	1.3	20
1630	LIVER BIOPSY: IMPORTANCE OF SPECIMEN SIZE IN THE DIAGNOSIS AND STAGING OF CHRONIC VIRAL HEPATITIS. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 10.	0.5	14
1631	Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1217.	2.0	1
1632	Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C. <i>Medical Science Monitor</i> , 2016, 22, 1817-1826.	0.5	3
1633	Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. <i>Balkan Medical Journal</i> , 2016, 33, 18-26.	0.3	4
1634	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. <i>World Journal of Hepatology</i> , 2016, 8, 1295.	0.8	37
1635	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. <i>Military Medicine</i> , 2016, 181, 1375-1381.	0.4	1
1636	Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 861.	0.9	9
1637	Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. <i>World Journal of Hepatology</i> , 2016, 8, 1557.	0.8	46
1638	Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin $\alpha_5\beta_3$ for staging liver fibrosis in rat model. <i>International Journal of Nanomedicine</i> , 2016, 11, 1097.	3.3	19
1639	Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014. <i>Public Health Reports</i> , 2016, 131, 65-73.	1.3	29

#	ARTICLE	IF	CITATIONS
1640	Treatment of Hepatitis C with First Generation Protease Inhibitors. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2016, 05, .	0.1	0
1641	Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. <i>Annals of Gastroenterology</i> , 2016, 29, 282-96.	0.4	11
1642	Ophthalmological side effects of interferon therapy of chronic hepatitis C. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 209-216.	0.7	14
1643	Vaccinating Adult Patients with Cirrhosis: Trends over a Decade in the United States. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	0.7	12
1644	Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C. <i>Case Reports in Hepatology</i> , 2016, 2016, 1-3.	0.4	16
1645	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 262.	1.4	96
1646	Hepatitis C Therapy " Related Haematological Side Effects are Associated with Treatment Outcome / HematoloÅjka NeÅ¾eljena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja. <i>Serbian Journal of Experimental and Clinical Research</i> , 2016, 17, 9-14.	0.2	1
1647	Daclatasvir combined with peginterferon-Î± and ribavirin for the treatment of chronic hepatitis C: a meta-analysis. <i>SpringerPlus</i> , 2016, 5, 1569.	1.2	1
1648	HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2016, 11, e0154433.	1.1	8
1649	Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels. <i>PLoS ONE</i> , 2016, 11, e0142378.	1.1	4
1650	Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0147789.	1.1	21
1651	The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0148596.	1.1	15
1652	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.	1.1	5
1653	Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. <i>PLoS ONE</i> , 2016, 11, e0158989.	1.1	5
1654	Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37. <i>Medical Science Monitor</i> , 2016, 22, 1398-1402.	0.5	6
1655	Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016, 95, e2482.	0.4	13
1656	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2016, 95, e2482.	0.4	23
1657	Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 305-312.	0.8	9

#	ARTICLE	IF	CITATIONS
1658	An Interferon-Induced Digital Vasculitis-Like Syndrome. American Journal of Therapeutics, 2016, 23, e920-e925.	0.5	1
1659	The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. Journal of Viral Hepatitis, 2016, 23, 473-478.	1.0	29
1660	Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. Journal of Viral Hepatitis, 2016, 23, 677-686.	1.0	7
1661	Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4. European Journal of Gastroenterology and Hepatology, 2016, 28, 42-47.	0.8	4
1662	Comparison of Elecsys Anti-HCV II Assay With Other HCV Screening Assays. Journal of Clinical Laboratory Analysis, 2016, 30, 451-456.	0.9	4
1663	<i>n-3</i> polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial. Journal of Human Nutrition and Dietetics, 2016, 29, 345-353.	1.3	6
1664	Literature review of the distribution of hepatitis C virus genotypes across Europe. Journal of Medical Virology, 2016, 88, 2157-2169.	2.5	23
1665	Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach. Infection, Genetics and Evolution, 2016, 44, 61-68.	1.0	3
1666	Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers. Alimentary Pharmacology and Therapeutics, 2016, 43, 356-363.	1.9	2
1667	Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C. British Journal of Clinical Pharmacology, 2016, 81, 658-666.	1.1	1
1668	Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. Journal of Medical Virology, 2016, 88, 1659-1671.	2.5	23
1669	A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology, 2016, 64, 415-424.	3.6	19
1670	First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response. American Journal of Therapeutics, 2016, 23, e1612-e1618.	0.5	1
1671	Risk Factors, Clinical Presentation, and Outcomes in Overdose With Acetaminophen Alone or With Combination Products. Journal of Clinical Gastroenterology, 2016, 50, 85-91.	1.1	35
1672	The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen. Journal of Viral Hepatitis, 2016, 23, 330-339.	1.0	35
1673	Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. American Journal of Public Health, 2016, 106, 1276-1277.	1.5	22
1674	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open, 2016, 6, e009889.	0.8	42
1675	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. Journal of Translational Medicine, 2016, 14, 257.	1.8	20

#	ARTICLE	IF	CITATIONS
1677	Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. <i>International Journal of Circumpolar Health</i> , 2016, 75, 30696.	0.5	8
1678	(âˆ™)-Epigallocatechin-3-Gallate Enhances Hepatitis C Virus Double-Stranded RNA Intermediates-Triggered Innate Immune Responses in Hepatocytes. <i>Scientific Reports</i> , 2016, 6, 21595.	1.6	23
1679	Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain. <i>GastroenterologËa Y HepatologËa (English Edition)</i> , 2016, 39, 656-662.	0.0	1
1680	Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4483.	0.4	5
1681	Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1300-1303.	1.1	7
1682	Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 3120-3122.	0.3	1
1683	Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals. <i>Biomedical Reports</i> , 2016, 4, 664-666.	0.9	1
1684	Clinical Guideline Inconsistency Regarding the Prevention of Hepatitis B and C Virus Transmission. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 744-745.	1.0	1
1685	Bio waiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1362-1369.	1.6	17
1686	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016, 10, 681-701.	1.9	75
1687	New combination antiviral for the treatment of hepatitis C. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1042-1050.	0.5	3
1688	Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 89-92.	0.4	3
1689	Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2603-2620.	1.4	6
1690	Pharmacologic Therapies in Gastrointestinal Diseases. <i>Medical Clinics of North America</i> , 2016, 100, 827-850.	1.1	22
1691	Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003â€“2010. <i>American Journal of Preventive Medicine</i> , 2016, 51, 206-215.	1.6	49
1692	Association Between Hepatitis C Virus and Head and Neck Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw035.	3.0	57
1693	Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. <i>Metabolic Brain Disease</i> , 2016, 31, 869-880.	1.4	31
1694	Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2900-2906.	1.0	14

#	ARTICLE	IF	CITATIONS
1695	History and Global Burden of Viral Hepatitis. <i>Digestive Diseases</i> , 2016, 34, 293-302.	0.8	20
1696	Investigation of the Immunomodulatory effect of <i>Berberis vulgaris</i> on core-pulsed dendritic cell vaccine. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 325.	3.7	5
1697	Seroprevalencia de hepatitis C en población con factores de riesgo del suroeste de la Comunidad de Madrid. <i>Gastroenterología Y Hepatología</i> , 2016, 39, 656-662.	0.2	3
1698	More clinical guideline inconsistency regarding the prevention of hepatitis B and C virus transmission. <i>American Journal of Infection Control</i> , 2016, 44, 1190-1191.	1.1	1
1699	Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw156.	0.4	6
1700	Mental disorders in HIV/HCV coinfecting patients under antiviral treatment for hepatitis C. <i>Psychiatry Research</i> , 2016, 246, 173-181.	1.7	7
1701	Liver Surface Nodularity Quantification from Routine CT Images as a Biomarker for Detection and Evaluation of Cirrhosis. <i>Radiology</i> , 2016, 280, 771-781.	3.6	91
1703	Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. <i>American Journal of Epidemiology</i> , 2016, 184, 249-258.	1.6	14
1704	Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. <i>International Journal of Cancer</i> , 2016, 139, 2519-2528.	2.3	32
1705	A novel real-time reverse transcription-polymerase chain reaction assay with partially double-stranded linear DNA probe for sensitive detection of hepatitis C viral RNA. <i>Journal of Virological Methods</i> , 2016, 236, 132-138.	1.0	1
1706	Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. <i>Hepatology International</i> , 2016, 10, 789-798.	1.9	14
1707	Chronic Hepatitis C Infection in Children. <i>Advances in Pediatrics</i> , 2016, 63, 173-194.	0.5	11
1708	A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 358-365.	1.0	28
1709	Detection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors. <i>Transfusion</i> , 2016, 56, 1883-1890.	0.8	10
1710	HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. <i>Digestive and Liver Disease</i> , 2016, 48, 1200-1207.	0.4	3
1711	Preparation of a Tricyclopropylamino Acid Derivative via Simmons-Smith Cyclopropanation with Downstream Intramolecular Aminoacetoxylation for Impurity Control. <i>Organic Process Research and Development</i> , 2016, 20, 2108-2115.	1.3	6
1712	How I treat hepatitis C virus infection in patients with hematologic malignancies. <i>Blood</i> , 2016, 128, 1449-1457.	0.6	27
1713	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43

#	ARTICLE	IF	CITATIONS
1714	Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. <i>Scientific Reports</i> , 2016, 6, 30846.	1.6	34
1715	Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis. <i>International Journal of Infectious Diseases</i> , 2016, 53, 52-58.	1.5	8
1716	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016, 6, 32303.	1.6	11
1717	Pegylated Interferon for the treatment of chronic hepatitis C with HIV-infected patients. <i>Acta Hepatologica Japonica</i> , 2016, 57, 34-41.	0.0	0
1718	Dual-Routine HCV/HIV Testing: Seroprevalence and Linkage to Care in Four Community Health Centers in Philadelphia, Pennsylvania. <i>Public Health Reports</i> , 2016, 131, 41-52.	1.3	13
1719	Delayed Viral Clearance after 6-Week Treatment with Peginterferon Plus Ribavirin in a Patient with Chronic Hepatitis C Virus Genotype 1b. <i>Case Reports in Gastroenterology</i> , 2016, 10, 417-422.	0.3	2
1720	Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. <i>BMC Gastroenterology</i> , 2016, 16, 91.	0.8	8
1721	Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon+ribavirin combined therapy. <i>Egyptian Liver Journal</i> , 2016, 6, 7-15.	0.3	0

1722

#	ARTICLE	IF	CITATIONS
1732	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 49.	1.0	2
1733	Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw105.	0.4	16
1734	Identity appropriateness and the structure of the theory of planned behaviour. <i>British Journal of Social Psychology</i> , 2016, 55, 109-125.	1.8	11
1735	Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India. <i>Tropical Doctor</i> , 2016, 46, 28-33.	0.2	0
1736	How to Treat Patients with Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2016, 15, 60-66.	0.4	1
1737	Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. <i>Journal of Clinical Microbiology</i> , 2016, 54, 265-273.	1.8	38
1738	Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C. <i>BMC Gastroenterology</i> , 2016, 16, 19.	0.8	21
1739	Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. <i>Laboratory Medicine</i> , 2016, 47, 112-118.	0.8	4
1740	Hepatitis C Treatment Exposed or Experienced?. <i>Annals of Pharmacotherapy</i> , 2016, 50, 328-328.	0.9	0
1741	Non-invasive assessment of liver fibrosis using acoustic structure quantification: comparison with transient elastography in chronic viral hepatitis. <i>Abdominal Radiology</i> , 2016, 41, 239-247.	1.0	8
1742	Phase angle is associated with advanced fibrosis in patients chronically infected with hepatitis C virus. <i>Life Sciences</i> , 2016, 154, 30-33.	2.0	10
1743	Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 353-361.	1.5	15
1744	Evaluation of abnormal liver function tests. <i>Postgraduate Medical Journal</i> , 2016, 92, 223-234.	0.9	218
1745	Impact of donor and recipient hepatitis C status in lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 228-235.	0.3	51
1746	Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis. <i>Current Infectious Disease Reports</i> , 2016, 18, 13.	1.3	6
1747	Types and predictors of interferon/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus. <i>Journal of Indian College of Cardiology</i> , 2016, 6, 16-21.	0.1	3
1748	Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. <i>Pharmacoeconomics</i> , 2016, 34, 403-417.	1.7	13
1749	A method for rapid detection and genotype identification of hepatitis C virus by one-step reverse transcription loop-mediated isothermal amplification. <i>International Journal of Infectious Diseases</i> , 2016, 43, 30-36.	1.5	33

#	ARTICLE	IF	CITATIONS
1750	Discovery of MK-8831, A Novel Spiro-Proline Macrocyclic as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 111-116.	1.3	31
1751	Entry inhibitors: New advances in HCV treatment. Emerging Microbes and Infections, 2016, 5, 1-8.	3.0	52
1752	Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clinical Pharmacokinetics, 2016, 55, 605-613.	1.6	44
1753	Effects of preventive versus on-demand nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 221-229.	0.7	1
1754	Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Review of Anti-Infective Therapy, 2016, 14, 157-165.	2.0	9
1755	Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Internal Medicine, 2016, 176, 65.	2.6	118
1756	Cancer prevention in HIV-infected populations. Seminars in Oncology, 2016, 43, 173-188.	0.8	42
1757	Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China. Public Health, 2016, 130, 13-20.	1.4	18
1758	Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children. Journal of Interferon and Cytokine Research, 2016, 36, 1-8.	0.5	13
1759	HCV infection, IFN response and the coding and non-coding host cell genome. Virus Research, 2016, 212, 85-102.	1.1	15
1760	Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2016, 5, 129-139.	0.6	6
1761	Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. Journal of Medical Economics, 2016, 19, 191-202.	1.0	20
1762	Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 65-73.	1.0	5
1763	A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. Journal of Public Health, 2016, 38, 130-137.	1.0	47
1764	HCV Prevalence in Asian Americans in California. Journal of Immigrant and Minority Health, 2017, 19, 91-97.	0.8	8
1765	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Management Science, 2017, 20, 16-32.	1.5	14
1766	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 T	0.1	59
1767	Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. Leukemia and Lymphoma, 2017, 58, 485-488.	0.6	7

#	ARTICLE	IF	CITATIONS
1768	Impact of genetic polymorphisms of four cytokine genes on treatment induced viral clearance in HCV infected Egyptian patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2017, 18, 111-119.	0.5	3
1769	New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment. <i>Journal of Pharmacy Practice</i> , 2017, 30, 359-365.	0.5	10
1770	Efficacy and safety of telaprevir with pegylated interferon α 2a and ribavirin in Japanese patients. <i>Hepatology Research</i> , 2017, 47, 514-521.	1.8	4
1771	Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 764-770.	0.7	3
1772	Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. <i>Journal of Advanced Research</i> , 2017, 8, 131-137.	4.4	15
1773	A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care. <i>Journal of Viral Hepatitis</i> , 2017, 24, 477-485.	1.0	29
1774	Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 97-102.	0.5	30
1775	Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 41516.	1.6	22
1776	<i>HLA-DQA1</i> regulatory polymorphisms are associated with susceptibility to HCV infection. <i>Hla</i> , 2017, 89, 135-142.	0.4	12
1777	Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. <i>Annals of Pharmacotherapy</i> , 2017, 51, 307-314.	0.9	13
1778	Pegylated interferon α 2a/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. <i>World Journal of Pediatrics</i> , 2017, 13, 346-352.	0.8	4
1779	Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. <i>Hepatology</i> , 2017, 66, 37-45.	3.6	35
1780	Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. <i>International Journal of Infectious Diseases</i> , 2017, 58, 8-17.	1.5	3
1781	Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. <i>American Journal of Nephrology</i> , 2017, 45, 267-272.	1.4	16
1782	In vitro fertilization for women infected by hepatitis C virus: a matched case-control study and a systematic literature review. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 587-597.	1.2	6
1783	European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1186-1192.	1.8	6
1784	Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000304.	1.2	142
1785	Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	28

#	ARTICLE	IF	CITATIONS
1786	Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. <i>Infectious Agents and Cancer</i> , 2017, 12, 12.	1.2	9
1787	Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C. <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 85-96.	0.5	3
1788	A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. <i>Hepatology International</i> , 2017, 11, 286-291.	1.9	11
1789	Cyanobacterial lectins characteristics and their role as antiviral agents. <i>International Journal of Biological Macromolecules</i> , 2017, 102, 475-496.	3.6	42
1790	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1922-1930.	1.4	40
1791	HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-infected subjects. <i>Journal of Viral Hepatitis</i> , 2017, 24, 865-876.	1.0	8
1792	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
1793	Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2017, 49, 1029-1035.	0.4	21
1794	A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. <i>MBio</i> , 2017, 8, .	1.8	38
1795	Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 275-281.	1.4	38
1796	Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3294-3300.	1.0	5
1797	Liver fibrosis: in vivo evaluation using intravoxel incoherent motion-derived histogram metrics with histopathologic findings at 3.0 T. <i>Abdominal Radiology</i> , 2017, 42, 2855-2863.	1.0	14
1798	Hepatitis B and C. <i>Pediatric Clinics of North America</i> , 2017, 64, 641-658.	0.9	31
1799	Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. <i>Nefrologia</i> , 2017, 37, 158-163.	0.2	4
1800	Variation in the Viral Hepatitis and HIV Policies and Practices of Methadone Maintenance Programs. <i>Journal of Addiction Medicine</i> , 2017, 11, 191-196.	1.4	4
1801	Medicinal applications of (benz)imidazole- and indole-based macrocycles. <i>Chemical Biology and Drug Design</i> , 2017, 89, 639-649.	1.5	24
1802	Solid-state transformations of ribavirin as a result of high-shear mechanical processing. <i>International Journal of Pharmaceutics</i> , 2017, 524, 339-350.	2.6	18
1803	Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations. <i>Value in Health</i> , 2017, 20, 736-744.	0.1	15

#	ARTICLE	IF	CITATIONS
1804	Cancer risk in patients with hepatitis C virus infection: a population-based study in Sweden. <i>Cancer Medicine</i> , 2017, 6, 1135-1140.	1.3	22
1805	Perceived health and alcohol use in individuals with HIV and Hepatitis C who use drugs. <i>Addictive Behaviors</i> , 2017, 72, 21-26.	1.7	8
1806	Effectiveness of conventional interferon and ribavirin combination therapy in chronic Hepatitis C patients in Pakistan. <i>Journal of Infection and Public Health</i> , 2017, 10, 692-693.	1.9	0
1807	Synthesis and biological evaluation of novel anti-hepatitis C virus (HCV) agents: 2-hydroxylphenethyl sulfanyl-oxypyrimidines. <i>Medicinal Chemistry Research</i> , 2017, 26, 1388-1396.	1.1	3
1808	What Are Clinically Relevant Levels of Cellular and Biomolecular Analytes?. <i>ACS Sensors</i> , 2017, 2, 193-197.	4.0	119
1809	Intrahepatic angiotensin II correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems. <i>Liver International</i> , 2017, 37, 1148-1156.	1.9	4
1810	Hepatic IFN λ 4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2017, 89, 1241-1247.	2.5	9
1811	Eficacia de los antivirales de acci3n directa en la infecci3n por el virus de la hepatitis C en pacientes en hemodi3lisis. <i>Nefrologia</i> , 2017, 37, 158-163.	0.2	7
1812	Chemistry-Driven Approaches for Ultrasensitive Nucleic Acid Detection. <i>Journal of the American Chemical Society</i> , 2017, 139, 1020-1028.	6.6	95
1813	Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. <i>Journal of Hepatology</i> , 2017, 66, 711-717.	1.8	22
1814	Prospective Comparison of the Diagnostic Performance of Magnetic Resonance Elastography with Acoustic Radiation Force Impulse Elastography for Pre-operative Staging of Hepatic Fibrosis in Patients with Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2783-2790.	0.7	15
1815	ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients. <i>Scientific Reports</i> , 2017, 7, 12918.	1.6	7
1816	Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. <i>Clinical Medicine Insights: Cardiology</i> , 2017, 11, 117954681771320.	0.6	9
1817	Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. <i>Antiviral Research</i> , 2017, 146, 191-200.	1.9	40
1818	Longitudinal Monitoring of Antibody Responses against Tumor Cells Using Magneto-nanosensors with a Nanoliter of Blood. <i>Nano Letters</i> , 2017, 17, 6644-6652.	4.5	13
1819	Chronic hepatitis C liver microenvironment: role of the Th17/Treg interplay related to fibrogenesis. <i>Scientific Reports</i> , 2017, 7, 13283.	1.6	16
1820	Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2017, 47, 102-106.	1.6	15
1821	Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. <i>VirusDisease</i> , 2017, 28, 233-241.	1.0	6

#	ARTICLE	IF	CITATIONS
1822	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. <i>Acta Tropica</i> , 2017, 176, 283-287.	0.9	6
1823	Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3193-3199.	1.1	0
1824	The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited. <i>Archives of Virology</i> , 2017, 162, 3587-3602.	0.9	14
1825	The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response. <i>Viral Immunology</i> , 2017, 30, 568-575.	0.6	2
1826	Chemical genetics-based development of small molecules targeting hepatitis C virus. <i>Archives of Pharmacal Research</i> , 2017, 40, 1021-1036.	2.7	6
1827	Influence of camel milk on the hepatitis C virus burden of infected patients. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1313-1320.	0.8	40
1828	Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud p�blico chileno. <i>Value in Health Regional Issues</i> , 2017, 14, 28-32.	0.5	1
1829	Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. <i>Journal of Medical Virology</i> , 2017, 89, 2181-2187.	2.5	39
1830	Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 329-337.	0.3	6
1831	Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 70-76.	1.1	14
1832	Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. <i>Medicine (United States)</i> , 2017, 96, e5321.	0.4	8
1833	Hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 271-276.	0.8	10
1834	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2-chloro-2-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4323-4330.	1.0	27
1835	Hepatitis C Genotype 3 Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 645-657.	1.0	4
1836	Causative agents, diseases, epidemiology and diagnosis of sexually transmitted infections. <i>Reviews in Medical Microbiology</i> , 2017, 28, 9-18.	0.4	2
1837	Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. <i>Intervirology</i> , 2017, 60, 82-89.	1.2	8
1838	Evaluation of Temporal Virological Responses to Interferon-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients. <i>Intervirology</i> , 2017, 60, 75-81.	1.2	2
1839	Liver stiffness measurement and spleen diameter as predictors for the presence of esophageal varices in chronic hepatitis C patients. <i>Medicine (United States)</i> , 2017, 96, e8621.	0.4	9

#	ARTICLE	IF	CITATIONS
1840	<scp>SOX</scp> 9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. <i>EMBO Molecular Medicine</i> , 2017, 9, 1696-1710.	3.3	38
1841	Exploring patient characteristics and barriers to Hepatitis C treatment in patients on opioid substitution treatment attending a community based fibro-scanning clinic. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 112-119.	1.0	21
1842	Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. <i>Indian Journal of Gastroenterology</i> , 2017, 36, 227-234.	0.7	16
1843	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	1.3	6
1844	Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. <i>BMC Health Services Research</i> , 2017, 17, 288.	0.9	1
1845	Limitations and artifacts in shear-wave elastography of the liver. <i>Biomedical Engineering Letters</i> , 2017, 7, 81-89.	2.1	41
1846	Prevalence of HCV Infection in General Population of District Malakand, Pakistan: A Comparative Analysis of the Diagnostic Techniques. <i>Arabian Journal for Science and Engineering</i> , 2017, 42, 2201-2205.	1.7	0
1847	Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 65-82.	0.6	8
1848	Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1-14.	0.8	10
1849	Peromyscus as a model system for human hepatitis C: An opportunity to advance our understanding of a complex host parasite system. <i>Seminars in Cell and Developmental Biology</i> , 2017, 61, 123-130.	2.3	5
1850	Real-world treatment patterns and clinical outcomes of HCV treatment-naïve patients in China: an interim analysis from the CCgenos study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 244-252.	1.4	27
1851	Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. <i>Hepatology Research</i> , 2017, 47, 767-772.	1.8	15
1852	Reinventing HCV Treatment: Past and Future Perspectives. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 287-296.	1.0	21
1853	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 37-42.	1.0	11
1854	Liver fibrosis staging with diffusion-weighted imaging: a systematic review and meta-analysis. <i>Abdominal Radiology</i> , 2017, 42, 490-501.	1.0	47
1855	IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. <i>Archives of Virology</i> , 2017, 162, 181-189.	0.9	14
1856	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. <i>Journal of Medical Virology</i> , 2017, 89, 665-671.	2.5	9
1857	Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 369-375.	1.0	6

#	ARTICLE	IF	CITATIONS
1859	Prokaryotic Expression of Hepatitis C Virus-NS3 Protein and Preparation of a Monoclonal Antibody. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2017, 36, 251-258.	0.8	4
1861	Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000181.	1.1	14
1862	Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. <i>Romanian Journal of Laboratory Medicine</i> , 2017, 25, 355-363.	0.1	2
1863	Viral and host factors associated with outcomes of hepatitis C virus infection. <i>Molecular Medicine Reports</i> , 2017, 15, 2909-2924.	1.1	25
1864	Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors. <i>Life Sciences</i> , 2017, 187, 58-63.	2.0	11
1865	Visceral Adiposity Index and the Degree of Hepatic Fibrosis and Inflammation in Egyptian Patients with Chronic Hepatitis C. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, OC11-OC14.	0.8	1
1866	Influence of OASL gene polymorphisms on host response to interferon therapy in chronic hepatitis C virus patients. <i>The EuroBiotech Journal</i> , 2017, 1, 117-125.	0.5	0
1867	Role of intrafamilial transmission in high prevalence of hepatitis C virus in Egypt. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 27-33.	0.9	15
1868	MicroRNAs in the Pathogenesis, Diagnosis, and Treatment of Liver Disease. , 2017, , 55-92.		1
1869	Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. <i>Molecules</i> , 2017, 22, 191.	1.7	301
1870	Design and Development of HCV NS5B Polymerase Inhibitors. , 2017, , 189-219.		0
1871	Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. <i>Frontiers in Microbiology</i> , 2017, 8, 1833.	1.5	17
1872	Prevalence of Diabetes Type 2 in Hepatitis C Infected Patients in Kpk, Pakistan. <i>BioMed Research International</i> , 2017, 2017, 1-4.	0.9	3
1873	Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 657-676.	1.6	5
1874	High prevalence of insulin resistance among Brazilian chronic hepatitis C patients. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 628-632.	0.3	1
1875	Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. <i>PLoS ONE</i> , 2017, 12, e0180927.	1.1	8
1876	Co-infection of <i>Schistosoma mansoni</i> /hepatitis C virus and their associated factors among adult individuals living in fishing villages, north-western Tanzania. <i>BMC Infectious Diseases</i> , 2017, 17, 668.	1.3	5
1877	Impact of alcohol consumption among patients in hepatitis C virus treatment. <i>Arquivos De Gastroenterologia</i> , 2017, 54, 232-237.	0.3	10

#	ARTICLE	IF	CITATIONS
1879	Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. , 0, , .		3
1880	Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 151.	1.4	53
1881	Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection. <i>Bangladesh Journal of Pharmacology</i> , 2017, 12, 12.	0.1	5
1882	Assessment of baseline pretreatment factors and on-treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. <i>Advances in Digestive Medicine</i> , 2017, 4, 4-11.	0.1	2
1883	Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. <i>Electronic Physician</i> , 2017, 9, 5646-5656.	0.2	40
1884	The Molecular Basis of Anti-HCV Drug Resistance. , 0, , .		0
1885	Analysis of polymorphism rs1990760 of <i>IFIH1</i> gene and treatment outcomes in HCV infection. <i>Future Virology</i> , 2018, 13, 181-187.	0.9	1
1886	Chrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients. <i>Gene</i> , 2018, 649, 74-79.	1.0	8
1887	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 451-456.	0.9	3
1888	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	3.6	158
1889	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. <i>Viral Immunology</i> , 2018, 31, 358-361.	0.6	1
1890	Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 741-746.	0.8	17
1891	Clinical connection between rheumatoid arthritis and liver damage. <i>Rheumatology International</i> , 2018, 38, 715-724.	1.5	40
1892	Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 457-461.	1.3	9
1893	Approaches for simplified HCV diagnostic algorithms. <i>Journal of the International AIDS Society</i> , 2018, 21, e25058.	1.2	47
1894	Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MRI in patients with chronic liver disease. <i>Clinical Science</i> , 2018, 132, 813-824.	1.8	19
1895	Evaluation of transient elastography in assessing liver fibrosis in patients with advanced schistosomiasis japonica. <i>Parasitology International</i> , 2018, 67, 302-308.	0.6	15
1896	Hepatitis C Virus. , 2018, , 1135-1142.e3.		1

#	ARTICLE	IF	CITATIONS
1897	Laboratory Diagnosis of Infection Due to Viruses, Chlamydia, Chlamydothila, and Mycoplasma. , 2018, , 1434-1447.e5.		1
1898	Chronic Hepatitis C Screening, Evaluation, and Treatment Update in the Age of Direct-Acting Antivirals. <i>Workplace Health and Safety</i> , 2018, 66, 302-309.	0.7	4
1900	Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. <i>Journal of Immunology</i> , 2018, 200, 1124-1132.	0.4	4
1901	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	2.5	14
1902	Precision analysis of a quantitative CT liver surface nodularity score. <i>Abdominal Radiology</i> , 2018, 43, 3307-3316.	1.0	15
1903	Evaluation of abnormal liver tests in the adult asymptomatic patient. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 272-279.	1.0	9
1904	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	1.6	18
1905	Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 129-136.	0.5	13
1906	Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak. <i>Digestive and Liver Disease</i> , 2018, 50, 630-632.	0.4	2
1907	Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment-naïve chronic HCV patients. <i>Clinical and Experimental Medicine</i> , 2018, 18, 45-50.	1.9	11
1908	Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 641-647.	1.1	39
1909	The Predictive Value of International Classification of Disease Codes for Chronic Hepatitis C Virus Infection Surveillance: The Utility and Limitations of Electronic Health Records. <i>Population Health Management</i> , 2018, 21, 110-115.	0.8	8
1910	Diagnostic reliability of Architect anti-HCV assay: Experience of a tertiary care hospital in India. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	10
1911	After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	4
1912	GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects. <i>Journal of Viral Hepatitis</i> , 2018, 25, 19-27.	1.0	9
1913	Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 27-32.	0.8	17
1914	Establishment of a platform for molecular and immunological characterization of the RNA-dependent RNA polymerase NS5B of an Egyptian HCV isolate. <i>Journal of Medical Virology</i> , 2018, 90, 545-558.	2.5	0
1915	Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 833-840.	0.8	12

#	ARTICLE	IF	CITATIONS
1916	Population-level intervention and information collection in dynamic healthcare policy. <i>Health Care Management Science</i> , 2018, 21, 604-631.	1.5	6
1917	Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. <i>Journal of Viral Hepatitis</i> , 2018, 25, 134-143.	1.0	27
1918	Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 121-124.	0.4	5
1919	Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, E203-E212.	1.8	26
1920	Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials. <i>Journal of Human Nutrition and Dietetics</i> , 2018, 31, 168-177.	1.3	12
1921	The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. <i>Liver International</i> , 2018, 38, 1064-1073.	1.9	11
1922	Increased hope following successful treatment for hepatitis C infection. <i>Journal of Advanced Nursing</i> , 2018, 74, 724-733.	1.5	3
1923	Significance of day 1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1264-1270.	1.4	1
1924	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 970-982.	2.6	18
1925	Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents. <i>Histopathology</i> , 2018, 72, 990-996.	1.6	16
1926	Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. <i>Medical Microbiology and Immunology</i> , 2018, 207, 65-74.	2.6	2
1927	Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region. <i>Immunologic Research</i> , 2018, 66, 67-73.	1.3	2
1928	Diffusion kurtosis imaging with the breath-hold technique for staging hepatic fibrosis: A preliminary study. <i>Magnetic Resonance Imaging</i> , 2018, 47, 33-38.	1.0	21
1929	Efficacy and safety of sofosbuvir-based, interferon-free therapy. <i>Zeitschrift Fur Rheumatologie</i> , 2018, 77, 621-628.	0.5	8
1930	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 262-279.	1.8	160
1931	Management of hepatitis C infection in the era of direct-acting antiviral therapy. <i>IOP Conference Series: Earth and Environmental Science</i> , 2018, 125, 012087.	0.2	0
1932	microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. <i>Experimental and Therapeutic Medicine</i> , 2018, 17, 1817-1824.	0.8	4
1933	Evaluation of liver fibrosis with a monoexponential model of intravoxel incoherent motion magnetic resonance imaging. <i>Oncotarget</i> , 2018, 9, 24619-24626.	0.8	1

#	ARTICLE	IF	CITATIONS
1934	Fibrosis and Inflammatory Activity Analysis of Chronic Hepatitis C Based on Extreme Learning Machine. , 2018, , .		1
1935	A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfecting patients treated with interferon and ribavirin in an Asian cohort. <i>Medicine (United States)</i> , 2018, 97, e13383.	0.4	5
1936	Antibody Detection: Principles and Applications. , 2018, , 127-147.		0
1937	The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2018, 72, 197.	0.2	0
1938	Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. <i>Hepatology Communications</i> , 2018, 2, 1311-1319.	2.0	22
1939	Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma: Clinical Application to Therapeutic Drug Monitoring. <i>International Journal of Analytical Chemistry</i> , 2018, 2018, 1-9.	0.4	11
1940	The adoption of sustainable agricultural practices by smallholder farmers in Ethiopian highlands: An integrative approach. <i>Cogent Food and Agriculture</i> , 2018, 4, 1552439.	0.6	38
1941	One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 418-423.	0.3	3
1942	Determination of Sustained Virological Response in Hepatitis C Virus Genotypes by the Number of Mutations in the E2 and NS5A-ISDR Regions: A Meta-Analysis. <i>Russian Journal of Genetics</i> , 2018, 54, 1013-1024.	0.2	0
1943	Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 14-20.	0.4	2
1944	Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. <i>PLoS ONE</i> , 2018, 13, e0196747.	1.1	5
1945	<i>Molecular Microbiology</i> . , 2018, , 87-124.		0
1946	Ultrasensitive Genosensor Based on Minor Groove Binding (MGB) Probe for L28B Single Nucleotide Polymorphism (SNP) Detection Using SYBR Green as Electrochemical Indicator. <i>Electroanalysis</i> , 2018, 30, 2847-2852.	1.5	1
1947	Study of Hepatitis C Virus Detection Assays. <i>Annals of Medicine and Surgery</i> , 2018, 36, 47-50.	0.5	5
1948	Molecular Monitoring of Viral Infections. <i>Advances in Molecular Pathology</i> , 2018, 1, 65-80.	0.2	0
1949	Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. <i>Cells</i> , 2018, 7, 165.	1.8	27
1950	Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1146-1155.	1.9	14
1951	Hepatitis C-Associated B-cell Non-Hodgkin Lymphoma. <i>Ultrasound Quarterly</i> , 2018, 34, 156-166.	0.3	9

#	ARTICLE	IF	CITATIONS
1952	First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 146-154.	0.4	2
1953	Results of an unannounced proficiency test for the quantification of hepatitis C virus (HCV) RNA in Shanghai, China. <i>Accreditation and Quality Assurance</i> , 2018, 23, 277-284.	0.4	0
1954	Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication – comparison of the new direct-acting antiviral agents with the old regimens. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 857-863.	0.6	33
1955	Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 347-370.	1.9	25
1956	Drug Interactions of Non-HIV Antiviral Agents. , 2018, , 381-424.		0
1957	Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients. <i>Journal of Transplantation</i> , 2018, 2018, 1-10.	0.3	4
1958	Sample-to-Answer Droplet Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation. <i>Scientific Reports</i> , 2018, 8, 9793.	1.6	49
1959	Analysis of hepatitis C infection using Raman spectroscopy and proximity based classification in the transformed domain. <i>Biomedical Optics Express</i> , 2018, 9, 2041.	1.5	22
1960	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C. <i>Pilot and Feasibility Studies</i> , 2018, 4, 92.	0.5	4
1961	The Role of the Signal-to-Cutoff Ratio in Automated Anti-HCV Chemiluminescent Immunoassays by Referring to the Nucleic Acid Amplification Test and the Recombinant Immunoblot Assay. <i>Annals of Laboratory Medicine</i> , 2018, 38, 466-472.	1.2	16
1962	Clinical value of hepatitis C virus core antigen levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance. <i>Journal of Medical Virology</i> , 2018, 90, 1787-1792.	2.5	0
1964	Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 713-722.	1.5	6
1965	Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. <i>Pilot and Feasibility Studies</i> , 2018, 4, 55.	0.5	4
1966	Comparison of APRI, FIB-4 and fibro test in prediction of fibrosis and cirrhosis in patients with hepatitis C. , 2018, , .		2
1967	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 33-42.	0.9	3
1968	Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. <i>Adolescent Health, Medicine and Therapeutics</i> , 2018, Volume 9, 103-110.	0.7	2
1969	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0200568.	1.1	7
1970	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. <i>Infection</i> , 2018, 46, 761-783.	2.3	20

#	ARTICLE	IF	CITATIONS
1971	Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 255-260.	0.5	6
1972	Factores de riesgo para adquirir VHC en una institución de salud en Hidalgo. <i>Revista De Gastroenterología De México</i> , 2019, 84, 36-43.	0.4	3
1973	Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2019, 51, 142-148.	0.4	1
1974	Simultaneous quantification of simeprevir sodium: A hepatitis C protease inhibitor in binary and ternary mixtures with sofosbuvir and/or ledipasvir utilizing direct and H-point standard addition strategies. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2019, 210, 290-297.	2.0	10
1975	HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 25-32.	0.5	18
1976	Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 703-710.	0.5	8
1977	The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy. <i>Intervirology</i> , 2019, 62, 23-29.	1.2	2
1978	Occult hepatitis C infections: time to change the defined groups. <i>Microbiology and Immunology</i> , 2019, 63, 474-475.	0.7	3
1979	Update on Hepatitis C Screening and Management: Actions for Emergency Departments. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 53-58.	0.6	1
1980	Hepatitis A, B, and C. , 2019, , 697-710.		0
1981	Vaccination in Organ Transplant Patients. , 2019, , 1095-1109.		1
1982	Undetectable Hepatitis C Viral Load Is Associated With Improved Outcomes Following Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2019, 34, 2890-2897.	1.5	17
1983	Chronic Viral Hepatitis. , 2019, , 155-173.		0
1984	Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. <i>Viral Immunology</i> , 2019, 32, 402-413.	0.6	22
1985	Liver Fibrosis Assessment with Diffusion-Weighted Imaging: Value of Liver Apparent Diffusion Coefficient Normalization Using the Spleen as a Reference Organ. <i>Diagnostics</i> , 2019, 9, 107.	1.3	16
1986	Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus. <i>International Journal of Infectious Diseases</i> , 2019, 89, 131-136.	1.5	13
1987	Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program. <i>Journal of Substance Abuse Treatment</i> , 2019, 98, 9-14.	1.5	5
1988	Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?. <i>Hepatology International</i> , 2019, 13, 190-198.	1.9	4

#	ARTICLE	IF	CITATIONS
1989	Elastodiagnosis of diseases: A review. <i>Extreme Mechanics Letters</i> , 2019, 27, 102-123.	2.0	19
1990	An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 – April 2015. <i>BMC Public Health</i> , 2019, 19, 466.	1.2	8
1991	Hepatitis C Competency and Outreach of Occupational Health Nurses. <i>Workplace Health and Safety</i> , 2019, 67, 399-413.	0.7	3
1992	Acute Hepatitis C. , 2019, , 197-217.		0
1993	A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. <i>Journal of Chemotherapy</i> , 2019, 31, 274-283.	0.7	1
1994	Prioritizing Hepatitis C Treatment in U.S. Prisons. <i>Operations Research</i> , 2019, 67, 853-873.	1.2	21
1995	Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis. <i>Indian Journal of Gastroenterology</i> , 2019, 38, 110-116.	0.7	6
1996	How are HCV-infected patients being identified in Brazil: a multicenter study. <i>Brazilian Journal of Infectious Diseases</i> , 2019, 23, 34-39.	0.3	4
1997	Epidemiology and management of hepatitis C virus infections in immigrant populations. <i>Infectious Diseases of Poverty</i> , 2019, 8, 17.	1.5	42
1998	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	0.6	5
1999	Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. <i>PLoS Medicine</i> , 2019, 16, e1002780.	3.9	36
2000	Global Epidemiology of Acute Viral Hepatitis A-E. , 2019, , 1-16.		1
2001	Acute Hepatitis C. , 2019, , 45-65.		0
2002	Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. <i>PLoS ONE</i> , 2019, 14, e0210724.	1.1	9
2003	Inflammasome Genes™ Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	1.4	12
2004	Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2019, 41, 539-549.	0.4	7
2005	A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 382-388.	0.8	3
2006	<p>Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study<p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 273-279.	1.1	23

#	ARTICLE	IF	CITATIONS
2007	Perceptions of Barriers and Benefits of HCV Treatment and Correlates to Treatment Intention in Methadone Patients. <i>Journal of Health Care for the Poor and Underserved</i> , 2019, 30, 1433-1454.	0.4	3
2008	A pilot study of Livin gene and Yes-associated protein 1 expression in hepatocellular carcinoma patients. <i>Heliyon</i> , 2019, 5, e02798.	1.4	1
2009	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 506-513.	0.8	16
2010	Oncologic Implications of Chronic Hepatitis C Virus Infection. <i>Journal of Oncology Practice</i> , 2019, 15, 629-637.	2.5	19
2011	Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	2
2012	Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 82-87.	0.7	11
2013	Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population. <i>Journal of Infection and Public Health</i> , 2019, 12, 32-36.	1.9	24
2014	Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. <i>Liver International</i> , 2019, 39, 844-853.	1.9	4
2015	Polymorphism in interferon γ /interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. <i>Journal of Medical Virology</i> , 2019, 91, 659-667.	2.5	9
2016	In a Critical State: Ongoing Barriers to Treatment for Hepatitis C Virus (HCV). <i>American Journal of Medicine</i> , 2019, 132, 547-549.	0.6	6
2017	Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. <i>Journal of Public Health</i> , 2019, 41, 700-706.	1.0	12
2018	Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. <i>Hepatology Research</i> , 2019, 49, 570-578.	1.8	32
2019	Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators. <i>American Journal of Epidemiology</i> , 2019, 188, 1181-1191.	1.6	7
2020	Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2019, 14, e0208858.	1.1	4
2021	Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?. <i>Digestive and Liver Disease</i> , 2019, 51, 258-262.	0.4	4
2022	Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study. <i>Infection, Genetics and Evolution</i> , 2019, 67, 112-120.	1.0	2
2023	Risk factors for acquiring HCV at a healthcare center in Hidalgo, Mexico. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019, 84, 36-43.	0.1	0
2024	An Observational Study to Evaluate the Maternal and Foetal Outcomes in Pregnancies Complicated with Jaundice. <i>Journal of Obstetrics and Gynecology of India</i> , 2019, 69, 31-36.	0.3	9

#	ARTICLE	IF	CITATIONS
2025	Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. <i>Virology</i> , 2020, 540, 132-140.	1.1	10
2026	Do compensatory health beliefs predict behavioural intention in a multiple health behaviour change context? Evidence in individuals with cardiovascular diseases?. <i>Psychology, Health and Medicine</i> , 2020, 25, 593-600.	1.3	4
2028	Detecting liver fibrosis using a machine learning-based approach to the quantification of the heart-induced deformation in tagged MR images. <i>NMR in Biomedicine</i> , 2020, 33, e4215.	1.6	15
2029	Intravoxel incoherent motion imaging for diagnosing and staging the liver fibrosis and inflammation. <i>Abdominal Radiology</i> , 2020, 45, 15-23.	1.0	19
2030	Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 233-242.	1.7	19
2031	Gadoxetate-disodium-enhanced magnetic resonance imaging for liver fibrosis staging: a systematic review and meta-analysis. <i>Clinical Radiology</i> , 2020, 75, 319.e11-319.e19.	0.5	7
2032	Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. <i>Tropical Doctor</i> , 2020, 50, 141-146.	0.2	2
2033	Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. <i>Clinical Cardiology</i> , 2020, 43, 222-234.	0.7	18
2034	Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs. <i>Apmis</i> , 2020, 128, 326-334.	0.9	3
2035	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
2036	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	0.8	8
2037	Going beyond Good Intentions for the Sustainable Conservation of Built Heritage: A Systematic Literature Review. <i>Sustainability</i> , 2020, 12, 9649.	1.6	10
2038	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115679.	1.4	3
2039	Innovative procedures for micro-elimination of HCV infection in persons who use drugs. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1437-1443.	1.0	14
2040	Studies on the prevalence of Hepatitis C virus infection in diabetic patients attending a tertiary health-care facility South-west Nigeria. <i>BMC Infectious Diseases</i> , 2020, 20, 664.	1.3	5
2041	Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1053-1059.	2.0	8
2042	Novel Hepatitis C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. <i>Journal of Infectious Diseases</i> , 2020, 222, S758-S772.	1.9	15
2043	Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. <i>JAMA Network Open</i> , 2020, 3, e2015756.	2.8	19

#	ARTICLE	IF	CITATIONS
2044	Fully automated rapid quantification of Hepatitis C Virus RNA in human plasma and serum by integrated on-chip RT-qPCR and capillary electrophoresis. <i>Scientific Reports</i> , 2020, 10, 7379.	1.6	6
2045	Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. <i>Viral Immunology</i> , 2020, 33, 507-513.	0.6	3
2046	Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. <i>Reviews in Medical Virology</i> , 2020, 30, e2120.	3.9	2
2047	Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2784-2792.e7.	2.4	34
2048	Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e59-e65.	1.1	4
2049	Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection. <i>Journal of Medical Virology</i> , 2020, 92, 3516-3524.	2.5	2
2050	Pediatric Hepatitis C. <i>Advances in Pediatrics</i> , 2020, 67, 47-56.	0.5	0
2051	Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. <i>PLoS ONE</i> , 2020, 15, e0234811.	1.1	1
2052	Impact of Blood Transfusion on the Prevalence of HHV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e213-e218.	0.3	4
2053	LncRNAs in HCV Infection and HCV-Related Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2255.	1.8	31
2054	Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. <i>Harm Reduction Journal</i> , 2020, 17, 39.	1.3	9
2055	Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	25
2056	Utility and accuracy of transient elastography in determining liver fibrosis: a case-control study. <i>European Journal of Pediatrics</i> , 2020, 179, 671-677.	1.3	11
2057	Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3159-3174.	1.1	3
2058	Safety and Efficacy of 8-Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. <i>Journal of Pediatrics</i> , 2020, 219, 106-110.	0.9	10
2059	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. <i>PLoS ONE</i> , 2020, 15, e0232186.	1.1	3
2060	Energy Saving at Work: Exploring the Role of Social Norms, Perceived Control and Ascribed Responsibility in Different Office Layouts. <i>Frontiers in Built Environment</i> , 2020, 6, .	1.2	11
2061	KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. <i>American Journal of Kidney Diseases</i> , 2020, 75, 665-683.	2.1	13

#	ARTICLE	IF	CITATIONS
2062	Clinical Usefulness of HCV Core Antigen Assay for the Management of Patients with Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 393-396.	0.5	18
2063	A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV&HCV Co-infection Who Drink Alcohol. <i>AIDS and Behavior</i> , 2021, 25, 1013-1025.	1.4	9
2064	Genetic variant of RXR involved in the vitamin D metabolic pathway was linked to HCV infection outcomes among a high-risk Chinese population. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104641.	1.0	3
2065	Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers. <i>Clinical and Experimental Immunology</i> , 2020, 203, 3-12.	1.1	9
2066	Evaluation of HCV RNA by PCR and Signal-to-Cutoff Ratios of HCV Antibody Assays for Diagnosis of HCV Infection. <i>Laboratory Medicine</i> , 2021, 52, 240-244.	0.8	1
2067	Chemiluminescent-microparticle-immunoassay-based detection and prevalence of human immunodeficiency virus infection in Islamabad, Pakistan. <i>Archives of Virology</i> , 2021, 166, 581-586.	0.9	3
2068	Treatment of hepatitis C in a case of pediatric B-cell acute leukemia. <i>Journal of Global Infectious Diseases</i> , 2022, 14, 35.	0.2	3
2069	Texture Analysis of Gray-Scale Ultrasound Images for Staging of Hepatic Fibrosis. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 116.	0.1	3
2070	Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 951.	0.3	4
2071	Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2175-2193.	1.8	3
2072	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 739-754.	1.0	23
2073	Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. <i>Addiction</i> , 2021, 116, 2734-2745.	1.7	4
2074	Elastografía en tiempo real (Supersonic), experiencia de un centro en Bogotá. <i>Revista Colombiana De Gastroenterología</i> , 2021, 36, 58-64.	0.1	2
2075	High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California. <i>PLoS ONE</i> , 2021, 16, e0249219.	1.1	11
2076	People with HIV-1 Demonstrate Type 1 Interferon Refractoriness Associated with Upregulated USP18. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
2077	Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.. <i>Journal of the National Medical Association</i> , 2021, 113, 147-157.	0.6	1
2078	Concordance of 24- and 48-h diagnostic follow-up ascitic fluid polymorphonuclear leukocyte count in the guidance of the antibiotic therapy in spontaneous bacterial peritonitis. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	0
2079	Comorbid Communicable Diseases of Substance Abuse in Thailand: A 5-Year Retrospective Study. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e380-e384.	0.1	0

#	ARTICLE	IF	CITATIONS
2080	Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. <i>Minerva Medica</i> , 2021, 112, 162-174.	0.3	12
2081	Viral hepatitis: A brief introduction, review of management, advances and challenges. <i>World Journal of Meta-analysis</i> , 2021, 9, 139-151.	0.1	0
2082	Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients. <i>Viruses</i> , 2021, 13, 716.	1.5	0
2083	Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection. <i>Journal of Pediatrics</i> , 2021, 231, 110-116.	0.9	6
2084	Association of hepatitis C infection and acute coronary syndrome. <i>Medicine (United States)</i> , 2021, 100, e26033.	0.4	2
2085	Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-10.	0.7	2
2086	The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. <i>Liver International</i> , 2021, 41, 2341-2357.	1.9	3
2087	Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels. <i>Virus Research</i> , 2021, 298, 198404.	1.1	12
2088	Solubility Behavior of Boc-L-proline in 14 Pure Solvents from 283.15 to 323.15 K. <i>Journal of Chemical & Engineering Data</i> , 2021, 66, 2812-2821.	1.0	7
2089	Beyond Good Intentions: The Role of the Building Passport for the Sustainable Conservation of Built Heritage to Behavioural Change. <i>Sustainability</i> , 2021, 13, 8280.	1.6	1
2090	Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 772.	1.1	4
2091	Host-Targeting Antivirals for Treatment of Hepatitis C. , 0, , .		0
2092	Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN- α /RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients. <i>Viruses</i> , 2021, 13, 1448.	1.5	3
2093	Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. <i>Internal Medicine</i> , 2021, 60, 2437-2443.	0.3	4
2094	Inverse relationship between the level of miRNA 148a-3p and both TGF- β 1 and FIB-4 in hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2021, 27, 101082.	0.7	2
2095	Thiosemicarbazides: Updates on Antivirals Strategy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 20, 2135-2152.	1.1	17
2096	Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. <i>PLoS ONE</i> , 2021, 16, e0244939.	1.1	22
2098	Antibody Detection: Principles and Applications. , 2013, , 53-73.		3

#	ARTICLE	IF	CITATIONS
2099	Treatment of Chronic Hepatitis C in Children. , 2010, , 67-87.		2
2100	Chronic Viral Hepatitis B and C. , 2016, , 681-691.		1
2101	Drug-Cytokine Interactions. , 2018, , 163-204.		5
2102	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. , 2017, , 553-627.		2
2105	Liver Disease. , 2012, , 1637-1693.		4
2106	Replication of Hepatitis C Virus. , 2012, , 97-110.		1
2107	Chronic viral hepatitis. , 2012, , 53-69.		2
2108	Treatment of Chronic Hepatitis C Using a 4-week Lead-in With Nitazoxanide Before Peginterferon Plus Nitazoxanide. Journal of Clinical Gastroenterology, 2010, 44, 504-509.	1.1	37
2109	Comparing the Aspartate Aminotransferase (AST) to Platelet Ratio Index (APRI) Between African American and White Veterans with Chronic Hepatitis C. Southern Medical Journal, 2011, 104, 309-314.	0.3	4
2110	Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains. Journal of General Virology, 2018, 99, 1633-1642.	1.3	4
2111	Molecular epidemiological analysis of three hepatitis C virus outbreaks in Jammu and Kashmir State, India. Journal of Medical Microbiology, 2016, 65, 804-813.	0.7	4
2112	Aqueous flare and choroidal thickness in patients with chronic hepatitis C virus infection. Acta Ophthalmologica, 2012, 90, 0-0.	0.6	1
2113	Hepatitis C Virus. , 0, , 1599-1616.		2
2114	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egyptian Liver Journal, 2020, 10, .	0.3	4
2115	Role of genetic polymorphisms in hepatitis C virus chronic infection. World Journal of Clinical Cases, 2015, 3, 807.	0.3	18
2116	Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World Journal of Clinical Cases, 2019, 7, 1270-1281.	0.3	14
2117	Simeprevir for the treatment of genotype 1 chronic hepatitis C virus. Drugs of Today, 2013, 49, 769.	0.7	14
2118	Treatment of Hepatitis C in Children: A Systematic Review. PLoS ONE, 2010, 5, e11542.	1.1	30

#	ARTICLE	IF	CITATIONS
2119	A Novel Hepatitis C Virus Genotyping Method Based on Liquid Microarray. PLoS ONE, 2010, 5, e12822.	1.1	12
2120	Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy. PLoS ONE, 2011, 6, e24514.	1.1	8
2121	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	1.1	41
2122	Intrinsically Unstructured Domain 3 of Hepatitis C Virus NS5A Forms a "Fuzzy Complex" with VAPB-MSP Domain Which Carries ALS-Causing Mutations. PLoS ONE, 2012, 7, e39261.	1.1	39
2123	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. PLoS ONE, 2012, 7, e39652.	1.1	78
2124	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. PLoS ONE, 2012, 7, e44930.	1.1	242
2125	Effect of Different Interferon- α 2 Preparations on IP10 and ET-1 Release from Human Lung Cells. PLoS ONE, 2012, 7, e46779.	1.1	13
2126	Different HCV Genotype Distributions of HIV-Infected Individuals in Henan and Guangxi, China. PLoS ONE, 2012, 7, e50343.	1.1	24
2127	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. PLoS ONE, 2012, 7, e52048.	1.1	23
2128	Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis. PLoS ONE, 2012, 7, e52158.	1.1	12
2129	Interferon-Based Therapy Decreases Risks of Hepatocellular Carcinoma and Complications of Cirrhosis in Chronic Hepatitis C Patients. PLoS ONE, 2013, 8, e70458.	1.1	31
2130	Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. PLoS ONE, 2013, 8, e71262.	1.1	11
2131	Can Antidepressants Prevent Pegylated Interferon- α /Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?. PLoS ONE, 2013, 8, e76799.	1.1	11
2132	In Silico Identification and Evaluation of Leads for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease Using Complex Based Pharmacophore Mapping and Virtual Screening. PLoS ONE, 2014, 9, e89109.	1.1	31
2133	IL28B Polymorphisms and Clinical Implications for Hepatitis C Virus Infection in Uzbekistan. PLoS ONE, 2014, 9, e93011.	1.1	9
2134	In Depth Analysis on the Binding Sites of Adamantane Derivatives in HCV (Hepatitis C Virus) p7 Channel Based on the NMR Structure. PLoS ONE, 2014, 9, e93613.	1.1	8
2135	Plasma Sphingolipids as Potential Indicators of Hepatic Necroinflammation in Patients with Chronic Hepatitis C and Normal Alanine Aminotransferase Level. PLoS ONE, 2014, 9, e95095.	1.1	16
2136	Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. PLoS ONE, 2014, 9, e99426.	1.1	12

#	ARTICLE	IF	CITATIONS
2137	Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis. PLoS ONE, 2014, 9, e100128.	1.1	14
2138	Peginterferon Alfa-2a Is Associated with Elevations in Alanine Aminotransferase at the End of Treatment in Chronic Hepatitis C Patients with Sustained Virologic Response. PLoS ONE, 2014, 9, e100207.	1.1	4
2139	Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients. PLoS ONE, 2014, 9, e101760.	1.1	14
2140	Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon $\hat{\pm}$ -2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. PLoS ONE, 2014, 9, e107592.	1.1	17
2141	Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent. PLoS ONE, 2015, 10, e0122844.	1.1	38
2142	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Na $\hat{\pm}$ ve Patients in Chile. PLoS ONE, 2015, 10, e0141660.	1.1	13
2143	Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS ONE, 2016, 11, e0153895.	1.1	9
2144	Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?. PLoS ONE, 2016, 11, e0161002.	1.1	10
2145	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS ONE, 2017, 12, e0170933.	1.1	8
2146	Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS ONE, 2017, 12, e0178398.	1.1	29
2147	Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS ONE, 2017, 12, e0183851.	1.1	16
2148	Hepatitis B and Hepatitis C Reactivation in the Biologic Era. Journal of Clinical and Translational Hepatology, 2014, 2, 240-6.	0.7	15
2149	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-na $\hat{\pm}$ ve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8.	0.7	12
2150	Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon $\hat{\pm}$ -2a and Ribavirin for Chronic Hepatitis C. ACG Case Reports Journal, 2015, 2, 247-249.	0.2	4
2151	Inter-platform reproducibility of liver stiffness measured with two different point shear wave elastography techniques and 2-dimensional shear wave elastography using the comb-push technique. Ultrasonography, 2019, 38, 345-354.	1.0	7
2152	Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment. Gastroenterology Research, 2014, 7, 123-130.	0.4	2
2154	EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION "œUNDER REAL LIFE"œ CONDITIONS. Medicinos Teorija Ir Praktika, 2014, 21, 23-32.	0.0	1
2155	MOLECULAR EPIDEMIOLOGY FEATURES OF HEPATITIS C VIRUS ISOLATES FROM DIFFERENT REGIONS OF THE REPUBLIC SAKHA (YAKUTIA). Russian Journal of Infection and Immunity, 2016, 5, 359-372.	0.2	3

#	ARTICLE	IF	CITATIONS
2156	Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 1470-1475.	0.3	5
2158	Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1. <i>Journal of Gastroenterology and Hepatology Research</i> , 2014, 3, 1335-1339.	0.2	6
2159	Predictors of Tuberculosis in HIV/AIDS Patients Referred to Behavioral Diseases Consultation Center: A Registry-Based Study in Abadan, Southwest of Iran. <i>Shiraz E Medical Journal</i> , 2016, 17, .	0.1	7
2160	RNA-Seq-based analysis of differential gene expression associated with hepatitis C virus infection in cell culture. <i>Acta Biochimica Polonica</i> , 2017, 63, 789-798.	0.3	5
2161	Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation. <i>Oncotarget</i> , 2016, 7, 84575-84586.	0.8	9
2162	Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling. <i>Oncotarget</i> , 2018, 9, 5627-5640.	0.8	4
2163	Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients. <i>Current Cancer Drug Targets</i> , 2020, 20, 638-645.	0.8	4
2164	QSAR Studies on Thiazole Derivatives as HCV NS5A Inhibitors via CoMFA and CoMSIA Methods. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 453-460.	0.4	1
2165	A Novel Simultaneous Estimation of Sofosbuvir and Velpatasvir in Human Plasma by Liquid Chromatography Tandem-Mass Spectrometry after Protein Precipitation Method. <i>Current Pharmaceutical Analysis</i> , 2019, 15, 710-715.	0.3	2
2166	The Natural History of Hepatitis C Viral Infection: Clinical Evaluation and Monitoring. <i>Open Medicine Journal</i> , 2016, 3, 52-57.	0.5	3
2167	The Role of Physicians' Attitudes and the Provision of Hepatitis C Virus Treatment to People Who Inject Drugs. <i>Open Medicine Journal</i> , 2016, 3, 104-112.	0.5	2
2168	Introduction of an Automated System for the Diagnosis and Quantification of Hepatitis B and Hepatitis C Viruses. <i>The Open Virology Journal</i> , 2012, 5, 122-134.	1.8	11
2169	Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus. <i>Open Public Health Journal</i> , 2014, 7, 1-5.	0.1	1
2170	Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. <i>JMIR Research Protocols</i> , 2015, 4, e68.	0.5	3
2171	Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. <i>Revista Colombiana De Gastroenterología</i> , 2014, 29, 424-432.	0.1	2
2172	Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C. <i>Jurnal Infektologii</i> , 2019, 11, 65-71.	0.1	1
2173	Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b. <i>Archives of Biological Sciences</i> , 2014, 66, 193-201.	0.2	1
2174	Management of Bipolar Disorder in Liver Transplantation: A Single Center Experience. <i>International Journal of Transplantation Research and Medicine</i> , 2015, 1, .	0.1	3

#	ARTICLE	IF	CITATIONS
2175	The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12. <i>Acta Hepatologica Japonica</i> , 2010, 51, 48-50.	0.0	3
2176	Treatment Guidelines of Hepatitis C. <i>Acta Hepatologica Japonica</i> , 2012, 53, 355-395.	0.0	2
2177	Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. <i>In Silico Biology</i> , 2011, 11, 213-24.	0.4	10
2178	Management of HCV infection in chronic kidney disease. <i>Nefrologia</i> , 2011, 31, 260-7.	0.2	8
2179	Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 376.	4.5	12
2180	KASL clinical practice guidelines: Management of Hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 89.	4.5	35
2181	Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 368.	4.5	13
2182	Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 390-395.	4.5	2
2183	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.	4.5	12
2184	Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 259-266.	4.5	8
2185	Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 316-322.	4.5	20
2186	Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 168-171.	4.5	7
2187	KASL clinical practice guidelines: management of hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 76-139.	4.5	68
2188	Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 42-51.	4.5	12
2189	Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. <i>The Korean Journal of Hepatology</i> , 2011, 17, 183.	1.5	4
2190	Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfecting with hepatitis B virus. <i>The Korean Journal of Hepatology</i> , 2011, 17, 199.	1.5	25
2191	Recent trends in the treatment of chronic hepatitis C. <i>The Korean Journal of Hepatology</i> , 2012, 18, 22.	1.5	12
2192	The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. <i>The Korean Journal of Hepatology</i> , 2012, 18, 29.	1.5	4

#	ARTICLE	IF	CITATIONS
2193	Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 62-82.	0.6	2
2194	Is chronic hepatitis C virus infection a risk factor for breast cancer?. <i>World Journal of Gastroenterology</i> , 2010, 16, 3687.	1.4	12
2195	Hepatocellular carcinoma xenograft supports HCV replication: A mouse model for evaluating antivirals. <i>World Journal of Gastroenterology</i> , 2011, 17, 300.	1.4	5
2196	Peginterferon and ribavirin treatment for hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2011, 17, 419.	1.4	49
2197	FibroSURE [®] and FibroScan [®] in relation to treatment response in chronic hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2011, 17, 4581.	1.4	20
2198	"Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2011, 17, 4607.	1.4	5
2199	Current treatment options and response rates in children with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 99.	1.4	41
2200	New perspectives in occult hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2012, 18, 2887.	1.4	64
2201	Impact of ribavirin dose on retreatment of chronic hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 2966.	1.4	1
2202	Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012, 18, 5514.	1.4	21
2203	Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 6060.	1.4	28
2204	Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. <i>World Journal of Gastroenterology</i> , 2013, 19, 7846.	1.4	74
2205	Scotomas in molecular virology and epidemiology of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 7910.	1.4	10
2206	Addicts with chronic hepatitis C: Difficult to reach, manage or treat?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8011.	1.4	10
2207	Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013, 19, 8678.	1.4	4
2208	Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. <i>World Journal of Gastroenterology</i> , 2013, 19, 8940.	1.4	33
2209	Challenges in managing hepatitis C virus infection in cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 2771.	1.4	31
2210	Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. <i>World Journal of Gastroenterology</i> , 2014, 20, 3431.	1.4	35

#	ARTICLE	IF	CITATIONS
2211	Efficacy and tolerability of low-dose interferon- α in hemodialysis patients with chronic hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 4071.	1.4	6
2212	Safety and efficacy of <i>Hansenu</i> -derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. <i>World Journal of Gastroenterology</i> , 2014, 20, 4681.	1.4	16
2213	Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. <i>World Journal of Gastroenterology</i> , 2014, 20, 6707.	1.4	15
2214	Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. <i>World Journal of Gastroenterology</i> , 2014, 20, 7555.	1.4	40
2215	Role of the ^{13}C -methacetin breath test in the assessment of acute liver injury in a rat model. <i>World Journal of Gastroenterology</i> , 2014, 20, 11305.	1.4	2
2216	Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 12722.	1.4	24
2217	<i>IL28B</i> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 13146.	1.4	20
2218	Clinical characteristics and current management of hepatitis B and C in China. <i>World Journal of Gastroenterology</i> , 2014, 20, 13582.	1.4	19
2219	New treatments for chronic hepatitis C: An overview for paediatricians. <i>World Journal of Gastroenterology</i> , 2014, 20, 15965.	1.4	14
2220	Three-Tesla magnetic resonance elastography for hepatic fibrosis: Comparison with diffusion-weighted imaging and gadoxetic acid-enhanced magnetic resonance imaging. <i>World Journal of Gastroenterology</i> , 2014, 20, 17558.	1.4	19
2221	Interferon- α -related genes and therapeutic response in Chinese hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 4006.	1.4	2
2222	Management of hepatitis C in patients with chronic kidney disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 408.	1.4	33
2223	Liver disease in menopause. <i>World Journal of Gastroenterology</i> , 2015, 21, 7613.	1.4	93
2224	Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 10215-10223.	1.4	8
2225	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. <i>World Journal of Gastroenterology</i> , 2015, 21, 10749.	1.4	23
2226	Serum vitamin D ₃ does not correlate with liver fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 11152.	1.4	10
2227	Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. <i>World Journal of Gastroenterology</i> , 2015, 21, 12430.	1.4	4
2228	Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. <i>World Journal of Gastroenterology</i> , 2015, 21, 1972.	1.4	9

#	ARTICLE	IF	CITATIONS
2229	Retreatment with peginterferon and ribavirin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 1994.	1.4	2
2230	Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. <i>World Journal of Gastroenterology</i> , 2016, 22, 3418-3431.	1.4	17
2231	Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. <i>World Journal of Gastroenterology</i> , 2016, 22, 5173.	1.4	4
2232	Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. <i>World Journal of Gastroenterology</i> , 2016, 22, 1367.	1.4	22
2233	Angiotensin-2/angiotensin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2016, 22, 9744.	1.4	16
2234	Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2018, 24, 1478-1485.	1.4	6
2235	Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study. <i>Antiviral Therapy</i> , 2019, 24, 473-483.	0.6	4
2236	Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFN±2b. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 1098-1100.	0.7	2
2237	Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 989-997.	0.7	2
2238	Diagnostic Tests for Viral Hepatitis. <i>Korean Journal of Medicine</i> , 2013, 85, 267.	0.1	1
2239	Hepatitis C virus: Prevention, screening, and interpretation of assays. <i>Cleveland Clinic Journal of Medicine</i> , 2010, 77, 616-626.	0.6	23
2240	Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. <i>Materiales De Construccion</i> , 1957, 7, 131.	0.2	1
2242	Psychiatric Care of the Patient With Hepatitis C. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	22
2243	Telaprevir. <i>Journal of Postgraduate Medicine</i> , 2013, 59, 42-47.	0.2	10
2244	SASLT guidelines: Update in treatment of Hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 25.	0.5	21
2245	Hepatitis C virus infection among people who inject drugs in Bangkok, Thailand, 2005–2010. <i>WHO South-East Asia Journal of Public Health</i> , 2019, 8, 50.	1.7	5
2246	Quantitative nucleic acid amplification methods and their implications in clinical virology. <i>International Journal of Applied & Basic Medical Research</i> , 2017, 7, 3.	0.2	10
2247	Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. <i>Indian Journal of Medical Research</i> , 2018, 147, 445.	0.4	24

#	ARTICLE	IF	CITATIONS
2248	Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian Journal of Medical Research, 2017, 146, 23.	0.4	16
2249	Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management. Indian Journal of Pathology and Microbiology, 2018, 61, 345.	0.1	3
2250	The Utilization of Hormonal Interaction during Stress to Get Better Performance. Journal of Pharmacogenomics & Pharmacoproteomics, 2018, 09, .	0.2	1
2251	Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. Journal of Addiction Research & Therapy, 2011, 02, 2-10.	0.2	17
2252	Comparison between Fibroscan and Serum Taurine for Early Diagnosis of Liver Fibrosis in Egyptian Patients Infected with HCV. Clinical & Medical Biochemistry Open Access, 2017, 03, .	0.1	1
2253	Risk Factors and Genotypes of Hepatitis C Virus Infection in Libyan Patients. Libyan Journal of Medicine, 2008, 3, 162-165.	0.8	14
2254	HIV Prevalence among HCV Egyptian Infected Patients and Its Impact on the Result of HCV Treatment. Advances in Infectious Diseases, 2013, 03, 71-77.	0.0	4
2255	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World Journal of Hepatology, 2019, 11, 442-449.	0.8	5
2256	Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report. World Journal of Hepatology, 2010, 2, 162.	0.8	9
2257	An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World Journal of Hepatology, 2011, 3, 198.	0.8	4
2258	IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World Journal of Hepatology, 2013, 5, 635.	0.8	2
2259	Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World Journal of Hepatology, 2013, 5, 496.	0.8	26
2260	Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World Journal of Hepatology, 2014, 6, 520.	0.8	5
2261	Vertical transmission of hepatitis C virus: Current knowledge and perspectives. World Journal of Hepatology, 2014, 6, 643.	0.8	73
2262	Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World Journal of Hepatology, 2015, 7, 1606.	0.8	3
2263	Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology, 2015, 7, 1617.	0.8	71
2264	Hepatitis C virus: A global view. World Journal of Hepatology, 2015, 7, 2676.	0.8	92
2265	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World Journal of Hepatology, 2015, 7, 725.	0.8	47

#	ARTICLE	IF	CITATIONS
2266	<i>CD36</i> genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection. World Journal of Hepatology, 2016, 8, 1067.	0.8	20
2267	Prevention of hepatitis C recurrence after liver transplantation: An update. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 36.	0.6	4
2268	AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turkish Journal of Gastroenterology, 2011, 22, 279-285.	0.4	34
2269	Five-year follow-up of patients with chronic C hepatitis and sustained virological response. Revista Espanola De Enfermedades Digestivas, 2011, 103, 56-61.	0.1	6
2270	Acute hepatitis C in Spain: a retrospective study of 131 cases. Revista Espanola De Enfermedades Digestivas, 2012, 104, 21-28.	0.1	11
2271	Delayed Viral Clearance of Chronic Hepatitis C in Patients after Treatment Failure. Gut and Liver, 2011, 5, 110-114.	1.4	3
2272	Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study. Gut and Liver, 2012, 6, 98-106.	1.4	29
2273	A Lower Serum Gamma-Glutamyltransferase Level Does Not Predict a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1. Gut and Liver, 2013, 7, 74-81.	1.4	3
2274	A Low Serum $\hat{\beta}$ -Glutamyltransferase Level Predicts a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1. Gut and Liver, 2014, 8, 113-115.	1.4	5
2275	Prediction of a Null Response to Pegylated Interferon $\hat{\beta}$ -2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C. Gut and Liver, 2014, 8, 421-427.	1.4	3
2276	Low-Dose Pegylated Interferon $\hat{\beta}$ -2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Gut and Liver, 2016, 10, 617-623.	1.4	5
2277	Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut and Liver, 2017, 11, 335-348.	1.4	16
2278	Biologic response modifiers. Journal of the Korean Medical Association, 2013, 56, 135.	0.1	3
2279	Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. Annals of Saudi Medicine, 2012, 32, 174-199.	0.5	26
2280	Viral hepatitis B and C in HIV-infected patients in Saudi Arabia. Annals of Saudi Medicine, 2014, 34, 207-210.	0.5	20
2281	Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Medical Journal, 2015, 32, 266-272.	0.3	7
2282	PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN $\hat{\beta}$) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1. Journal of IMAB, 2011, 17, 1, 197-199.	0.1	1
2283	The Prevalence and Subtype Distribution of Hepatitis C Virus Infection among Hemodialysis Patients in a Private Hospital in Surabaya, Indonesia. Microbiology Indonesia, 2012, 6, 173-179.	0.2	4

#	ARTICLE	IF	CITATIONS
2284	Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World Journal of Virology, 2012, 1, 174.	1.3	28
2285	Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World Journal of Virology, 2013, 2, 6.	1.3	19
2286	Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV?. World Journal of Virology, 2013, 2, 139.	1.3	4
2287	What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?. World Journal of Virology, 2015, 4, 13.	1.3	3
2288	Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. Annals of Hepatology, 2016, 15, 154-9.	0.6	29
2289	HCV Genotyping with Concurrent Profiling of Resistance-Associated Variants by NGS Analysis. , 0, , .		1
2290	Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China. Hepatitis Monthly, 2015, 15, e28836.	0.1	5
2291	The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin. Hepatitis Monthly, 2014, 14, e18793.	0.1	8
2292	Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. Hepatitis Monthly, 2012, 12, 77-84.	0.1	8
2293	The Impact of Host Factors on Management of Hepatitis C Virus. Hepatitis Monthly, 2012, 12, 235-241.	0.1	1
2294	A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. Hepatitis Monthly, 2018, In Press, .	0.1	1
2295	Hepatic Arterial Blood Flow Index Is Associated with the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection. Hepatitis Monthly, 2020, 20, .	0.1	1
2296	Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iranian Red Crescent Medical Journal, 2016, 18, e28566.	0.5	5
2297	Treatment of HCV Patients Before and After Renal Transplantation. Hepatitis Monthly, 2011, 11, 880-886.	0.1	2
2298	Incidence of Post-Liver Transplant Hepatic Dysfunction After Sustained Virologic Response Following Direct-Acting Anti-Hepatitis C Therapy. Experimental and Clinical Transplantation, 2020, 18, 345-352.	0.2	1
2299	Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience. Experimental and Clinical Transplantation, 2015, 13, 7-10.	0.2	4
2300	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
2301	Dynamics and Liver Disease Specific Aspects of Quality of Life Among Patients with Chronic Liver Disease in Yunnan, China. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4765-4771.	0.5	16

#	ARTICLE	IF	CITATIONS
2302	Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1037-1040.	0.5	8
2303	High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1873-1880.	0.5	21
2304	Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. <i>Journal of Biomedical Research</i> , 2014, 28, 476-83.	0.7	4
2305	The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. <i>PeerJ</i> , 2016, 4, e2576.	0.9	11
2306	Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C. <i>PeerJ</i> , 2019, 7, e7666.	0.9	9
2307	Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2012, 33, 189-192.	0.0	17
2308	Statistical Prediction Model for Relapse Rate in Chronic Hepatitis C Patients Treated with Conventional Interferon and Ribavirin Therapy. <i>British Journal of Medicine and Medical Research</i> , 2011, 1, 122-131.	0.2	1
2309	Hepatoprotective Activities and Bioactive Constituents of <i>Stephania abyssinica</i> . <i>British Journal of Pharmaceutical Research</i> , 2016, 10, 1-9.	0.4	22
2310	Magnetic resonance quantification of non-Gaussian water diffusion in hepatic fibrosis staging: a pilot study of diffusion kurtosis imaging to identify reversible hepatic fibrosis. <i>Annals of Translational Medicine</i> , 2021, 9, 1569-1569.	0.7	0
2311	Evaluation of the Curative and Protective Role of Fresh Chicory Juice in Treatment of Hepatic Fibrosis in Male Albino Rats. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 1331-1343.	0.2	0
2312	Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. <i>Viruses</i> , 2021, 13, 2008.	1.5	3
2313	Basic aspects of the treatment for hepatitis C: mechanisms of action of interferon alpha and ribavirin and the bases of individualization. <i>Brazilian Journal of Infectious Diseases</i> , 0, 11, 43-44.	0.3	0
2314	Sexually Transmitted Infections (STI) in Men Who Have Sex with Men (MSM). <i>The Open Infectious Diseases Journal</i> , 2009, 3, 118-127.	0.6	0
2315	Chronic Hepatitis. , 2010, , 133-161.		0
2316	Primary Care of Children with Viral Hepatitis: Diagnosis, Monitoring, and General Management. , 2010, , 151-167.		0
2319	Epidemiology and Natural History of Hepatitis C in Children. , 2010, , 55-66.		0
2320	Liver Disease in Pregnancy. , 2010, , 558-563.		0
2322	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon+ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	0.8	2

#	ARTICLE	IF	CITATIONS
2323	Nonneoplastic Hepatobiliary Disease. , 2011, , 1771-1827.		0
2324	Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage. Revista Espanola De Enfermedades Digestivas, 2010, 102, 587-90.	0.1	1
2325	Pegylated interferon induced interstitial pneumonitis in a patient with hepatitis C infection. Revista Espanola De Enfermedades Digestivas, 2010, 102, 606-8.	0.1	2
2327	Viral Hepatitis C. , 2011, , 427-432.		2
2328	Role of vitamin D in chronic hepatitis C. The Korean Journal of Hepatology, 2011, 17, 170.	1.5	0
2329	The Complex Management of Viral-Related Autoimmune Diseases. , 2011, , 345-357.		0
2331	Non-HIV Antiviral Agents. , 2011, , 471-508.		0
2335	Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. Journal of the Nepal Medical Association, 2013, 51, .	0.1	1
2337	A Call for Routine HIV Testing Among Patients with Hepatitis C Virus Infection. The Open Infectious Diseases Journal, 2011, 5, 19-20.	0.6	0
2338	Hepatitis C: Natural History. , 2012, , 101-105.		0
2339	Hepatitis C Related Vasculitides. , 0, , .		1
2340	HBV/HCV Co-infection and Mixed Cryoglobulinemia. , 2012, , 227-231.		0
2341	The Genetics of Virologic Response. , 2012, , 183-192.		0
2343	Treatment with Interferon and Ribavirin. , 2012, , 115-130.		0
2344	A Study of Serum Interlukin-8 Level in Chronic Hepatitis C Infected Patients in Suez Canal Area. Indian Journal of Applied Research, 2011, 3, 56-59.	0.0	0
2345	Maintenance Therapy with Oral Antiviral Agents. , 2012, , 271-277.		0
2350	Clinical Approach to Treatment of Viral Infections. , 2012, , 111-116.		0
2353	Chronic Hepatitis. , 2012, , 404-407.e1.		0

#	ARTICLE	IF	CITATIONS
2355	Guidelines for the Quantification of HIV and HCV in Small Volume Whole Blood Samples. <i>Methods in Molecular Biology</i> , 2012, 903, 35-50.	0.4	0
2357	A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 272.	4.5	1
2358	Hepatitis C Virus. , 2012, , 1105-1112.e4.		1
2359	Treatment of chronic hepatitis C. <i>Journal of the Korean Medical Association</i> , 2012, 55, 1113.	0.1	1
2360	Chronic Hepatitis. , 2012, , 171-186.e4.		0
2361	Laboratory Diagnosis of Infection Due to Viruses, Chlamydia, Chlamydomphila, and Mycoplasma. , 2012, , 1384-1399.e8.		0
2363	Suggested guidelines for the diagnosis and management of chronic HCV infection in children. <i>Open Journal of Gastroenterology</i> , 2012, 02, 131-142.	0.1	0
2364	Emerging treatment advances in chronic hepatitis C. <i>Community Oncology</i> , 2012, , .	0.2	0
2365	Prognostic significance of transforming growth factor-beta-1 in chronic hepatitis C virus infection. <i>African Journal of Microbiology Research</i> , 2012, 6, .	0.4	0
2367	The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. <i>Journal of Microbiology and Infectious Diseases</i> , 2012, 2, 121-123.	0.1	1
2368	The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses. <i>Journal of Microbiology and Infectious Diseases</i> , 2012, 2, 100-108.	0.1	0
2369	THE SUCCESSFUL EXPERIENCE OF ANTIVIRAL THERAPY FOR HEPATITIS C IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE EARLY POSTOPERATIVE PERIOD. <i>Epidemiology and Infectious Diseases (Russian) Tj ETQq1 1 0784314 rgBT /Ove</i>		
2370	A Study of the Effect of the Use of Antioxidants in Patients with Hepatitis C Receiving Interferon/Ribavirin Therapy on the Response to Therapy. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2012, 2, 168-177.	0.1	0
2371	Assessment of HCV - Induced Insulin Resistance in Egyptian HCV End - Stage Cirrhotic Patients before and after Living Donor Liver Transplantation (LDT). <i>Ain Shams Medical Journal</i> , 2013, 64, 401-411.	0.0	0
2372	Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2. <i>World Journal of Gastroenterology</i> , 2013, 19, 5754.	1.4	0
2374	HIV Co-Infections with Hepatitis B and C. <i>Journal of AIDS & Clinical Research</i> , 2013, 01, .	0.5	4
2375	Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. <i>Gastroenterology Research</i> , 2013, 6, 161-170.	0.4	10
2376	Transient Elastography (Fibroscan®): A New Look of Liver Fibrosis and Beyond. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2013, 3, 70-77.	0.1	1

#	ARTICLE	IF	CITATIONS
2377	Recent Progress in the Electrochemical Detection of Disease-Related Diagnostic Biomarkers. RSC Detection Science, 2013, , 89-128.	0.0	1
2378	Hyperhomocysteinemia as a risk factor for coronary heart diseases in chronic hepatitis C patients. World Journal of Cardiovascular Diseases, 2013, 03, 499-505.	0.0	0
2379	The Different Distribution of Hepatitis C Virus Genotypes in Eastern Black Sea Region of Turkey. Journal of Microbial & Biochemical Technology, 2013, 05, .	0.2	0
2380	Hepatitis C Virus: Gastrointestinal Features. , 2013, , 165-166.		0
2381	Treatment of ANCA-Negative Small Vessel Vasculitis. , 0, , .		0
2382	Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests. Journal of Virology and Microbiology, 2013, , 1-7.	0.6	1
2385	Glomerular Diseases Associated with HIV, Hepatitis B, and Hepatitis C Infections. , 2014, , 209-228.		0
2386	Cryoglobulinemias. , 2014, , 87-103.		1
2387	Management algorithm for genotype 1 hepatitis C virus. F1000prime Reports, 2013, 5, 24.	5.9	1
2388	Hepatitis C Virus Testing. , 2014, , 57-80.		0
2389	Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea. Gut and Liver, 2013, 7, 585-593.	1.4	0
2390	A 50-Year-Old Male with Cirrhosis, HCV, Alcohol-Use Disorder, and Unexpected Decline While on DAA Therapy. Psychiatric Annals, 2013, 43, 412-415.	0.1	0
2391	Update on the Development of Anti-Viral Agents Against Hepatitis C. Journal of Clinical and Translational Hepatology, 2013, 1, 9-21.	0.7	2
2392	B-Cell Targeted Therapies in Cryoglobulinemia. Milestones in Drug Therapy, 2014, , 181-191.	0.1	0
2393	The Geoepidemiology of Autoimmune Liver Disease. , 2014, , 27-43.		0
2394	Diagnostic Liver Immunology. , 2014, , 45-53.		0
2396	Infections of the Liver. , 2014, , 285-312.		1
2397	Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. European Journal of Basic Medical Sciences, 2013, 3, 78-82.	0.2	2

#	ARTICLE	IF	CITATIONS
2398	Hepatitis C Virus: Pathogenesis and Host Immune Response. , 2014, , 51-86.		0
2399	A New Era in the Management of the Hepatitis C. International Journal of Clinical Medicine, 2014, 05, 660-666.	0.1	1
2400	Endotoxemia in antiviral therapy for chronic hepatitis C and its potential pharmacologic corrections. Medical News of North Caucasus, 2014, 9, .	0.0	0
2401	Prevalence of HCV in apparently healthy voluntary blood donors. IOSR Journal of Dental and Medical Sciences, 2014, 13, 01-04.	0.0	0
2402	Liver Disease in Renal Transplant Recipients. , 2014, , 247-255.		1
2403	Sustained Virological Response among Chronic Hepatitis C Virus Infected Patients Treated with Pegylated Interferon (INF) and Ribavirin (RBV) in Sana'a Yemen 2013. Egyptian Journal of Medical Microbiology, 2014, 23, 17-25.	0.1	0
2405	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
2406	Issues in the Care and Treatment of HCV/HIV Co-Infection for Key Populations in Resource-Constrained Settings. Health, 2014, 06, 1803-1815.	0.1	1
2407	Effect of Vitamin D Supplementation with Pegylated Interferon- α and Ribavirin on Erythrocyte Indices, Iron Parameters and Erythropoietin Expression in Male Wistar Rats. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
2408	Clinical Evaluation of Chronic Hepatitis C and Indications for HCV Treatment. North American Journal of Medicine & Science, 2014, 07, 017.	3.8	0
2409	The impact of clinicopathological parameters in predicting response to pegylated interferon and ribavirin in chronic hepatitis C patients. Menoufia Medical Journal, 2014, 27, 785.	0.1	0
2410	Role of Oxidative Stress in Hepatitis B and C Virus. , 2014, , 90-107.		0
2411	Sustained Virologic Response with Triple Therapy in a Hemodialysis Patient with Chronic HCV Infection. Mediterranean Journal of Infection, Microbes and Antimicrobials, 2014, 3, 1-6.	0.2	0
2412	Chapitre 9. HÃ©patite C, addictions etÃ©comorbiditÃ©s psychiatriques. , 2014, , 153-167.		0
2413	EFFICIENCY OF IMMUNOCORRECTION IN CHRONIC VIRAL HEPATITIS C PATIENTS TREATED BY ANTIVIRALS. Russian Journal of Infection and Immunity, 2014, 3, 59.	0.2	0
2414	Retrospective Study of Hepatitis C Virus Genotypes and its Association with Lymphoma. Journal of Cancer Research Updates, 2014, 3, 129-133.	0.3	0
2415	Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, .	0.0	0
2416	Improvement of Glycemic Control after Conversion from Tacrolimus to Cyclosporine A in Liver Transplanted Patient with Hepatitis C Virus Reinfection : Case Report. Journal of Korean Society of Health-System Pharmacists, 2014, 31, 992-1000.	0.1	0

#	ARTICLE	IF	CITATIONS
2417	Prevalence of Liver Disease in Russia's Largest City: A Population-based Study. American Journal of Clinical Medicine Research, 2014, 2, 99-102.	0.1	3
2418	A psychiatric pharmacist in a liver clinic managing treated patients with chronic hepatitis C viral infection. Mental Health Clinician, 2014, 4, 266-270.	0.5	0
2419	Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries. Journal of Clinical and Translational Hepatology, 2014, 2, 247-52.	0.7	5
2420	Hepatitis C Risk Factors in a Cambodian American Population in Lowell, Massachusetts. Open Forum Infectious Diseases, 2015, 2, .	0.4	0
2421	Chapter 33. Infectious Disease. , 2015, , .		0
2422	Hepatitis C Therapy: Serendipitous Successes. The Medicine Forum, 2015, 15, .	0.0	0
2423	Does Visceral Adiposity Influence the Standard of Care Response for Hepatitis C Patients?. Journal of Asian Scientific Research, 2015, 5, 16-30.	0.0	0
2424	Antiviral Agents. , 0, , 1867-1893.		0
2425	Insights into the role of HCV Plus-/Minus strand RNA, IFN- γ and IL-29 in relapse outcome in patients infected by HCV. Asian Pacific Journal of Allergy and Immunology, 2015, 33, 173-81.	0.2	5
2427	Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?. Annales Academiae Medicae Silesiensis, 2015, 69, 91-98.	0.1	0
2428	Gastrointestinal Issues. , 2016, , 1209-1224.		0
2429	Noninvasive prediction of HCV-4 SVR by 2D US: a randomized study using data mining algorithm. Al-Azhar Assiut Medical Journal, 2016, 14, 14.	0.1	0
2430	Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. Journal of Postgraduate Medicine, 2016, 62, 20-25.	0.2	0
2431	Cryoglobulins and Cryoglobulinemia. , 2016, , 633-645.		1
2432	TRATAMENTO DA HEPATITE C PELO SISTEMA ÃŠNICO DE SAÃŠDE NO BRASIL. Revista Da Universidade Vale Do Rio Verde, 2016, , .	0.1	0
2433	Hepatitis B and C Viruses. , 2016, , 641-657.		0
2434	Innate Immune Recognition of Hepatitis C Virus. , 2016, , 299-329.		0
2435	Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian Journal of Hepato-gastroenterology, 2016, 6, 35-42.	0.1	0

#	ARTICLE	IF	CITATIONS
2436	Clinical Profile and Response to First-Line Anti-Retroviral Therapy in Human Immunodeficiency Virus Infected Patients in Manipur. International Journal of Medical and Dental Sciences, 2016, 5, 970.	0.1	0
2437	Donor-Derived Infections: Incidence, Prevention, and Management. , 2016, , 113-127.		0
2438	GAMMA GLUTAMYL TRANSFERASE LEVELS IN PATIENTS WITH VIRAL HEPATITIS C. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 286-287.	0.0	0
2439	The Fibrosis-Cirrhosis Index (FCI) for Staging of Liver Fibrosis in Chronic Hepatitis C. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2016, 6, 7-15.	0.1	0
2441	Implications of prognostic variables in the assessment of autoimmunity in hepatitis C patients receiving interferon therapy. Bioinformation, 2016, 12, 131-134.	0.2	1
2442	VITAMIN D AS ONE OF PREDICATORS OF THE STABLE VIRAL RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C. EUREKA Health Sciences, 2016, 4, 18-22.	0.1	1
2443	A VA Perspective: The Expanding Role of the Clinical Health Psychologist in the New Era of Hepatitis C and Advanced Liver Disease Clinical Care. Open Medicine Journal, 2016, 3, 113-129.	0.5	0
2444	Transient Elastography with Serum Hepatitis B Surface Antigen Enhances Liver Fibrosis Detection. Medical Science Monitor, 2016, 22, 2878-2885.	0.5	1
2445	VIRAL HEPATITIS C PATIENTS. The Professional Medical Journal, 2018, 23, 1263-1268.	0.0	0
2446	Viral Hepatitis: Hepatitis C. , 2017, , 143-163.		0
2448	Hepascore and Its Application to Liver Disease. Biomarkers in Disease, 2017, , 23-45.	0.0	0
2449	Kidney Transplantation in the Hepatitis C Infected Recipient. , 2017, , 653-663.		0
2450	Early Experience of Sofosbuvir based Combination Therapy in "Real-Life" Cohort with Chronic Hepatitis-C Infection. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OC05-OC08.	0.8	2
2451	Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research) Tj ETQq1 1 0.784314 rgBT /Overl		0
2453	Evaluation of the Performance Characteristics of an In-House One Step TaqMan Real Time-Polymerase Chain Reaction Assay for Detection and Quantification of Hepatitis C Virus. Jundishapur Journal of Microbiology, 2017, 10, .	0.2	2
2454	The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. Journal of Clinical and Translational Hepatology, 2017, 5, 59-66.	0.7	14
2455	Molecular Characterization of HCV and Introduction of Biorisk Management CWA 15793-2008 at DHQ Divisional Headquarters Teaching Hospital & MBBS Medical College, Chattar Parri, Mirpur District AJK. Journal of Microbiology & Experimentation, 2017, 4, .	0.1	0
2456	Prevalence of Hepatitis C Virus among Patients with Human Immunodeficiency and Its Association with Intra-Venous Drugs Addiction in Jeddah, Saudi Arabia. The Egyptian Journal of Hospital Medicine, 2017, 67, 514-517.	0.0	0

#	ARTICLE	IF	CITATIONS
2477	Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents. <i>Journal of Medical Microbiology and Infectious Diseases</i> , 2020, 8, 1-6.	0.1	0
2479	Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals. <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 79, 503-508.	0.0	0
2480	A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India. <i>Cureus</i> , 2021, 13, e19342.	0.2	1
2481	Avaliaç�o epidemiol�gica da infec�o pelo v�rus da hepatite B no Estado do Piau� no per�odo de 2008 a 2018. <i>Research, Society and Development</i> , 2020, 9, e693986540.	0.0	0
2484	The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV. <i>HIV Clinical Trials</i> , 2012, 13, 33-45.	2.0	3
2485	Diffuse Liver Diseases. , 2021, , 69-97.		0
2486	Diffusion-weighted MRI in staging of post hepatitis C fibrosis: does ADC value challenge liver biopsy?. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2020, 51, .	0.3	0
2487	Hepatitis C virus infection in nephrology patients. <i>Journal of Nephropathology</i> , 2013, 2, 217-33.	0.1	11
2488	A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome. <i>Gastroenterology and Hepatology</i> , 2010, 6, 233-6.	0.2	6
2489	Improving the detection and care of people with hepatitis B and C. <i>Gastroenterology and Hepatology</i> , 2010, 6, 363-5.	0.2	0
2490	Management of recurrent hepatitis C following liver transplantation. <i>Gastroenterology and Hepatology</i> , 2010, 6, 637-45.	0.2	8
2491	Direct-acting antiviral medications for chronic hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2011, 7, 154-62.	0.2	23
2492	Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection. <i>Hepatitis Monthly</i> , 2010, 10, 165-7.	0.1	2
2493	Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patients. <i>Hepatitis Monthly</i> , 2010, 10, 229-30.	0.1	0
2495	Anemia management in the era of triple combination therapy for chronic HCV. <i>Gastroenterology and Hepatology</i> , 2012, 8, 1-16.	0.2	9
2497	Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. <i>Annals of Hepatology</i> , 2012, 11, 15-31.	0.6	18
2498	Screening for hepatitis B virus and hepatitis C virus at a community fair: a single-center experience. <i>Gastroenterology and Hepatology</i> , 2013, 9, 293-9.	0.2	5
2499	This is hepatitis: know it, confront it. <i>Indian Journal of Medical Research</i> , 2013, 138, 8-10.	0.4	4

#	ARTICLE	IF	CITATIONS
2500	Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. <i>Indian Journal of Medical Research</i> , 2013, 138, 766-78.	0.4	4
2501	New markers for diagnosis and management of chronic hepatitis C virus infection. <i>Annals of Gastroenterology</i> , 2013, 26, 98-99.	0.4	1
2503	Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. <i>Gastroenterology and Hepatology</i> , 2013, 9, 682-3.	0.2	0
2504	Evaluated outcomes in patients with Chronic Hepatitis C. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, S58-64.	0.6	2
2505	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. <i>Hippokratia</i> , 2014, 18, 57-64.	0.3	5
2506	Role of primary care providers in hepatitis C prevention and care: one step away from evidence-based practice. <i>Canadian Family Physician</i> , 2014, 60, 881-2, e468-70.	0.1	7
2507	Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 2667-76.	1.3	12
2508	Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. <i>North American Journal of Medicine & Science</i> , 2014, 7, 21-27.	3.8	5
2509	Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. <i>Annals of Gastroenterology</i> , 2015, 28, 55-65.	0.4	39
2510	Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 7446-56.	1.3	2
2511	Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-1 α and ribavirin. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 10284-303.	1.3	2
2512	Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 459-63.	9.0	32
2513	Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011. <i>Morbidity and Mortality Weekly Report</i> , 2013, 62, 357-61.	9.0	21
2514	Testing for HCV infection: an update of guidance for clinicians and laboratorians. <i>Morbidity and Mortality Weekly Report</i> , 2013, 62, 362-5.	9.0	195
2515	The Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current Challenges. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2015, 74, 386-9.	0.4	0
2516	Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2015, 15, 1-45.	3.0	14
2517	Sofosbuvir-ribavirin duo for chronic hepatitis C. <i>Connecticut Medicine</i> , 2014, 78, 355-6.	0.2	3
2518	Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population. <i>American Health and Drug Benefits</i> , 2016, 9, 74-82.	0.5	1

#	ARTICLE	IF	CITATIONS
2544	Management of HCV-2 and HCV-3 Non-Responders and Relapsers. , 0, , 43-46.		0
2545	Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment. Journal of the College of Physicians and Surgeons–Pakistan: JCPSP, 2012, 22, 635-9.	0.2	0
2547	Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Annals of Hepatology, 2016, 15, 834-845.	0.6	1
2548	PEG-Interferon-Î± ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria, 2015, 39, 29-43.	0.6	1
2549	Case study of hepatitis C virus control in Egypt: impact of access program. Antiviral Therapy, 2022, 27, 135965352110675.	0.6	6
2550	Interferon-alfa: um interferente endÃ³crino. , 2021, , 95-122.		0
2551	O vÃ¡rus da Hepatite C e a Hepatite C. , 2021, , 53-76.		0
2552	HCV Treatment in Decompensated Disease. Current Hepatology Reports, 0, , .	0.4	0
2554	Wnt signaling in liver regeneration, disease, and cancer. Clinical and Molecular Hepatology, 2023, 29, 33-50.	4.5	8
2555	Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2022, 240, 114595.	2.6	4
2556	Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children. Current Opinion in Infectious Diseases, 2022, 35, 468-476.	1.3	2
2557	Genomic divergence of Hepatitis C virus towards common prescribed interferon regimens on sustained virologic response (SVR) â€Ž. Journal of Advanced Pharmacy Education and Research, 2022, 12, 59-64.	0.2	1
2559	Machine Learning Model for Hepatitis C Diagnosis Customized to Each Patient. IEEE Access, 2022, 10, 106655-106672.	2.6	4
2560	Clinical Significance of MiR-130b and MiR-125b as Biomarkers in Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2687-2693.	0.5	0
2561	Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Journal of Clinical Medicine, 2022, 11, 5781.	1.0	1
2562	Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs. Egyptian Liver Journal, 2022, 12, .	0.3	0
2563	Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine (United States), 2022, 101, e30608.	0.4	0
2564	Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review. Nutrients, 2022, 14, 4556.	1.7	16

#	ARTICLE	IF	CITATIONS
2566	Laboratory Diagnosis of Infection Due to Viruses,Chlamydia, and Mycoplasma. , 2023, , 1472-1484.e5.		0
2567	Hepatitis C Virus. , 2023, , 1156-1160.e3.		0
2568	Chronic Hepatitis C: Pathophysiology and Clinical Issues. Biology, 2022, 11, 1737.	1.3	0
2569	Hepatitis B, Hepatitis A, and Pneumococcal Immunization Status in Patients with Cirrhosis of the Liver: A Questionnaire Survey. Gastroenterology, Hepatology and Endoscopy Practice, 2023, 3, 21.	0.1	0
2570	Updates on Quantitative MRI of Diffuse Liver Disease: A Narrative Review. BioMed Research International, 2022, 2022, 1-15.	0.9	2
2571	Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?. European Medical Journal (Chelmsford, England), 0, , 126-132.	3.0	2
2572	Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines, 2023, 11, 271.	1.4	3
2573	Sero-prevalence and genotypes of hepatitis c among people who inject drugs in Nairobi Kenya. Journal of Human Virology & Retrovirology, 2020, 8, 86-92.	0.1	0
2574	Impaired long-term anti-HBs responses in choronic hepatitis C patients: Results from a five-year follow-up study with healthy control. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	1
2575	Seroprevalence of hepatitis C virus in Jinan, China, 2008â€“2020. European Journal of Medical Research, 2023, 28, .	0.9	1
2576	Raman scattering-based optical sensing of chronic liver diseases. Photodiagnosis and Photodynamic Therapy, 2023, 42, 103505.	1.3	1
2577	A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach. Molecules, 2023, 28, 1300.	1.7	0
2578	Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of â‰¥ 2 cm. PLoS ONE, 2023, 18, e0281154.	1.1	0
2579	The transmission risk factors of hepatitis B and C infection in dental treating and tattooing among hemodialysis patients. Research Journal of Pharmacy and Technology, 2023, , 418-422.	0.2	0
2580	Rheumatic manifestations of hepatitis C virus infection are associated with autoantibodies but not viremia. Journal of Microbiology, Immunology and Infection, 2023, , .	1.5	0
2581	Hepatitis C Treatment in Persons Who Inject Drugs in a Medication Assisted Treatment Program: A Retrospective Review of an Integrated Model. Journal of Primary Care and Community Health, 2023, 14, 215013192311648.	1.0	1
2586	Hepascore and Its Application to Liver Disease. Biomarkers in Disease, 2016, , 1-24.	0.0	0
2602	Hepatitis C Virus. , 2022, , 1-28.		0

#	ARTICLE	IF	CITATIONS
2607	Mannose-specific plant and microbial lectins as antiviral agents: A review. Glycoconjugate Journal, 2024, 41, 1-33.	1.4	0
2608	Cyanobacterial lectins: potential emerging therapeutics. , 2024, , 531-577.		0